









Submitted to the 
 
Faculty for Natural Sciences  
and Mathematics of the 
Christian-Albrechts University of Kiel, Germany 
 
 
for the degree of 
Doctor of Natural Sciences 
















The role of Signal Transducer and Activator 
of Transcription 5 (Stat5) and the  






Conducted at the  
Ludwig-Boltzmann-Institute for Cancer Research 
(LBI-CR)  







Prof. Dr. Holger Kalthoff
Prof. Dr. Dr. h.c. Thomas C. G. Bosch 
                                                                                                            Table of contents 
 
3 
Table of contents 
 
1. Summary.............................................................................................. 8 
Zusammenfassung ................................................................................ 10 
 
2. Introduction ...................................................................................... 12 
 
2.1. Metabolic homeostasis and the liver ...................................................... 12 
2.1.1. Uptake and systemic distribution of lipids.................................................... 12 
2.1.2. Glycolysis and hepatic beta-oxidation......................................................... 14 
2.1.3. Hepatic de novo lipogenesis...................................................................... 15 
 
2.2. Transcription factors and hepatic lipid metabolism ................................ 15 
2.2.1. Transcriptional regulation of hepatic beta-oxidation ..................................... 16 
2.2.2. Transcriptional regulation of hepatic de novo lipogenesis ............................. 17 
 
2.3. Insulin signaling and insulin resistance.................................................. 18 
 
2.4. Insulin resistance and liver steatosis...................................................... 20 
2.4.1. Mouse models of NAFLD .......................................................................... 21 
 
2.5. Fibrosis of the liver................................................................................. 22 
2.5.1. Molecular mechanisms underlying liver fibrogenesis.................................... 23 
 
2.6. Signal transducer and activator of transcription 5 (Stat5) ...................... 25 
2.6.1. Stat5 in health and disease ....................................................................... 27 
2.6.1.1. Stat5 and postnatal body growth................................................................ 28 
2.6.1.2. Stat5 and hepatic lipid metabolism............................................................. 28 
 
2.7. The glucocorticoid receptor (GR)........................................................... 29 
 
2.8. Linear Stat5-GR signal transduction: Two transcription factor pathways 
converge ................................................................................................ 30 
2.8.1. Growth hormone, glucocorticoids and body composition .............................. 30 




2.9. Conditional gene deletion using the Cre/LoxP system........................... 31 
 
2.10. Aim of the thesis .................................................................................... 33 
 
3. Results................................................................................................ 34 
 
3.1. A linear Stat5-GR axis controls postnatal body growth.......................... 34 
3.1.1. Loss of hepatic Stat5 and/or the GR signaling leads postnatal growth deficiency
............................................................................................................... 34 
3.1.2. Loss of hepatic Stat5 and/or the GR signaling leads to similar changes in gene 
expression profiles ................................................................................... 35 
3.1.3. The N-terminus of Stat5 constitutes the docking platform for the GR............. 38 
3.1.4. Socs2 as example for Stat5-GR co-dependent gene transcription................. 43 
3.1.4.1. The Socs2 promoter harbours putative Stat5-GR responsive elements ......... 43 
3.1.4.2. Putative Stat5-GR DNA binding sites in the proximal Socs2 promoter are Stat5 
responsive............................................................................................... 45 
3.1.4.3. The proximal Socs2 promoter is synergistically transactivated by Stat5-GR 
interplay .................................................................................................. 47 
3.1.4.4. Full transactivation of the Socs2 promoter depends on Stat5 and GR............ 48 
3.1.4.5. Synergistic Stat5 and GR signaling is required for full Socs2 promoter 
transactivation.......................................................................................... 49 
3.1.4.6. A linear Stat5-GR pathway controls hepatic Socs2 transcription ................... 51 
 
3.2. Compound loss of hepatic Stat5 and GR signaling leads to steatosis ... 52 
3.2.1. Loss of hepatic Stat5 signaling leads to increased lipogenesis ..................... 56 
3.2.2. Loss of hepatic Stat5 signaling induces hepatic insulin resistance................. 60 
3.2.3. Compound loss of hepatic Stat5 and GR signaling leads to peripheral 
lipodystrophy. .......................................................................................... 63 
3.2.4. Compound loss of hepatic Stat5 and Glucocorticoid Receptor signaling does not 
affect lipoprotein particle-mediated lipid distribution ..................................... 66 
3.2.5. Loss of Stat5 is not compensatory counteracted by Stat1 and Stat3 activation66 
3.2.6. Development of steatosis is independent of Jak2 upstream kinase ............... 67 
 
3.3. Loss of hepatic Stat5 leads to severe liver fibrosis in MDR2- mice ........ 68 
                                                                                                            Table of contents 
 
5 
3.3.1. Deletion of MDR2 proteins causes hepatic Stat5b activation ........................ 72 
3.3.2. MDR2-/Stat5AlfpCre mice display autocrine growth factor loops ....................... 73 
3.3.3. Fibrogenesis in MDR2-/Stat5AlfpCre mice is accompanied by ECM remodelling 74 
3.3.4. Loss of hepatic Stat5 in MDR2- mice leads to impaired bile acid circulation.... 76 
 
4. Discussion ........................................................................................ 79 
 
4.1. A linear Stat5-GR axis controls postnatal body growth.......................... 79 
 
4.2. Compound loss of hepatic Stat5 and GR signaling causes steatosis .... 82 
 
4.3. Loss of hepatic Stat5 signaling leads to severe liver fibrosis in the MDR2-
/- mouse model of inflammatory liver cancer .......................................... 85 
 
5. Materials and Methods.................................................................. 86 
 
5.1. Materials ................................................................................................ 86 
5.1.1. Chemicals and enzymes: .......................................................................... 86 
5.1.2. Standard solutions.................................................................................... 87 
5.1.3. Media for bacterial cultivation .................................................................... 87 
5.1.4. Plasmid constructs ................................................................................... 88 
 
5.2. Molecular biology................................................................................... 88 
5.2.1. Standard techniques................................................................................. 88 
5.2.1.1. DNA electrophoresis................................................................................. 88 
5.2.1.2. Extraction of DNA fragments from agarose gels .......................................... 88 
5.2.1.3. Transformation of bacteria ........................................................................ 89 
5.2.2. Vector cloning .......................................................................................... 89 
5.2.2.1. Cloning strategy for Socs2 reporter constructs ............................................ 89 
5.2.3. DNA isolation and analysis........................................................................ 90 
5.2.3.1. Isolation of plasmid DNA from bacteria....................................................... 90 
5.2.3.2. Isolation of tail DNA for genotyping ............................................................ 90 
5.2.3.3. Genotyping PCR ...................................................................................... 90 
5.2.4. RNA isolation and analysis........................................................................ 92 
5.2.4.1. Isolation of messenger RNA from murine livers ........................................... 92 
                                                                                                            Table of contents 
 
6 
5.2.4.2. Reverse transcription................................................................................ 93 
5.2.4.3. Quantitative RT-PCR (qPCR) .................................................................... 93 
5.2.4.4. Whole genome expression profiling (Affymetrix) and bioinformatics .............. 95 
5.2.4.5. Molecular signature analysis of Affymetrix expression data .......................... 95 
 
5.3. Protein chemistry ................................................................................... 96 
5.3.1. Protein isolation ....................................................................................... 96 
5.3.1.1. Preparation of liver homogenates .............................................................. 96 
5.3.1.2. Preparation of cell line extracts .................................................................. 97 
5.3.1.3. Protein quantification with the Bradford method........................................... 97 
5.3.2. Immunoprecipitation ................................................................................. 97 
5.3.3. Western Blot ............................................................................................ 98 
5.3.3.1. Sodium Dodecylsulfate Polyacrylamide Gel Electrophoresis......................... 98 
5.3.3.2. Protein transfer onto Nylon membranes...................................................... 99 
5.3.3.3. Immunoblot analysis (antibody staining) ..................................................... 99 
5.3.4. EMSA ....................................................................................................100 
5.3.5. Tissue analysis and paraffin embedding ....................................................102 
5.3.5.1. Histopathology ........................................................................................102 
5.3.5.2. Immunohistochemistry .............................................................................102 
5.3.6. Electron microscopy ................................................................................103 
 
5.4. Cell biology ...........................................................................................103 
5.4.1. Cell lines ................................................................................................103 
5.4.2. Handling of cell lines and transient transfection ..........................................103 
5.4.3. Luciferase reporter assay.........................................................................105 
 
5.5. Colony breeding and management.......................................................106 
5.5.1. Transgenic mouse lines ...........................................................................106 
5.5.2. Metabolic function tests ...........................................................................106 
5.5.2.1. Glucose tolerance test .............................................................................106 
5.5.2.2. Insulin tolerance test................................................................................107 
5.5.3. Blood sampling and serum parameter quantification ...................................107 
5.5.3.1. Lipoprotein profile....................................................................................107 
5.5.4. Immuno assays.......................................................................................107 
                                                                                                            Table of contents 
 
7 
5.5.4.1. Radio Immunoassay (RIA) .......................................................................108 
5.5.4.2. Enzyme Linked Immuno Sorbent Assay (ELISA) ........................................108 
5.5.5. Colorimetric assays .................................................................................108 
5.5.5.1. Quantification of free fatty acids (FFA).......................................................108 
5.5.5.2. Isolation and quantification of hepatic triglycerides .....................................109 
 
6. Literature: ...........................................................................110 
 
7. Abbreviations .....................................................................123 
 
8. Bibliography .......................................................................126 
 
9. Acknowledgements ...........................................................128 
 
 
10. Acknowledgements .........................................................1289 
 
 




Signal transducer and activator of transcription 5 (Stat5) represents a cytokine- and 
growth factor-dependent transcription factor regulating important biological processes 
such as postnatal body growth, erythropoiesis and the expression of milk protein 
genes. The glucocorticoid receptor (GR) binds Stat5 in a cofactor fashion and was 
reported to modulate Stat5 target gene specificity. In this study we aimed to elucidate 
the role of Stat5 in pivotal hepatocyte processes such as the regulation of postnatal 
body growth, fatty acid metabolism and liver fibrogenesis, taking into account its 
propensity to interact with the GR. The major findings of this study are summarized in 
the following: 
 
(i) Hepatic loss of Stat5, the GR or both resulted in comparable defects in 
postnatal body growth. This was accompanied by quantitatively similar changes in 
transcription profiles, affecting predominantly growth-related Stat5 target genes (e.g. 
IGF-1 and Socs2). These observation suggested the existence of a linear Stat5-GR 
signal transduction pathway essential for regulating postnatal body growth. Using 
protein interaction studies the Stat5 aminoterminus was identified as docking platform 
for the GR. Luciferase reporter assays confirmed the Stat5-GR-dependent synergism 
in vitro exemplarily for transactivation of the Socs2 promoter.  
 
(ii) Hepatic loss of Stat5 in mice leads to the pathological accumulation of 
lipids in hepatocytes (steatosis). This coincides with perturbations of hepatic lipid 
metabolism such as hepatic insulin resistance and induction of de novo lipogenesis 
mediated by lipogenic master regulators PPARgamma and SREBP-1c. Compound 
loss of Stat5 and GR in hepatocytes severely aggravates this phenotype, leading to 
late-stage hepatopathologies such as severe steatosis and liver fibrosis already in 
young animals. At older ages, these mutants additionally exhibit depletions of 
peripheral fat stores (lipodystrophy) leading to an increased lipid flux into hepatic 
tissues and thus exacerbating disease. The two-step pathogenesis observed in 
double knockout animals closely mimics the onset and progression of human non-
alcoholic fatty liver disease (NAFLD). 
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(iii) Hepatic loss of Stat5 in a murine model for proinflammatory liver 
carcinogenesis (MDR2- model) leads to extrahepatic cholestasis (bile duct 
obstruction) causing secondary liver fibrosis at young ages. The pathogenesis in 
these animals comprises major hallmarks observed in fibrotic states such as the 
activation of hepatic stellate cells and remodelling of the extracellular matrix. Ablation 
of Stat5 in hepatocytes leads to a direct loss of Stat5-dependent basolateral bile acid 
transporter transcription in hepatocytes and thus coincides with perturbations in 
hepatic bile acid circulation and recycling. This may eventually cause hepatocyte 
damage and, finally, liver fibrosis and cirrhosis. 
 
Taken together, two published first-author manuscripts and one first-author 
manuscript in preparation resulted from this (see section 8). 
. 





Signal transducer and activator of transcription 5 (Stat5) stellt einen wichtigen, 
Zytokin- und Wachstumsfaktor-abhängigen Transkriptionsfaktor dar mit essentiellen 
Funktionen z.B. bei der Regulation des postnatalen Größenwachstums, der 
Erythropoese sowie der Expression von Milchproteinen während der Laktation. Der 
Glukocorticoid Rezeptor (GR) bindet als akzessorischer Transkriptionskofaktor an 
Stat5 und kann dessen Zielgen Spezifität unter bestimmten Umständen modifizieren. 
In der vorliegenden Arbeit sollte der Einfluss von Stat5 auf Hepatozyten-vermittelte 
Prozesse wie postnatales Größenwachstum, Lipidstoffwechsel sowie 
Leberfibrogenese untersucht werden, unter Berücksichtigung der 
Proteinwechselwirkung mit dem GR. Die wichtigsten Resultate der vorliegenden 
Studie sind im Folgenden zusammengefasst: 
 
(i) Die hepatische Deletion von entweder Stat5, dem GR oder beiden führt zu 
vergleichbaren Störungen des postnatalen Größenwachstums. Gleichzeitig wurden 
quantitativ ähnliche Änderungen des Transkriptionsprofils beobachtet, welche 
besonders solche Stat5-abhängige Gene betraf welche für das postnatal 
Größenwachsum essentiell sind (z.B. IGF-1 oder Socs2). Diese Beobachtungen 
ließen auf die Existenz eines linearen Stat5-GR Signaltransduktionsweges schließen, 
welcher wichtig für die Regulation des Größenwachstums nach der Geburt ist. Der 
Aminoterminus von Stat5 wurde als Stat5-GR Interaktiondomäne identifiziert. 
Luciferase Reporter assays bestätigten eine synergistische Transaktivierung des 
Socs2 Promoters durch Stat5 und den GR in vitro. 
 
(ii) Die hepatische Deletion von Stat5 führt zur milden Akkumulation von 
Fetten in Hepatozyten (Steatose). Dieses wird begleitet von Störungen des 
hepatischen Lipidstoffwechsels wie z.B. dem Auftreten von hepatischer 
Insulinresistenz sowie der Induktion der de novo Lipogenese, vermittelt durch die 
essentiellen prolipogenen Transkriptionsfaktoren PPARgamma und SREBP-1c. Die 
simultane Deletion von Stat5 und dem GR führt zu einer dramatischen Verschärfung 
der Steatose sowie zum frühen Auftreten von Leberfibrosen welche normalerweise 
erst im Endstadium von Steatosen beobachtet werden können. Mit zunehmendem 
Alter kommt es zu einer Abnahme peripherer Fettspeicher (Lipodystrophie). Dies 
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resultiert in einem verstärkten Zustrom von Fetten in die Leber und somit einer 
Verschlimmerung der bestehenden Steatose. Stat5/GR Doppelmutanten zeigen 
somit eine zweistufige Pathogenese, welche an den humanen NAFLD 
Krankheitsverlauf erinnert. 
 
(iii) Die hepatische Deletion von Stat5 in einem murinen Modell für 
inflammatorische Leberkarzinogenese (MDR2- Modell) führt zu extrahepatischer 
Cholestase (Verschluss der Gallengänge). Diese führt schon in jungen Mäusen zu 
einer schweren Leberfibrose und Zirrhose. Die Pathogenese in diesen Tieren wird 
begleitet durch das Auftreten Fibrose-assoziierter Parameter wie z.B. der Aktivierung 
von hepatischen Sternzellen sowie der Akkumulation von extrazellulären 
Matrixproteinen. Mechanistisch führt die hepatische Deletion von Stat5 zu einem 
direkten, transkriptionellen Verlust wichtiger basolateraler Gallentransporter. Dies 
wiederum resultiert in indirekten Störungen der hepatischen Gallenzirkulation, welche 
eine konstante Schädigung von Hepatozyten und schließlich Leberfibrose und 











2.1. Metabolic homeostasis and the liver  
 
Obesity and its underlying causes are major concerns in the industrialized world 
affecting both adults and children 1. Little physical activity and calory excess are 
associated with the onset of obesity and constitute the second-most preventable 
source of death in the US 2. Nutrition in the industrialized world is based 
predominantly on saturated fatty acids which leads to increasing body fat content, 
especially in concert with carbohydrate enriched, high-calory diets 3. Obesity is highly 
correlated to the Metabolic Syndrome, a cluster of nutrition-derived pathologies such 
as coronary hypertension, insulin resistance and Type 2 Diabetes (T2D) 4. Another 
epidemiologic feature associated with obesity and T2D is a condition called non-
alcoholic fatty liver disease (NAFLD), usually coined to circumscribe a pathology 
reminiscent of liver damage caused by alcohol abuse. The liver as central metabolic 
organ possesses essential functions in synthesis and catabolism of nutrients. 
Postprandially, carbohydrates, lipids, vitamins and mineral salts are resorbed by the 
intestinal tract, funnelled into the liver and metabolised therein. During fasting 
periods, the liver releases stored nutrients in order to ensure proper functioning of 
metabolite-sensitive extrahepatic tissues like the brain. The liver also controls the 
body’s protein, glucose and lipid metabolism 5 and synthesises essential lipid carrier 
proteins such as lipoproteins and albumins which are abundantly secreted into the 
circulation 6. Another hepatic function is the synthesis and secretion of bile, which 
aids in emulsifying and thus resorbing dietary lipids. In addition, the liver possesses 
important detoxification properties as it clears xenobiotics and metabolic waste such 
as bilirubin, an abundantly heme degradation product. Finally, it removes peptide 
hormones from the circulation and exhibits immunomodulatory as well as vitamin 
storage functions 7. 
 
2.1.1. Uptake and systemic distribution of lipids  
 
The liver is crucial for metabolizing dietary lipids. These lipids are composed primarily 
of free fatty acids (FFA) and triglycerides (TG), a tricarboxylic acid esterified with 
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saturated and unsaturated fatty acids (FA). A three step process is necessary for 
proper absorption of FFA and TG in the intestinal lumen and subsequent transport 
into the liver:  
(i) Nutritional triglycerides are emulsified by endogenous detergents such as 
bile acids (BA) and enzymatically cleaved by the pancreatic lipase (PL) in the 
intestinal tract yielding free fatty acids and monocarboxylic acid esters. Other dietary 
sources of fatty acids are hydrolysed phospholipids and cholesterol esters.  
(ii) Triglyceride cleavage products are subsequently absorbed by the intestinal 
epithelium in the distal jejunum and ileum via facilitated transport across the epithelial 
cell layer 8.  
(iii) Finally, triglycerides are resynthesised and loaded onto lipoprotein 
particles (chylomicrons) which enter the bloodstream and efficiently deliver dietary 
triglycerides into hepatic, adipose and other target tissues. In the liver, hepatic lipase 
(HL) cleaves triglycerides off the lipoproteinparticle surface and translocates fatty 
acids into the cytoplasm 9. Subsequently, fatty acids are catabolically degraded by 
the mitochondrial and peroxisomal beta-oxidation machinery leading eventually to 
synthesis of ATP energy equivalents. Alternatively, lipids are incorporated into newly 
synthesised triglycerides for long-term storage. Of note, the hepatic fat-storage 
capabilities are limited; the most abundant lipid store is represented by the peripheral 
white adipose tissue (WAT). Moreover, fatty acids are utilized for synthesis of hepatic 
inflammation mediators such as prostaglandins and leukotrienes. Finally, via 
enzymatic remodelling of the fatty acid carbon backbone, fatty acids cleavage 
products indirectly serve as substrates for synthesis of glucose (gluconeogenesis). 
The liver possesses potent lipogenic properties: Triglycerides are synthesized 
in hepatocytes by esterification of glycerol and fatty acids hailing from two sources: 
Non-esterified fatty acids (NEFA) derived from lipolysis of peripheral fat stores 
(adipose tissues) and dietary fatty acids. 
Newly synthesised triglycerides and excess dietary TG are packaged onto 
very-low density lipoparticles (VLDL) and shuttled into the periphery. Subsequently, 
the lipoprotein lipase (LPL), which is abundantly expressed on adipocytes in the 
periphery efficiently cleaves triglycerides from VLDL particles and releases glycerol 
and fatty acids into the adipocyte cytoplasm 10. Thus, in the periphery, consecutive 
triglyceride hydrolysis of lipoproteinparticles leads to an increase in their protein/lipid 
ratio. So called ‘remnants’ of hydrolysed lipoproteinparticles are recycled in the liver 
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via clathrin-mediated endocytosis. Alternatively, excess lipoparticles are conveyed to 
the hepatic proteasome machinery for protein degradation 11.  
 
2.1.2. Glycolysis and hepatic beta-oxidation  
 
The liver constitutes the key regulator of energy homeostasis in the body. Two major 
substrates can be metabolised by hepatic tissue to yield energy equivalents such as 
ATP and pyruvat eventually utilised to catalyze energy-consuming processes in the 
body: 
(i) Glucose, (a six-carbon (6-C) carbohydrate) is enzymatically processed in an 
oxygen-independent process called glycolysis yielding two pyruvat molecules (3-C). 
Pyruvat is decarboxylated into a two-carbon residue (2-C, Acetyl residue) esterified to 
Coenzyme A (Acetyl-CoA). The Acetyl-CoA pool is constantly replenished by 
oxidative catabolism of proteins, lipids and carbohydrates. Subsequently, Acetyl-CoA 
is funnelled into the cytoplasmic citrate cycle, where two consecutive 
decarboxylations of the acetyl residue yield eight reduced reduction equivalents 
(NADH/H and FADH2). These reduction equivalents are used to replenish cellular 
ATP stores via oxidative phosphorylation of ADP, a reaction catalyzed by respiratory 
complexes localized in the outer mitochondrial membranes.  
(ii) Fatty acids, long-chain carbohydrates hailing either from hydrolysed 
triglycerides or hepatic de novo lipogenesis are catabolised by beta-oxidation in 
mitochondria and peroxisomes. Mitochondria are specialised in beta-oxidation of 
saturated short, medium and long-chain fatty acids. In contrast, peroxisomes 
accommodate enzymes specialised in metabolising more exotic and branched fatty 
acids. Prior to beta-oxidation, fatty acids are activated by esterification to Coenzyme 
A yielding high energy Acyl-(n)-CoA thioesters. Subsequently, repetitive cleavage of 
two-carbon residues from the Acyl carbon backbone leads to Acetyl-CoA and 
truncated Acyl-(n-2)-CoA molecules. Acetyl-CoA is processed via translocation across 
the mitochondrial membranes and funnelled into the citrate cycle (see above). 
Alternatively, Acetyl-CoA is utilised for biosynthesis of cholesterol. Under conditions 
of energy deprivation, Acetyl-CoA may serve as substrate for the biosynthesis of 
ketone bodies. These compounds serve as energy carriers nourishing glucose-
dependent tissues (e.g. the brain) under conditions of glucose deprivation.  
 
                                                                                                                     Introduction 
 
15 
2.1.3. Hepatic de novo lipogenesis  
 
The biosynthesis of fatty acids takes place in the cytoplasm of most somatic cells. 
Enzymatic carboxylation of Acetyl-CoA residues yields activated three-carbon-CoA 
compounds (Malonyl-CoA); a reaction catalyzed by the Acetyl-CoA Carboxylase 
(ACC), the rate limiting enzyme of hepatic de novo lipogenesis. The biosynthesis of 
fatty acids is orchestrated by a multi-enzyme complex called fatty acid synthase 
(FAS). FAS catalyses the condensation of long-chain, saturated fatty acids under 
consumption of Malonyl-CoA substrates. During fatty acids synthesis, precursor 
thioesters (Acyl-CoA) get elongated by two carbon residues (2-C) in each step, 
leading to saturated 16-C (palmityl-CoA) or 18-C (stearyl-CoA) fatty acids. Branched 
and unsaturated fatty acids are essential for high membrane fluidity and are 
generated by enzymatic oxidation of saturated fatty acids. So-called ‘essential fatty 
acids’ have to be provided by the nutrition as they cannot be synthesised in the body. 
Hepatic de novo lipogenesis of fatty acids is tightly controlled by allosteric inhibition of 
rate limiting enzymes (e.g. ACC). Independently, metabolic master regulators like 
insulin lead to increased transcription of lipogenic enzymes (see below); whereas 
others repress lipogenesis indirectly by inhibiting FAS through elevated intracellular 
cAMP concentrations (e.g. elicited by glucagon or catecholamines). Long-chain, poly-
unsaturated fatty acids also inhibit FAS activity, constituting an efficient negative 
feedback loop essential for times of abundant fatty acid levels 12.  
 
2.2. Transcription factors and hepatic lipid metabolism 
 
Eukaryotic chromatin consists of long stretches of DNA intertwined to spatially 
compact structures called nucleosomes. Each nucleosome consists of octamer 
nucleoprotein (histones) complexes bound to chromosomal DNA 13. Efficient 
transcription of exonic DNA sequences into complementary messenger RNA (mRNA) 
strands thus depends on conformational rearrangement of nucleosomes facilitating 
binding to basal transcription machinery components such as RNA polymerase II.  
Transcription factors are DNA-binding proteins characterized by strong binding 
affinities towards defined DNA sequences (responsive elements; RE). Transcription 
factors are essential for the recruitment of additional transcription cofactors like 
p300/CBP which possess potent histone acetylases (HAT) activity crucial for 
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removing acetyl residues from nucleosome lysine moieties. These modifications lead 
to electrostatic repulsion of nucleoproteins resulting in accessible, ‘open chromatin’ 
structures 14, 15. Histone Deacetylases (HDAT) reverse this process leading to ‘closed 
chromatin’ and abrogated gene expression 16. Classical transcription factors are 
activated by ‘upstream kinases’, which itself are triggered by extracellular stimuli such 
as cytokines or growth factors binding to cognate receptors. Alternatively, nuclear 
hormone transcription factors are activated directly via binding of membrane-
permeable ligands. Generally, activated transcription factors integrate extracellular 
signals, leading to specific gene expression changes. This flexibility enables the cell 
to react to everchanging extracellular nutrient supplies. Aberrant transcription factor 
activity and concomitant dysregulation of target gene expression was demonstrated 
to account for a rising number of metabolic disorders 17. 
 
2.2.1. Transcriptional regulation of hepatic beta-oxidation 
 
Beta-oxidation of fatty acids takes place in subcellular organelles such as 
mitochondria and peroxisomes. In addition, the endoplasmatic reticulum harbours 
high levels of cytochrome p450 family members (e.g. CYP4a) which catalyze the so-
called omega-oxidation, the hydroxylation and subsequent catabolic breakdown of 
saturated and unsaturated fatty acids yielding Acetyl-CoA and dicarboxylic acids in 
times of nutrient excess. Dicarboxylic acids in turn constitute potent ligands for 
PPARalpha, a member of the PPAR class of transcription factors. This class of 
nuclear hormone receptors was initially discovered for binding compounds known to 
induce proliferation of peroxisomes 18. The PPAR class of transcription factors 
consists of four isoforms, which exhibited distinct functions in hepatic lipid 
metabolism 19, 20. Whereas PPARgamma constitutes the key regulator for lipid 
biosynthesis in liver and adipose tissue (section 2.2.2 and 21), PPARalpha regulates 
the beta-oxidation of lipids in hepatocytes in concert with PPARbeta and PPARdelta 
22. PPARalpha was identified as key transcriptional regulator for beta-oxidation of 
fatty acids in hepatocytes 23. PPARalpha senses extracellular serum levels of dietary 
lipids and, under satiety conditions, stimulates transcription of lipid-degrading 
enzymes 24. Upon prolonged fasting, fatty acids get shuttled from peripheral fat 
depots into hepatocytes, leading to activation of PPARalpha and induction of beta-
oxidation in order to fulfil the body’s energy demands 25. PPAR isoforms require 
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heterodimerization with the retinoic acid receptor (RXR) in order to initiate 
transcription of PPAR target genes 23. PPAR-RXR complexes specifically recognize 
and bind DNA elements containing AGGTCAnAGGTCA sequences termed PPAR 
responsive elements (PPRE) in the 5’-promoter region of target genes 23. Most 
rodent and human genes, which possess crucial functions in transport or catabolism 
of fatty acids contain at least one PPRE in their promoter sequence (reviewed in 26). 
Experimentally validated PPAR target genes encode apolipoproteins, fatty acid 
translocases, lipases, cytochrome p450 family members and Acyl-CoA oxidases, yet 
many putative PPAR target genes still lack experimental proof 26. Very-long chain 
fatty acids represent the most established in vivo ligand of PPARalpha 27. The 
importance of PPARalpha in regulating fatty acid catabolism is underpinned by the 
phenotypes observed in PPARalpha knockout mice. These animals are unable to 
translocate fatty acids into the hepatocyte cytoplasm 28 and exhibit defects in 
clearance of fatty acids accumulated in hepatocytes upon prolonged fasting 29. The 
same phenotype is observed upon feeding of special diets known to channel the flux 
of lipids into the liver 30. The same hold true for mice harbouring a genetic abrogation 
of PPARalpha downstream targets (e.g. ACOX1) 27. 
 
2.2.2. Transcriptional regulation of hepatic de novo lipogenesis 
 
Three nuclear hormone transcription factors, which are independently regulated by 
glucose and insulin orchestrate the hepatic biosynthesis of fatty acids (de novo 
lipogenesis) 31, 32:  
(i) Insulin induces the de novo lipogenesis of fatty acids by activating the sterol 
regulatory element binding protein 1-c (SREBP-1c), a membrane-tethered member of 
the basic helix-loop-helix leucine zipper family of transcription factors (bHLH-Leu-Zip) 
33. Upon triggering by insulin, SREBP-1c translocates into the nucleus and initiates 
the transcription of lipogenic target genes 34, 35. Hepatic insulin resistance, the 
insensitivity of the liver to respond to insulin action leads to unbalanced increases in 
serum insulin levels (hyperinsulinaemia) and concomitant rises in lipogenic SREBP-
1c activity 35, 36. Thus, insulin resistance is characterized by a high biosynthesis of 
fatty acids contributing to the development of steatosis 37. The significance of 
SREBP-1c-dependent lipogenesis has been demonstrated in vivo by generating 
SREBP-1c transgenic mice. These mutants exhibit a severe accumulation of 
                                                                                                                     Introduction 
 
18 
intrahepatic fat 38. On the contrary, loss of SREBP-1c in hepatocytes leads to 
significant reductions of the hepatic lipid load 39. 
(ii) The carbohydrate response element binding factor/protein (ChREBP), another 
bHLH-Leu-Zip transcription factor mediates hepatic responses to varying plasma 
glucose levels 40. Briefly, glucose induces binding of ChREBP to the promoter region 
of rate-limiting glycolytic enzymes such as pyruvat kinase (PK), in turn leading to an 
increased catabolism of glucose, the cleavage products of which are metabolized in 
the tricarbon cycle. Studies utilizing ChREBP knockout mice pinpointed towards 
additional lipogenic properties of ChREBP under hyperglycaemic conditions 41. High 
serum glucose levels (hyperglycaemia, closely associated with insulin resistant 
states) thus lead to ChREBP-1c-mediated induction of hepatic lipid biosynthesis and 
a concomitant accumulation of intrahepatic lipids. 
(iii) PPARgamma, a member of the PPAR nuclear hormone receptor class of 
transcription factors exhibits key functions in the biosynthesis of fatty acids in liver. 
Abundantly expressed in adipocytes, PPARgamma was initially thought to be solely 
implicated in the differentiation of peripheral adipose tissues 42, 43. Later, it was 
recognized that PPARgamma is expressed at low levels in hepatocytes. Interestingly, 
loss of hepatic PPARgamma expression interferes with the development of steatosis 
in respective mouse models 44, whereas PPARgamma overexpression leads to 
development of fatty liver disease 45, 46. Strikingly, a rising number of steatotic mouse 
models display increased hepatic PPARgamma transcript and protein levels 47. 
Finally, an indirect crossactivation of PPARgamma-dependent transcription by 
SREBP-1c-mediated biosynthesis of PPARgamma ligands was demonstrated, 
thereby exacerbating fatty liver disease 48. 
 
2.3. Insulin signaling and insulin resistance 
 
Binding of insulin to the heterotypic insulin receptor (IR) triggers insulin-dependent 
signal transduction. Two intracellular beta-chains and two extracellular alpha-chains 
(alpha2beta2) form the functional IR. Upon ligand binding, insulin induces 
conformational changes in the IR leading to autophosphorylation of specific tyrosine 
(Tyr960) residues in the IR beta-subunit (IRb) and subsequent exposure of docking 
sites for the Insulin Receptor Substrate 1 (IRS-1) adaptor protein 49. IRS proteins (in 
humans comprising the IRS-1, IRS-2, and IRS4 isoform) are activated by IR-
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mediated tyrosine phosphorylation leading to simultaneous recruitment of specific 
effector proteins such as Grb2 and Shc, which are responsible for triggering non-
canonical IR-dependent signal transduction 50, 51, e.g. the Mitogen Activated Protein 
Kinase (MAPK) and Stat5 pathways upon insulin challenge 52-54. MAPK eventually 
phosphorylates IRS-1 at specific serine residues leading to abrogation of IR-
dependent signal transduction 55. In contrast, the canonical insulin-dependent 
signaling are conveyed via activation of phosphatidyl-inositol-3-kinase (PI3K) effector 
proteins, which in turn synthesise phosphatidyl-inositol (3,4,5) trisphosphate (PIP3), a 
potent intracellular second messenger 56. PIP3 triggers activation of the AKT family of 
serine and threonine kinases leading to the translocation glucose transporters to the 
plasma membrane (e.g. GLUT4).  
 Studies using IR knockout animals shed further light onto the role of individual 
IR signal transduction components: Hepatocyte-specific loss of IR proteins led to 
severely insulin resistant states and concomitant hyperinsulinaemia, decreased 
insulin clearance and adenoma formation 57. Deletion of either IRS-1 or IRS-2 in the 
liver surprisingly had little effects 58, 59, yet combined loss of IRS-1 and IRS-2 was 
embryonically lethal 60. Thus, redundant roles of IRS-1 and IRS-2 in hepatic 
metabolism were assumed 61 although this concept recently came under scrutiny as 
refined genetic analyses rather claimed distinct functions for IRS-1 in the regulation 
of hepatic glucose metabolism and for IRS-2 in regulation of hepatic lipid metabolism 
51. 
The term insulin resistance was coined to circumscribe a condition frequently 
observed in metabolic disorders such as obesity and NAFLD 62. Insulin resistant 
states are generally characterized by blunted responses towards insulin action and 
harbour molecular impairments in IR-dependent signal transduction. Clinically 
relevant, insulin resistance often precedes severe metabolic conditions like T2D and 
NAFLD for decades and is associated with high risks for contracting cardiovascular 
diseases 63. Interestingly, an inverse correlation exists between hepatic insulin 
sensitivity and the accumulation of intrahepatic lipids (steatosis) 64, yet the causal 
relationship between steatosis and insulin resistance remains enigmatic 65, 66. It is 
undisputed that central and visceral obesity constitute a risk factor for developing 
insulin resistance. Surprisingly, serious insulin resistance is also observed among 
patients suffering from dystrophies of peripheral adipose tissues (lipodystrophy) 67.  
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2.4. Insulin resistance and liver steatosis 
 
The development of fatty liver disease is closely associated with chronic alcohol 
abuse (alcoholic fatty liver disease; AFLD) 68 as well as calory-excess; both leading 
to obesity and insulin resistance and NAFLD 22, 69. NAFLD comprises a wide 
spectrum of diseases, ranging from the simple accumulation of intrahepatic lipids 
(steatosis) to inflammatory processes such as non-alcoholic steatohepatitis (NASH), 
fibrosis and degenerative processes such as liver cirrhosis and hepatocellular 
carcinoma (HCC) 70. Steatosis as component of NAFLD was initially regarded as a 
benign condition, but was recently recognized to lead to more severe liver 
pathologies such as steatohepatitis and hepatic fibrosis. The incidence of NAFLD is 
considerable in the industrialized world, affecting up to 25 % of the population 71, 
more than 50 % of chronically obese and up to 90 % of morbidly obese patients 72, 73. 
The significance of NAFLD is reflected in the observation that steatosis constitutes 
the leading cause of pathological liver tests in the US 70. In addition, liver biopsies of 
one third of adult US citizens exhibit steatosis 74. Microscopically, steatosis is 
diagnosed by the appearance of abundant cytoplasmic lipid droplets 75. 
Macroscopically, steatosis is diagnosed whenever the amount of intrahepatic fat 
exceeds >5 % of total liver weight 76.  
 The causal relationship between steatosis and insulin resistance remains 
uncertain (see section 2.2 and 2.3), although a significant correlation between insulin 
resistance and fatty liver disease exists 77, 78. A similar correlation is observed in 
several mouse models for steatosis (section 2.4.1). Mechanistically, hepatic insulin 
resistance-derived hyperinsulinaemia was proposed to trigger SREBP-1c-mediated 
lipogenesis which subsequently induces steatosis 79, 80 (see section 2.2.2 and Figure 
1). An alternative notion, the clinical manifestation of insulin resistance secondary to 
liver steatosis remains provocative, although recently researchers reported that 
transgenic overexpression of DGAT1, the rate-limiting enzymes of hepatic 
lipogenesis induces steatosis without accompanying insulin resistance 65. 
 




Figure 1. Interplay between insulin resistance and liver steatosis 
Metabolic perturbations leading to the hepatic accumulation of triglycerides (steatosis) in insulin 
resistant states: One aspect of hepatic insulin resistance is the concomitant hyperinsulinaemia leading 
to increases in gluconeogenesis and induction of ChREBP-mediated lipogenesis. Insulin resistance in 
the adipose tissue triggers the activity of hormone-sensitive lipase (HSL), leading to hydrolysis of 
triglycerides in adipocytes and increased serum levels of free fatty acids which are eventually stored in 
the liver. High serum levels of insulin trigger SREBP-1c activation and results in increased hepatic 
lipogenesis. In concert with ChREBP, SREBP-1c activates enzymes essential for hepatic lipogenesis 
(ACL, ACC, FAS and SCD). Another aspect of insulin resistance is the impaired capability of 
hepatocytes to remove excess FFA by beta-oxidation. 
 
2.4.1. Mouse models of NAFLD 
 
NAFLD affects approximately one quarter of the healthy population in the western 
world 81, constituting a significant risk factor for contracting more severe liver 
diseases. Therefore it represents a logic disease stage applicable for therapeutic 
intervention. Apart from obvious modification of lifestyle habits this could also involve 
pharmacological manipulation. The need for animal models mimicking the complex 
onset and progression of NAFLD through genetic and environmental factor is 
apparent. The laboratory mouse, Mus Musculus shares many physiological, 
anatomical and metabolic features with humans and has been accepted as the 
species of choice in metabolic research. Transgenic mice harbouring specific genetic 
manipulations leading to defined metabolic phenotypes are well-suitable for 
therapeutic interventions in defined, homogenous populations. Generally, murine 
models for NAFLD are subdivided into two classes:  
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(i) Mouse models harbouring specific genetic modifications leading to deletion 
or overexpression of lipid metabolism-related genes. This strategy is exemplified in 
the ablation of anorexic genes (e.g. leptin) leading to hyperphagia and weight gain 
(ob/ob mouse 82; db/db mouse 83). An alternative approach is based on the systemic 
relocation of fatty acids from peripheral adipose tissues to the liver (CD36-/- mouse 84) 
or on increased of hepatic de novo lipogenesis by transgenic overexpression of 
lipogenic transcription factors (PPARgammatg 45, 46, SREBP-1ctg 85, 86 and ChREBPtg 
41). Finally, the hepatic combustion of fatty acids can be disrupted, leading to the 
defective clearance of lipids by beta-oxidation and the development of steatosis 
(ACOX-/- mouse; 27). 
(ii) Mice develop NAFLD-like symptoms upon feeding high-calory, carbohydrate-
rich diets 87. Moreover, specific diets, e.g. deficient for methionine and choline (MCD 
diet) interfere with the hepatic beta-oxidation machinery 88 leading to steatosis, late-
stage steatohepatitis and hepatic fibrosis. The exact mechanism underlying 
pathogenesis remains elusive, yet an increase in reactive oxygen species (ROS) was 
noted 89.  
Taken together, the rising morbidity of diseases like insulin resistance, obesity 
and NAFLD make animal models closely mimicking human disease imperative. 
Genetic and nutritional mouse models for NAFLD are well-suited for dissecting the 
complex metabolic processes underlying NAFLD pathogenesis.  
 
2.5. Fibrosis of the liver  
 
Liver fibrosis constitutes an abundantly diagnosed intermediate step in the 
progression of chronic liver diseases. It is widely believed to be secondary to multiple 
viral, bacterial and metabolic liver insults 90. One hallmark of liver fibrosis is the 
remodelling of extracellular matrix (ECM) constituents leading to abundant collagen 
deposition around hepatic lobes. High amounts of collagen eventually impede vital 
hepatic processes and lead to degenerative processes like fibrosis, cirrhosis and 
HCC 91. These processes are accompanied by activation and transdifferentiation of 
non-epithelial, mesenchymal cells termed hepatic stellate cells (HSC) 92. A multitude 
of stimuli such as high ROS level, immunological activation by parasites 
(Schistosoma mansony) or intrahepatic accumulation of lipids was demonstrated to 
activate HSCs which in turn transdifferentiate into pro-fibrogenic cells called 
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myofibroblasts (MFB). This is accompanied by the appearance of mesenchymal 
differentiation markers such as alpha-smooth-muscle actin (SMA) and the 
subsequent deposition of collagens and proteoglycans 93 in the space of Dissé 
secondary to perturbations in ECM turnover auch as an altered matrix 
metalloproteinase (MMPs) and tissue inhibitor of MMPs (TIMPs) secretion. Following 
transdifferentiation, MFB are rendered responsive to pro-fibrogenic signals such as 
platelet-derived growth factor (PDGF) and transforming growth factor beta (TGFb) 94. 
This in turn leads to activation of MAPK signaling 95, further proliferation of MFB and 
aggravation of disease. If left untreated, liver fibrosis cumulates in cirrhotic organ 
failure, liver carcinoma and death (Figure 2).  
 
reproduction with author’s consent from 96 
Figure 2. Canonical pathogenesis of liver fibrosis (fibrogenesis) 
According to the "canonical principle of fibrogenesis” primary hepatocyte damage leads to cell death 
and activation of HSC. The latter undergo epithelial-mesenchymal transition (EMT) into MFB. This 
process is accompanied by synthesis and secretion of ECM components such as collagen. Repetitive 
damage of fibrotic tissues leads to necrotic processes such as liver cirrhosis if left untreated. The MFB 
pool is replenished by bone marrow-derived fibrocytes, circulating monocytes or transdifferentiation 
hepatocytes and bile duct cells. Constantly refuelled, the MFB pool actively synthesizes ECM 
components, a process mediated by canonical fibrosis mediators such as platelet derived growth 
factor (PDGF), IGF-1, endothelin 1 (ET-1) or ROS. Abbreviations: ASH – alcoholic steatohepatitis; 
HBV/HCV, hepatitis B/C virus. 
 
2.5.1. Molecular mechanisms underlying liver fibrogenesis 
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Specific cellular events accompany hepatic fibrogenesis: Firstly, HSC undergo 
transdifferentiation into MFB, upon which they actively secrete collagen into the 
intercellular space of Dissé. Secondly, activated MFB possess high proliferation 
capacities leading to elevated numbers of fibrogenic cells. These processes are 
mirrored in activation of two distinct PDGF-dependent mitogenic signaling pathways 
97, 98:  
 (i) PDGF receptor (PDGFR) activation triggers activation of Raf, Mitogen 
Induced Extracellular Kinase (MEK) and Extracellular Signal Regulated Kinase (ERK) 
signaling 99, 100. Simultaneous activation of multiple MAPK pathways leads to 
accelerated MFB cell cycle progression 101 and cellular proliferation 102. The 
significance of PDGFR-driven cell proliferation is reflected in the observation that 
pharmacological targeting of MAPK family members delays MFB proliferation and 
decelerates progression of liver fibrosis 102. 
 (ii) In addition, PDGFR phosphorylates Focal Adhesion Kinase (FAK) leading 
to active PI3K signaling 103. FAK and PI3K then synergistically drive MFB proliferation 
104. Furthermore, phosphorylated PI3K activates AKT, an essential survival regulator 
stimulating cellular proliferation 105 leading to phosphorylation of p70 kinase: Taken 
together, these cellular events, result in sustained protein synthesis and the 
concomitant growth of fibrogenic cells 106. The paramount significance of PGDFR-
FAK-PI3K-AKT pathway activation for fibrogenesis was confirmed by studies 
demonstrating that pharmacological inhibition of pathway constituents severely 
impairs MFB proliferation and ameliorates liver disease 104, 107. 
Transforming growth factor beta (TGFb) constitutes another crucial profibrogenic 
cytokine. Upon ligand binding to the TGFb receptor (TGFbR), TGFb-derived signals 
are relayed to the nucleus by activation of cytoplasmic SMAD2 and SMAD3 
transcription factors. SMAD2 and SMAD3 are closely associated with the TGFbR, 
constituting activated core complexes. Secondary association with SMAD4 yields 
trimeric transcription-competent complexes initiating RNA transcription of 
profibrogenic genes like type I and III collagens (COL1 and COL3) 108.  
Taken together it is widely recognized that activation of PDGF signaling leads to 
potent HSC proliferation which triggers multiple cellular signaling cascades 
simultaneously (e.g. the MAPK and FAK-PI3K-AKT-p70 axes). MFB which have 
undergone the process of transdifferentiation from quiescent HSC require autocrine 
TGFb stimuli to sustain their fibrogenic properties. 




2.6. Signal transducer and activator of transcription 5 (Stat5) 
 
Signal transducer and activator of transcription 5 (Stat5) constitutes a critical 
transcription factor involved in controlling developmental and differentiation 
processes throughout the body. A component of linear Jak (Janus Kinase)/Stat signal 
transduction pathway, Stat5 is essential for the signal transduction of external stimuli 
triggered by upstream cytokine and growth factor receptor binding (Figure 3). 
Mechanistically, ligand binding induces conformation changes in receptors which in 
turn activate Jak kinases (Jak2 in the case of Stat5). This leads to phosphorylation 
and nuclear translocation of latent cytosolic Stat transcription factors. Activated Stat5 
proteins recognize and bind specific DNA sequence motifs (so-called Stat5 
responsive elements or Stat5 RE) located in the 5’ promoter region of Stat5 target 
genes. Additional cofactors essential for transcriptional initiation are recruited, leading 
to the formation of transcription-competent protein complexes and transcription of 
genes implicated in cell proliferation, development, differentiation and survival 
(reviewed in 109). A schematic illustration of growth factors and cytokines known to 
activate Stat5 is given in (Figure 3). Latent Stat5 monomers form homodimers upon 
phosphorylation, yet heterodimeric Stat3/Stat5 complexes have been reported, 
putatively in order to modulate Stat5 target gene specificity 110. Stat5 comprises two 
distinct isoforms, Stat5a and Stat5b, encoded by two different genes, precursors of 
which are already found in Drosophila 111. The Stat5a/b isoforms readily form 
heterodimers and thus complicate the understanding of Stat5 biology. Stat5a is 
predominantly expressed in the hematopoietic system and mammary epithelia, 
whereas Stat5b constitutes the most frequent isoform expressed in hepatocytes. 
Because of this tissue-specific pattern, we focussed predominantly on the role of 
Stat5b in the current work. 
 




(Kornfeld et al., Front. Biosci., 2008) 
Figure 3. Mechanisms of Stat5 activation by growth factors and cytokines 
Stat5 is activated by ligands binding to cytokine and growth factor receptors. In this representation, 
cytokines and growth factor were clustered according to structural and functional homologies. After 
ligand binding, receptors undergo conformational changes leading to recruitment of Jak2 molecules in 
turn phosphorylating monomeric Stat5 molecules in the cytosol. Following nuclear translocation 
phosphorylated Stat5 dimers bind to Stat5 RE found in Stat5 target gene promoters. Among others, 
Stat5 target genes regulate postnatal body growth, cytochrome p450-dependent detoxification and 
hepatic lipid metabolism. Stat5 hyperactivation, e.g. by transformed tyrosine kinases such as Bcr-Abl, 
can induce leukaemic transformation. Hypoactived Stat5 results in defective erythropoiesis and 
anaemia. Finally, Stat5 molecules possess a propensity to form oligomeric structures inducing 
conformational chromatin changes (DNA loop formation). 
 
Like most Stat molecules, Stat5 consists of a flexible aminoterminal domain (N-
terminus) followed by a alpha-helical coiled-coil (CCD) and a src homology 2 (SH2) 
domain; the latter is located in vicinity to the tyrosine residue critical for activation by 
Jak kinases such as Jak1-3. The carboxyterminal transactivation domain (TAD) 
constitutes the most divergent part of Stat5. A schematic illustration of the protein 
structure of Stat5a is given in Figure 4. 
 
 
Figure 4. Protein structure of Stat5a 
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Stat5a proteins are encoded by seventeen exons leading to translation of five functionally 
discriminable domains: The N-terminal domain (NTD), responsible for cofactor interaction, (e.g. with 
the glucocorticoid receptor (GR, see below)), the coiled-coil domain (CCD), essential for lateral 
diffusion of Stat5 molecules on the DNA. Efficient DNA binding is also warranted by the DBD. The 
SH2 domain is indispensable for Stat5 protein interaction with its upstream kinase Jak2. The C-
terminal transactivation domain (TAD) harbours critical tyrosine and serine residues, which are 
phosphorylated by Jak2 and lead to efficient dimerization and nuclear translocation of Stat5 
molecules. Transcriptional coactivators like CBP/p300 also interact with this domain. 
 
Unphosphorylated Stat5 forms rigid, antiparallel dimers with the N-terminal domain 
retaining its flexibility leading to protrusion from the dimeric Stat5 core complex. 
Formation of higher order complexes of Stat5 (particular Stat5 tetramers) depends on 
the Stat5 N-terminus. In addition, the Stat5 N-terminus constitutes the docking 
platform for essential transcription cofactors like TUDOR domain coactivators 112, 
CBP/p300 113 and (as revealed in this work), the glucocorticoid receptor (GR) 114. A 
schematic representation of established Stat5 protein interactors is given in Figure 5. 
 
 
(Kornfeld et al., Front. Biosci., 2008) 
Figure 5. Stat5 oligomerization and cofactor interaction 
Oligomeric Stat5 molecules (Stat5 tetramers) potently rearrange the chromatic architecture and induce 
DNA loop formation. In addition, Stat5 tetramers recruit transcriptional cofactors/corepressors which in 
turn modulate Stat5 target gene specificity. Several components of the basal transcription machinery 
are reported to interact with Stat5 and are illustrated to the right. 
 
2.6.1. Stat5 in health and disease 
 
Among others, Stat5 possesses critical functions in regulating hematopoiesis and 
hepatic lipid metabolism. Hyperactivation of Stat5 is associated with severe 
conditions such as myeloproliferative diseases 115, 116, inflammation 117, autoimmunity 
118 and cancer 119. However, Stat5 hypoactivation can cause diseases such as 
myeloid hyperplasia and anaemia 120, 121, dwarfism 122, 123, immunodeficiency and 
metabolic problems 124. One important aspect of this work was unravelling the 
significance of hepatic Stat5 signaling in regulating the postnatal body growth and 
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hepatic lipid metabolism. Hitherto known functions of Stat5 in controlling body growth 
and lipid metabolism are summarized in the following (section 2.6.1.1 and 2.6.1.2). 
 
2.6.1.1. Stat5 and postnatal body growth 
 
Serum Growth hormone (GH) potently activates hepatic Stat5 which in turn mediates 
the effects of GH on longitudinal body growth by transcription of bioactive Insulin-Like 
growth factor (IGF-1) 125. Using transgenic mouse models, which express 
dysfunctional GH receptors (GHR) 126 or harbours deletions of hepatic Stat5 123, 127, it 
was confirmed that GH signal transduction is largely mediated via Stat5 activation 122, 
124. Impaired secretion of GH or mutations of the GHR leads to dwarfism secondary 
to reduced levels of IGF-1, a condition termed Laron’s syndrome 128. In line with this, 
human patients harbouring Stat5 missense mutations are severely growth retarded 
129. Interestingly, a role for the glucocorticoid receptor (GR) in synergistic transcription 
of Stat5 target genes 114, 122 was demonstrated. 
 
2.6.1.2. Stat5 and hepatic lipid metabolism 
 
Stat5 signal transduction in the liver differs from other tissues in the regard that 
hepatocytes express predominantly the Stat5b isoform transcribing Stat5 target 
genes. An essential role of hepatic Stat5b, among others, is transcription of growth-
promoting genes (e.g. IGF-1 and ALS) upon rhythmic GH pulses 129, 130. Strikingly, 
hepatic loss of Stat5b leads to impairments of postnatal body growth and elevated 
levels of serum GH 123. Studies involving GHR knockout mice elegantly demonstrated 
that elevated levels of lipolytic GH lead to substantial reductions of peripheral 
adipose tissues (lipodystrophy), an effect mediated by Stat5 in adipocytes 131. Further 
proof for the role of hepatic Stat5 in indirectly influencing adipose tissues came from 
mice expressing aminoterminally truncated Stat5 proteins (termed Stat5ΔN mice) 127. 
These animals harboured reduced lipid reservoirs (lipodystrophy) 122, 127, 132 and in 
this regard resembled GHR knockout mice., The lipodystrophy was attributed to 
impaired negative feedback signaling via IGF-1 In both strains (GHR-/- and Stat5ΔN) 
126, 133, the main feedback inhibitor of GH secretion in the anterior pituitary gland.  
                                                                                                                     Introduction 
 
29 
Recently, the ablation of hepatic Stat5 was reported utilising Albumin-Cre-
mediated recombination of floxed Stat5 alleles (Stat5AlbCre) 124, a targeting approach 
leading to an approximate 80% reduction in protein levels. Missing defects in 
postnatal body growth were attributed to incomplete losses of Stat5 in hepatocytes. 
Interestingly, mild perturbations of hepatic fat metabolism leading to mild liver 
steatosis were reported. Compensatory activation of Stat1 and Stat3 signaling was 
another consequence of incomplete hepatic Stat5 loss.  
 
2.7. The glucocorticoid receptor (GR) 
 
The GR transcription factor is expressed in most somatic cell types and is activated 
by compounds called glucocorticoids (GC), which are secreted under stress 
conditions by the adrenal gland. The GR constitutes an important executor of the 
neuroendocrine hypothalamus-pituitary-adrenal (HPA) axis. After GC binding, 
cytoplasmic GR dissociates from bound heat shock proteins (e.g. Hsp90), 
translocates into the nucleus and induces the transcription of GR-target genes 134, 135. 
Loss of hepatic GR signaling leads to well-studied defects in glucose metabolism 
such as impaired gluconeogenesis leading to hypoglycaemia under fasting conditions 
136. This was attributed to blunted transcription of key gluconeogenic enzymes like 
phoshoenol pyruvat carboxykinase (PEPCK) 137 and glucose-6-phosphatase (G6P) 
138. Adrenal release of GC is negatively regulated by serum GC itself. Impaired 
negative feedback leads to hypercortisolic conditions which are characterized by 
pathological lipid accumulation in peripheral adipose tissue or dermis 139. Structurally, 
murine GR is composed of several unique domains forming structural units: An 
aminoterminal TAD domain (termed AF-1) was shown to be responsible for 
cooperation with Stat5 140. The AF-1 function is followed by a DBD, which comprises 
two zinc finger domains, warranting specific GR binding to hormone response 
elements. The carboxyterminal ligand binding domain (LBD) guarantees ligand 
specificity and contains amino acid sequences important to homogenous 
dimerization, nuclear localisation signals and possesses another TAD termed AF-2 
(Figure 6). 




Figure 6. Gene and protein structure of the glucocorticoid receptor 
GR proteins are encoded by nine exons encoding the aminoterminal TAD (also termed AF-1) 
responsible for binding to GRE in the promoter region of GR target genes. The DBD encompasses two 
zinc finger moieties and is indispensable for GR homodimerization. Finally, the LBD harbours nuclear 
localisation sequences, a second dimerization domain and the carboxyterminal AF-2 TAD.  
 
2.8. Linear Stat5-GR signal transduction: Two transcription factor 
pathways converge 
 
Activated GR not only potently binds onto GRE sequences leading to activation or 
repression of GR target genes. Strikingly, the GR was demonstrated to bind as 
cofactor to other transcription factors, thus modulating their transcriptome. This 
process does not require DNA binding of the GR 141. The existence of a linear Stat5-
GR signal transduction pathway was initially found in mammary epithelia, in which 
efficient Stat5-GR protein interaction was demonstrated to be a prerequisite for 
transcription of milk proteins during lactation (e.g. beta-Casein) 142. Interestingly, loss 
of hepatic GR leads to stunted postnatal body growth reminiscent of mice deficient 
for hepatic Stat5 114. Thus, it has been postulated that Stat5-GR protein interaction is 
mandatory for transcription of hepatic target genes essential for postnatal growth.  
 
2.8.1. Growth hormone, glucocorticoids and body composition 
 
Growth hormone and GCs, two major effectors of the neuroendocrine HPA axis 
potently activate Stat5 and GR in various organs. Both compounds have profound 
effects on body composition 143, 144. In adipose tissues, GCs possess anti-lipolytic 
properties and stimulate fat accumulation via LPL-mediated triglyceride hydrolysation 
145, whereas GH exerts lipolytic effects by accelerating basal lipolysis in adipocytes 
143. In addition, GH blunts fatty acid synthesis in adipose tissues 146 and impairs 
sensitivity towards insulin action, thereby leading to a reduction of transcript and 
protein levels of crucial lipogenic genes 147. 
Thus, single administration of GH and GC leads to opposite effects on peripheral 
lipolysis 148. Intriguingly, combined stimulation with GH and GC in vivo leads to the 
dramatic mobilisation of peripheral adipose tissues exceeding GH-mediated lipolysis 
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alone 149. This concept was confirmed by in vitro reports demonstrating dramatic 
lipolytic drive in rat adipocytes elicited by co-administration of GH and 
Dexamethasone (DEX, a synthetic GR agonist extensively used in clinics) 150. 
 
2.9. Conditional gene deletion using the Cre/LoxP system 
 
The Cre/LoxP recombination system allows tissue-specific gene deletion in defined 
species such as the laboratory mouse 151. First described in bacteriophages, the 
Cre/LoxP system consists of two components 152: 
(i) DNA sequences essential for the function/structure of targeted proteins are 
flanked by palindromic loxP sequences (yielding a ‘floxed allele’).  
(ii) The tissue-specific expression of the Cre proteins induces DNA 
recombination of floxed alleles resulting in the excision or inversion of respective 
DNA sequences, depending on either parallel or anti-parallel orientation of the loxP 
sites 153. The tissue-specificity of Cre expression is warranted by respective tissue-
specific suituated upstream of the Cre expression cassette. This restricts Cre activity 
solely to promoter-responsive tissues. Usually, gene-sequences are floxed which do 
not interfere with overall expression of the protein; rather small domains essential for 
protein function are flanked by loxP sites. For example, for conditional inactivation of 
the GR, only the first zinc finger in the DNA binding domain is targeted, leading to 
transactivation-defective GR molecules. Another strategy is flanking whole genes loci 
with loxP sites. This is exemplified by conditional deletion of Stat5 by flanking the 
whole chromosomal locus of 110 kb containing Stat5a and Stat5b. Upon Cre activity, 
both Stat5 isoforms are excised. This representative example is illustrated in Figure 
7.  




Figure 7. Tissue-specific loss of Stat5 using Cre/LoxP technology 
The complete murine Stat5a/b locus, spanning 110kb of genomic DNA on chromosome 17, is flanked 
by loxP sites (‘floxed’ locus, Stat5fl/f). The crossing of Stat5fl/fl mice with animals expressing Cre 
recombinase in a tissue-specific manner results in the excision of floxed DNA sequences.  
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2.10. Aim of the thesis 
 
Stat5 possesses well-established functions critical for mediating cytokine and growth 
factors responses in the hematopoietic system. In contrast, the role of Stat5 in solid 
organs such as the liver remains poorly understood. It is widely recognized, that 
Stat5 in hepatocytes regulates postnatal body growth by transactivation of growth-
mediating target genes such as IGF-1. Apart from classical functions as cytokine and 
growth factor responsive transcription factor, Stat5 interacts with the glucocorticoid 
receptor (GR), together constituting a linear Stat5-GR signal transduction axis 
leading to modulation of the Stat5 transcriptome.  
 
Deletion of hepatic Stat5 alone leads to  
 
(i) severe perturbations of postnatal body growth  
(ii) (ii) an increased biosynthesis of lipids leading to fat accumulation in 
hepatocytes and  
(iii) (iii) defects in bile uptake leading to cholestasis, jaundice and secondary 
liver fibrosis.  
 
In this study we aimed to investigate the underlying molecular processes leading to 
aforementioned phenotypes observed upon hepatic ablation of Stat5. Using knockout 
mice in concert with molecular biological techniques such as expression profiling, 
quantitative mRNA analysis, protein biochemistry and immunohistochemistry we 
aimed to shed further light on the role of hepatic Stat5 in health and disease. In 
addition, we put special emphasis on addressing the question whether above 
phenotypes were solely the effect of loss of hepatic Stat5 signaling or necessitated 
additional ablation of the GR. 
 
 




3.1. A linear Stat5-GR axis controls postnatal body growth 
 
Hepatic Stat5 influences postnatal body growth via transcription of growth-related 
genes like IGF-1 and ALS upon GH action 154. Bioactive IGF-1 consists of IGF-1•ALS 
complexes, necessary for longitudinal growth of extremities such as bones and 
internal organs 155. Interestingly, hepatic deletion of the GR (GRAlfpCre) leads to similar 
growth retardations as observed for Stat5 knockout mice (Stat5AlfpCre) 156. In addition, 
classical GH-triggered Stat5 target genes like IGF-1 and ALS were significantly 
reduced in GRAlfpCre animals. Furthermore, Stat5 and the GR were reported to 
physically interact in the liver and the GR binds to Stat5 REs located in the promoter 
sequences of IGF-1 and ALS 114. Collectively, this indicates that Stat5 and the GR 
are constituents of a linear signal transduction pathway in hepatocytes necessary for 
full transcription of growth hormone regulated Stat5 target genes like IGF-1 and ALS. 
This however stands in stark contrast to the hypothesis that postnatal growth is 
mediated by local production of IGF-1 in bone, cartilage and muscles upon GH action 
and that GH action in liver is dispensable 157. However, the possibility remains that 
the dwarfism observed in GRAlfpCre mice is due to indirect consequences independent 
of Stat5, e.g. metabolic disturbances. To address the question whether (i) GH action 
in the liver is necessary for postnatal growth and (ii) whether and how this 
phenomenon involves physical Stat5-GR interaction, we generated mice harbouring 
deletions of Stat5 (Stat5AlfpCre), the GR (GRAlfpCre) or both (Stat5/GRAlfpCre) in 
hepatocytes.  
 
3.1.1. Loss of hepatic Stat5 and/or the GR signaling leads postnatal growth 
deficiency 
 




Figure 8. Growth deficiency in Stat5AlfpCre, GRAlfpCre and Stat5/GRAlfpCre mice 
Growth curves from control mice (control, black dashed line), mice lacking Stat5 in the hepatocytes 
(Stat5AlfpCre, red line), mice lacking GR in hepatocytes (GRAlfpCre, green line), and mice lacking both 
Stat5 and GR in hepatocytes (Stat5/GRAlfpCre, blue line). All mutants show a very similar growth defect 
starting around 3 wk. Error bars indicate mean ± SEM. 
 
 
We wanted to confirm the growth-promoting role of Stat5 123 in mice harbouring 
conditional deletions of Stat5 selectively in hepatocytes using Cre/loxP technology. 
We crossed mice carrying the Cre recombinase under control of the albumin 
promoter and alpha-fetoprotein enhancer elements (AlfpCre) 158 with mice harbouring 
Stat5a and Stat5b genes flanked by loxP sites 119. The resulting mutants (Stat5AlfpCre) 
displayed normal postnatal body growth up to 2-3 weeks of age. After weaning at 3-4 
weeks animals started exhibiting a severe growth retardation of ~30 % in males and 
~20 % in females (Figure 8). Notably, the postnatal growth pattern of these mice was 
identical to those observed in mice lacking the GR in hepatocytes (GRAlfpCre) 114. To 
investigate whether the dwarfism resulting from ablation of either Stat5 or GR in 
hepatocytes was causally linked, we generated mice with a combined loss of hepatic 
Stat5 and GR signaling (Stat5/GRAlfpCre). These animals showed overlapping growth 
curves compared to those of observed in Stat5AlfpCre and GRAlfpCre animals. This 
indicates that the dwarfism displayed by GRAlfpCre, Stat5AlfpCre and Stat5/GRAlfpCre mice 
is linked, likely by a linear signal transduction pathway involving transcription-
competent complexes consisting of Stat5 and GR.  
 
3.1.2. Loss of hepatic Stat5 and/or the GR signaling leads to similar changes in 
gene expression profiles 
 
We aimed to further underpin our hypothesis of a linear signal transduction axis 
comprising Stat5 and GR controlling growth-related genes upon GH action. In 
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addition, we questioned the fraction of the transcriptome co-dependently regulated by 
Stat5 and GR. We analysed livers from control, Stat5AlfpCre and GRAlfpCre animals and 
undertook Affymetrix whole genome expression analysis. Interestingly, the gene 
signatures significantly downregulated by ablation of either Stat5 or the GR overlap to 
a high extend (Figure 9A, left). The significance criterion was defined as either (i) 
p<0.001 or (ii) p<0.05 and fold change >2/<2-1. According to these criteria, 42 % of 
genes downregulated in GRAlfpCre mice were concomitantly downregulated in 
Stat5AlfpCre animals. Correspondingly, 26 % of genes downregulated in Stat5AlfpCre 
mice were also downregulated in GRAlfpCre mutants. The genes significantly 
upregulated in both mutants were far less abundant (Figure 9A, right). The high 
extend of overlapping genes was in the same range if less stringent criteria were 
applied (e.g. p<0.005 or p<0.01, not shown). To further corroborate the coordinate 
change of Stat5-GR co-dependent genes, we determined their expression changes 
in Stat5/GRAlfpCre double knockout animals. As expected, we observed that genes 
significantly changed in a given direction in the single mutants were changed in the 
same direction with the same magnitude in Stat5/GRAlfpCre mutants (Table 1A). 
 
  
Figure 9. Substantial similarities in expression profiles from Stat5AlfpCre, GRAlfpCre and 
Stat5/GRAlfpCre mice 
(A) Venn diagrams showing the overlap of genes significantly changed in livers from mice with 
hepatocyte-specific deletion of Stat5 or GR. As criterion for calling a gene significantly changed we 
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used p < 0.001, or the combined criterion of p < 0.0025 and a log ratio >1 or less than −1 (fold change 
>2 or <0.5). Note the substantial overlap of genes downregulated by the two mutations. (B) 
Comparison between Stat5AlfpCre and GRAlfpCre mutants of the expression changes for genes 
significantly changed in both mutants. All of these genes are changed in the same direction in the two 
mutants and the magnitude of change correlates tightly. (C) Comparison of expression changes in 
Stat5AlfpCre and Stat5/GRAlfpCre livers for the same genes as in B. There is no additional effect of 
deleting GR in the absence of Stat5 for the expression levels of these genes. 
 
The genes found to be significantly dependent on both, GR and Stat5, are listed in 
(Table 1), the complete list of genes significantly changed in a single knockout is 
accessible online at: http://www.genesdev.org/cgi/content/full/21/10/1157/DC1 
(Supplementary Table 1).  
 
 
Table 1. Genes and functional groups of genes that are regulated by Stat5-GR interaction 
(A) Genes significantly downregulated in Stat5AlfpCre, GRAlfpCre, Stat5/GR AlfpCre and Stat5ΔN mice. 
Expression changes are given as log2 ratios of fold changes. If they belong to any of the significantly 
changes gene sets (see below, B) it is indicated in the far right bar. Abbreviations indicate (s) 
Somatomedin mediators; (g) GH responsive genes; (m) male predominant genes; (d) steroid 
dehydrogenase; (r) genes encoding ribosomal proteins. (B) Functional gene sets in which changed 
genes are enriched, determined using MAPPfinder software (see Methods). 
 
The extensive overlap between expression changes observed in either single-
deletion knockout mouse could be explained by (i) a direct functional interaction of 
the two transcription factors acting in a linear signal transduction fashion or (ii) may 
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be due to independent regulation of the same set of genes. To distinguish between 
those two putative mechanisms, we argued the following way: If there is a direct 
physical interaction between Stat5 and the GR, the magnitude of change of a given 
gene should correlate in Stat5AlfpCre and GRAlfpCre mice. If, in contrast, this is not the 
case, the actions are probably independent. To address this issue, we plotted the 
fold change as log2 ratio of significantly changed genes in Stat5AlfpCre and GRAlfpCre 
against each other (Figure 9B). The positive correlation of fold changes between the 
two single mutants indicated the presence of a ‘positive’ interaction. In contrast to the 
general tendency, a small subset of genes was less affected in the GRAlfpCre mutants, 
indicating that Stat5 action on these Stat5-dependent promoters is not totally 
dependent on the GR. To further expand the interpretation of our data, we similarly 
plotted the expression changes of coregulated genes in Stat5/GR AlfpCre versus Stat5 
AlfpCre (Figure 9C). The similar positive correlation indicated that the GR is not able to 
significantly alter the expression changes under conditions in which Stat5 is lacking. 
We concluded that the activating effect of the GR is completely dependent on 
protein-protein interaction with Stat5. Collectively, these findings strongly support a 
model of Stat5 and GR regulated expression of specific gene subsets via direct 
interaction with each other. 
Next, we aimed to elucidate which functional groups of genes are predominantly 
affected by Stat5-GR interaction in the liver. We utilized the MAPPfinder software to 
find gene groups with coordinate changes 159. This approach can detect low-
amplitude changes common to many genes attributed to a functional group. This is 
superior to detecting high-amplitude changes given for a single gene as 
compensatory mechanisms exerted by functionally related genes are not taken into 
account. We found that Stat5-GR interaction is important for many gene sets (Table 
1B). Noteworthy was the strong dependency of the gene sets designated to “fatty 
acid metabolism” and “genes repressed by GH”. The coordinate expression changes 
elicited by Stat5 and the GR correlate closely with those found for various truncations 
of the GH receptor (GHR) 160. The observed changes for male-predominant genes 
were in line with earlier reports from the Waxman group 161 which reported sex-
specific gene expression to be dependent on GH action and hepatic Stat5. 
 
3.1.3. The N-terminus of Stat5 constitutes the docking platform for the GR 
 
                                                                                                                            Results 
 
39 
To shed further light on the nature of Stat5-GR protein interaction in hepatocytes, we 
utilized livers from mice harbouring N-terminally truncated versions of Stat5a and 
Stat5b proteins (Stat5ΔN mice). The N-terminus of Stat5 was reported to be of 
importance for oligomerization of Stat5 proteins 162. Initially designed as complete 
Stat5 knockout mouse, Stat5ΔN mice still express considerable amounts of N-
terminally truncated Stat5 proteins, approximately 30-40% of control protein levels 
115. We further utilized Stat5ΔN mice because they displayed growth retardations 
comparable to Stat5AlfpCre, GRAlfpCre and Stat5/GR AlfpCre mutants 114, putatively due to 
similar molecular perturbations in the liver. Collectively, these mice are regarded as 
an in vivo model for studying the physiological consequences which are secondary to 
the loss of the Stat5b N-terminus. As Stat5b is the predominant Stat5 isoform 
expressed in the liver, no considerable amounts of Stat5a were detected (not shown). 
We thus detected only the low-molecular weight Stat5bΔN isoform in livers of Stat5ΔN 
mutants, which were fully tyrosine phosphorylated upon GH stimulation (Figure 11A). 
Also, GRAlfpCre mice exhibited normal tyrosine phosphorylation properties upon GH 
challenge. To further investigate whether GH-induced tyrosine phosphorylation led to 
normal DNA binding of Stat5bΔN proteins we performed electrophoretic mobiliy shift 
assays (EMSA) on classical Stat5 responsive promoter elements (beta-Casein 
elements). Stat5bΔN proteins fully bound beta-Casein elements upon GH activation 
compared with full-length Stat5b (Figure 10).  
 
 
Figure 10. Stat5ΔN proteins fully bind to Stat5 responsive elements upon GH challenge in vivo  
Liver extracts from control and Stat5ΔN mice were subjected to EMSA analysis in order to assess the 
DNA-binding properties of Stat5 isoforms in vivo upon GH stimulation. Tyrosine phosphorylation of 
Stat5bΔN proteins resulted in a comparable DNA binding activity on classical Stat5 RE from the beta-
Casein promoter compared with full-length Stat5b.  




Next, we performed chromatin-immunoprecipitation (ChIP) assays to investigate the 
chromatin-binding properties of Stat5bΔN proteins on classical GH-triggered Stat5 
targets. GH stimulation led to significant binding of Stat5b as well as Stat5bΔN 
proteins to specific Stat5 responsive elements in the promoter regions of IGF, ALS 
and Socs2. N-terminally truncated Stat5bΔN proteins retained an approximately 70-
80% binding capacity to these chromatin regions compared with full-length Stat5b 
proteins (Figure 10B). To further investigate whether the N-terminus of Stat5b is 
essential for protein interaction with GR, we performed immunoprecipitation (IP) 
assays (Figure 10C). Reciprocal co-immunoprecipitation with anti-GR or anti-Stat5 
specific antibodies revealed Stat5-GR protein interaction in both directions. However, 
the specific Stat5-GR interplay was lost in Stat5bΔN mice.  
Thus, we concluded that the N-terminus of Stat5b constitutes the docking 
platform for the GR in hepatocytes. 
 
Figure 11. Stat5-GR interaction is dependent on the Stat5b N-terminus 
(A, top) Liver extracts were prepared from untreated or GH injected mice, followed by quantitative anti-Stat5b 
immunoprecipitation (IP) and subsequent immunoblotting with an anti-pY-Stat5 antiserum. (A, bottom) Blots were 
stripped and reprobed with an anti-Stat5b-specific antiserum. Stat5b and Stat5bΔN proteins are fully tyrosine-
phosphorylated upon GH stimulation. The amounts of total Stat5b were reduced to ~40% in Stat5ΔN mice. (B) In 
vivo binding of Stat5 to proximal enhancers of ALS, Socs2 and IGF-1. The fold enrichment for each DNA 
fragment upon immunoprecipitation by anti-Stat5 followed by quantitative PCR is illustrated as bar graphs (mean 
± SEM). Upon GH stimulation, wild-type Stat5b is highly bound to chromatin. Stat5bΔN displays ~50–70 % of the 
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DNA binding capacity of full-length Stat5b. (C) The N-terminus of Stat5b is essential for Stat5b-GR interplay. 
Reciprocal immunoprecipitation of liver extracts using anti-Stat5b (left) or anti-GR (right) antisera. (Left) Stat5bΔN 
as well as full-length Stat5b proteins are efficiently immunoprecipitated with anti-Stat5b antisera (bottom), but only 
wild-type Stat5b interacts with the GR (top). (Right) GR proteins are comparably pulled down (bottom), but only 
full-length Stat5b is co-immunoprecipitated (top). Four similar experiments were performed and one 
representative analysis is shown. 
 
Expression profiling of StatΔN livers revealed that some of those genes previously 
identified as Stat5 responsive genes were expressed at normal levels while some 
others were downregulated. Notably, most genes that were exclusively dependent on 
Stat5 but not on interaction between Stat5 and the GR were unchanged in StatΔN 
mice. In contrast, most genes co-dependent on Stat5-GR interaction displayed 
compromised expression in StatΔN animals (Figure 12A, B). In addition, Stat5 
responsive genes that were only partially dependent on the interaction with GR were 
concomitantly only partially dependent on the N-terminus of Stat5b (Figure 12C). 
These results supported our hypothesis that the N-terminus of Stat5 is important for 
protein interaction between Stat5 and the GR. Moreover, the overlapping expression 
changes observed in Stat5AlfpCre, GR AlfpCre, Stat5/GRAlfpCre and Stat5ΔN mutants are 
likely due to the disruption of Stat5-GR protein complexes.  
 




Figure 12. Deletion of the Stat5 N-terminus selectively reduces the expression of Stat5-GR co-
dependent genes 
(A, B) Magnitude (A) and significance (B) of expression changes of (i) GR independent (top panel) and 
(ii) GR dependent (bottom panel) Stat5 responsive genes in livers of mice lacking the N-terminus of 
Stat5 (Stat5ΔN). Those Stat5 responsive genes that are not dependent on the GR show very little 
dependence on the N-terminus while many of the Stat5 responsive genes that are dependent on the 
GR are severely affected by the loss of the Stat5 N-terminus. (C) Comparison within the group of GR 
dependent Stat5 target genes. Those genes that are only partially GR dependent (white and gray 
dots, left panel) are also only partially dependent on the N-terminus of Stat5 (right panel). 
 
Collectively, we could show that physical protein interaction between Stat5 and the 
GR in hepatocytes is necessary for ensuring proper postnatal growth. Using 
conditional mouse models, whole genome expression profiling (Affymetrix analysis) 
and biochemical methods we could corroborate that physical Stat5-GR interaction is 
necessary for full transcription of specific gene subsets. Functional gene groups 
depending on Stat5-GR interplay include genes responsible for fatty acid metabolism 
(not shown herein) and postnatal body growth. The latter includes genes like IGF-1, 
ALS and Socs2, important genes implicated in regulation of longitudinal body growth. 
In addition, we could identify the N-terminus of Stat5b as docking platform for the GR 
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in hepatocytes. Growth defects observed in mice harbouring N-terminally truncated 
Stat5 proteins (Stat5ΔN mice) are likely due to an impaired Stat5-GR protein 
interaction. GH-induced tyrosine phosphorylation and DNA binding of Stat5ΔN 
proteins were unaltered and thus could not account for the dwarfism seen in Stat5ΔN 
mice.  
 
3.1.4. Socs2 as example for Stat5-GR co-dependent gene transcription 
 
Suppressor of cytokine signaling 2 (Socs2) belongs to the Socs family of proteins 
which are transcribed upon cytokine action and serve as potent negative feedback 
regulators, e.g. for signals leading to activation of the Jak/Stat pathway 163. Although 
Socs proteins are rather promiscuous in their upstream specificity, the transcription of 
the Socs2 isoform is widely recognized to be driven by GH-induced Stat5 activation 
alone 164, 165. A growing body of evidence supports the notion of Socs2 serving as 
major negative regulator of the GH-Stat5 axis 166. Genetic studies underpinned the 
pivotal role of Socs2 in growth and development: Socs2 knockout mice exhibit 
gigantism, a severe increase in longitudinal growth due to sustained Stat5 activation 
and elevated IGF-1 levels. Recent reports revealed roles for activated glucocorticoid 
receptor (GR) in supporting Stat5-mediated transcription of Socs2 mRNA 114. In 
addition, a substantial decrease of Socs2 mRNA transcription in knockout mice 
lacking either Stat5 (Stat5AlfpCre; log2ratio (L2R) -4.6 vs. controls), the GR (GRAlfpCre; 
L2R -5.1 vs. controls) or both (Stat5/GRAlfpCre; L2R -5.1 vs. controls) in hepatocytes 
was observed using our whole genome expression analysis (Table 1). Moreover, 
Socs2 mRNA levels were severely decreased in mice which lack the aminoterminal 
Stat5 domain, which is critical for interaction with the GR (Stat5ΔN; L2R -2.8 vs. 
controls). Thus, we presumed that the decrease in Socs2 transcription was due to 
disrupted Stat5-GR protein interaction serving as example for genes regulated by 
linear Stat5-GR signal transduction. Interfering with either Stat5 or GR signaling thus 
results in decreased levels of Socs2 mRNA.  
 
3.1.4.1. The Socs2 promoter harbours putative Stat5-GR responsive elements  
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It is widely recognized that ample transcription of Stat5 target genes requires 
oligomerization/tetramerization of Stat family members, exemplified for Stat5a/b 
proteins 167, 168. Interestingly, those genes demonstrated to depend on functional 
Stat5-GR protein interaction often harbour tandem Stat5 responsive elements (Stat5 
tetramer sites, Stat5 2xRE) in their 5’ promoter regions. Promoters with several 
Stat52xRE were especially found in growth-related genes such as IGF-1, ALS and 
Socs2 114. To investigate this phenomenon in more detail we utilized bioinformatics 
screening of the Socs2 promoter region and identified three Stat5 2xRE therein 
(Accession No. NT_039500, Figure 13). All tandem sites were spaced in close 




Figure 13. The Socs2 promoter (-3443 to +1 bp) harbours three tandem Stat5 RE (Stat5 2xRE) 
Tandem Stat5 REs (Stat5 2xRE) were identified in the 5’ promoter region of Socs2 by bioinformatics screening for 
two tandem linked Stat5 RE (TTC(T/C)N(G/A)GAA) in close vicinity (n<30 bp; gray). Underlined sequences were 
used for EMSA analysis (see Figure 15). Black arrows indicate Stat5 2xRE#1 (-3351/-3329 bp upstream of ATG; 
top), Stat5 2xRE #2 (-2976/-2931bp; middle) and Stat5 2xRE #3 (-1964/-1944bp; bottom). Additional GR 
responsive elements found in the Socs2 promoter are capitalized. 
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To test whether transactivation of the Socs2 promoter requires synergistic Stat5 and 
GR signaling, we designed three Luciferase (LUC) reporter constructs harbouring 
truncated versions of the proximal Socs2 promoter. Each of these constructs (termed 
I-III) harboured:  
(i) A core region of the Socs2 promoter containing the three Stat5 2xRE (-3443 bp/-
1832 bp) 
(ii) Additional 5’- and 3’ regions flanking the three Stat5 2xRE-containing core region 
to assess the requirement for putative enhancer sequences.  
Promoter constructs I-III were amplified by polymerase chain reaction (PCR) as 
described in Methods (section 5.2.2.1) using 5’ overhang primers containing 
restriction sites for enzymes MluI, BgllI and HindIII. Subsequently, PCR products 
were cloned by appropriate restriction enzyme digestion and T4 ligation into the 
multiple cloning site (MCS) of a LUC reporter vector under the control of a 5’-minimal 
TA promoter (Figure 14 and Methods).   
 
 
Figure 14. Socs2 promoter regions cloned for LUC reporter assays  
Socs2 reporter constructs No. I-III containing the three Stat5 2xREs (Stat5 2xRE#1-3; left) were 
cloned into the MCS of a LUC reporter vector under the control of a minimal TA promoter (right). 
Additional 5’- and 3’- regions of the Socs2 promoter were included in Construct I+III to assess for 
putative enhancer elements. Correct assembly of vector constructs was confirmed by restriction 
analysis and DNA sequencing. 
 
3.1.4.2. Putative Stat5-GR DNA binding sites in the proximal Socs2 promoter 
are Stat5 responsive 
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First, we investigated whether the three Stat5 2xREs located in murine Socs2 
promoters are recognized activated Stat5 molecules. Figure 15 shows an EMSA 
analysis illustrating the Stat5 binding properties in vitro and in vivo on all three Stat5 
2xRE located in the Socs2 promoter. First, human HEK 293 cells were transfected 
with Stat5b and the erythropoietin (Epo) receptor (EpoR), a cytokine receptor 
structurally related to the GHR triggering potent activation of Stat5 upon Epo ligand 
binding. Subsequent stimulation with 25 U/ml Epo for 30 min led to significant binding 
of Stat5 protein onto all three Stat5 2xRE#1-3 in vitro, albeit to a less extend onto 
Stat5 2xRE #2. No DNA binding of Stat5 molecules was observed under basal, non-
stimulated conditions. Stat5 specificity was confirmed via supershift analysis using 
high affinity Stat5b-specific antisera. This led to the specific retention of 32P-labeled 
oligomer-Stat5-antibody complexes (Figure 15; upper panel). Similar as observed 
upon Epo stimulation of HEK293 cells in vitro, GH potently activated hepatic Stat5 in 
vivo leading to high affinity binding of Stat5 onto Stat5 2xRE#1-3 elements in the 
murine Socs2 promoter. Interestingly, Stat5 2xRE #2 recruited significantly less 
phosphorylated Stat5 molecules, corroborating observations for in vitro stimulated 
Stat5. All complexes bound to 32P-labeled oligomers contained Stat5 molecules as 
confirmed by supershift analysis (Figure 15; lower panel). Evidence for Stat5b 
tetramerisation on the Socs2 binding sites was not predominant; rather Stat5b dimers 
were detected. 




Figure 15. Activated Stat5 binds to Stat5 2xRE in the Socs2 promoter in vitro and in vivo 
Electromobility shift assay (EMSA) analysis of Stat5 2xRE#1-3 (as introduced in Figure 13). (Top) HEK 293 cell 
extracts were transfected with the EpoR and Stat5 and Epo-stimulated for 30 min. Extracts were analysed for 
binding of activated Stat5 onto Stat5 2xRE#1-3 located in the murine Socs2 promoter. (Bottom) Mice were 
stimulated with GH for 30 min and liver homogenates analysed for DNA binding properties of activated Stat5 on 
Stat5 2xRE#1-3. Fast-migrating complexes represent Stat5 dimers bound to 32P-labeled oligomers. Stat5-specific 
binding was confirmed via Stat5 antibodies yielding high molecular weight complexes migrating slower on 
respective oligomers (ss, supershift). Beta-Casein was used as positive control for a Stat5 responsive promoter 
sequence.  
 
Thus, Epo treatment stimulated high affinity binding of Stat5 onto all three Stat5 
2xRE located in the murine Socs2 promoter in vitro. In vivo analysis of GH activated 
Stat5 confirmed these results.  
 
3.1.4.3. The proximal Socs2 promoter is synergistically transactivated by Stat5-
GR interplay 
 
We demonstrated that the Stat5 2xRE#1-3 located in the proximal Socs2 promoter 
are recognized and bound by phosphorylated Stat5 dimers. Subsequently, we 
studied the transactivation properties of promoter fragments containing all three Stat5 
2xRE when placed in front of a LUC reporter construct (Reporter constructs I-III, see 
Figure 14). For this, pMSCV plasmids expressing murine Stat5, GR and EpoR were 
transiently transfected into COS7 cells and after 48 h stimulated for 30 min with 25 
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U/ml Epo and/or the glucocorticoid agonist Dexamethasone (Dex) at a final 
concentration of 10 nM. As shown in Figure 16 (bars 1-8), no LUC activity was 
observed upon Stat5-GR transactivation of the two distal Socs2 promoter fragments 
No. I+II. Contrarily, the 3’-most proximal Socs2 promoter fragment No. III exhibited 
LUC activity already under non-stimulated conditions (bar 9). Stimulation with Epo led 
to ~2fold increases in LUC activity (bar 10). No effect of Dex treatment alone was 
observed (bar 12). Strikingly, co-activation of Stat5 and GR signaling by 
simultaneous Epo and Dex treatment led to significant increases in LUC activity 
(~5fold, bar 11).  
Thus, Stat5 and GR signaling synergistically transactivated the Socs2 
promoter. This effect was demonstrated for the proximal Socs2 promoter, whereas 
distal promoter fragments did not show these synergies. This pinpointed towards 
additional 3’- enhancer elements, either located in the proximal Socs2 promoter itself 
or in Socs2 intron sequences. 
 
Figure 16. The proximal Socs2 promoter is synergistically activated by Stat5-GR signaling 
Synergistic Stat5-GR transactivation properties of  three Socs2 LUC constructs (No. I-III, as schematically shown 
in Figure 14) were determined. Briefly, COS7 cells were transfected with pMSCV plasmids expressing murine 
Stat5b, GR and EpoR. After 48 h, cells were stimulated with 25 U/ml Epo and/or 10 nM Dex. Cellular extracts 
were prepared and the LUC activity measured as described in Methods. Equal transfection efficiency was 
determined by co-transfection of a beta-Galactosidase (beta-Gal) expression plasmid and normalization of LUC 
activity to beta-Gal activity. Assays were performed in triplicate.  
 
3.1.4.4. Full transactivation of the Socs2 promoter depends on Stat5 and GR  
 
We identified the proximal Socs2 promoter to be strongly responsive to synergistic 
Stat5-GR transactivation. Next, we addressed the question whether this effect 
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required Stat5 and GR proteins. Thus, we compared conditions of Stat5 and GR 
overexpression and subsequent cytokine stimulation by Epo and/or Dex with mock-
transfected COS7 cells. COS7 cells were chosen since they lack endogenous Stat5 
expression. Untransfected COS7 cells exhibited a mere ~1.5fold induction in LUC 
activity upon Epo/Dex co-stimulation (Figure 17, bar 3). Epo treatment alone had no 
effect (Figure 17, bars 1-2). Dex treatment led to ~2fold increases in LUC activity 
compared with untreated cells. In strong contrast, overexpression of Stat5 and GR 
proteins led to potent increases in LUC activity (Figure 17, bars 5-8). A modest ~2fold 
increase of LUC activity was observed upon Epo stimulation alone. Combinatorial 
stimulation of Stat5 and GR proteins led to approximately 5fold increases in LUC 
activity, thereby significantly bypassing the effects of Epo treatment alone. 
Thus, we confirmed that the observed synergism of Stat5 and GR signaling in 
transactivating the proximal Socs2 promoter depends on Stat5-GR interaction. 
 
Figure 17. Synergistic Epo/Dex-dependent transactivation of the Socs2 promoter depends on Stat5 and 
GR proteins 
The Stat5-GR co-dependent transactivation of Socs2 LUC construct No. III (as schematically shown in Figure 14) 
was determined. Briefly, COS7 cells were transfected with pMSCV plasmids expressing murine Stat5b, GR and 
EpoR. After 48 h, cells were stimulated with 25 U/ml Epo and/or 10 nM Dex. Cellular extracts were prepared and 
the LUC activity measured as described in Methods. Equal transfection efficiency was determined by co-
transfection of a beta-Galactosidase (beta-Gal) expression plasmid and normalization of LUC activity to beta-Gal 
activity. Assays were performed in triplicate.  
 
3.1.4.5. Synergistic Stat5 and GR signaling is required for full Socs2 promoter 
transactivation. 
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Synergistic activation of Stat5 and GR signaling led to a pronounced transactivation 
of the proximal Socs2 promoter. This effect was dependent on Stat5 and GR 
proteins. We next followed the question whether two distinct Stat5 and GR or rather 
one linear Stat5-GR signal transduction pathway was responsible for the observed 
synergism. We previously identified the Stat5b N-terminus as the GR-docking domain 
disrupting the Stat5-GR protein interaction upon N-terminal truncation of Stat5b 122. 
We took advantage of these findings and transiently transfected cells with pMSCV 
plasmids encoding murine GR, EpoR and full-length Stat5b as well as 
aminoterminally (Stat5bΔN) or carboxyterminally (Stat5bΔ754) truncated Stat5b 
isoforms. The latter isoform lacks the carboxyterminal transactivation domain 
essential for cofactor recruitment of the basal transcription machinery. Transfection of 
full length Stat5b together with GR led to potent, synergistic Socs2 transactivation 
following Epo/Dex treatment (Figure 18, bar 3). Interestingly, this effect was severely 
impaired upon transfection with plasmid encoding Stat5bΔN instead of full-length 
Stat5b (Figure 18, bar 7). Transfection of the Stat5bΔ754 isoform almost completely 
abrogated Socs2 transcription upon Epo or Epo/Dex treatment (Figure 18, bar 11).  
Thus, synergistic Stat5-GR co-dependent transactivation of the proximal 
Socs2 promoter required Stat5-GR protein interaction, the disruption of which led to 
severe decreases in Socs2 transcription. Abrogation of Stat5 transactivation 
properties resulted in the complete shutdown of Socs2 transcription. 
 
 
Figure 18. Socs2 transactivation depends on physical Stat5-GR protein interaction 
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The Stat5-GR co-dependent transactivation of Socs2 LUC construct No. III (as schematically shown in Figure 14) 
was determined. Briefly, COS7 cells were transfected with pMSCV plasmids expressing murine Stat5, Stat5ΔN, 
Stat5Δ754, GR and EpoR. After 48 h, cells were stimulated with 25 U/ml Epo and/or 10 nM Dex. Cellular extracts 
were prepared and the LUC activity measured as described in Methods. Equal transfection efficiency was 
determined by co-transfection of a beta-Galactosidase (beta-Gal) expression plasmid and normalization of LUC 
activity to beta-Gal activity. Assays were performed in triplicate.  
 
3.1.4.6. A linear Stat5-GR pathway controls hepatic Socs2 transcription 
 
We demonstrated the existence of a linear Stat5-GR signaling pathway essential for 
full transactivation of murine Socs2 in a standard epithelial cell line (COS7 cells). As 
Stat5 functions depend largely on the cellular context we wanted to further 
investigate the extent of Stat5-GR synergism in transactivating the Socs2 promoter in 
other, more physiologically relevant cells such as hepatocytes. For this, we utilized 
primary hepatocytes isolated from p16/19ARF deficient mice (MIMp16/19ARF-/-). 
Growth factor supplementation with a defined panel of growth factors (IGF-II, TGFb 
and insulin) rendered these cells immortal in vitro, yet an epithelial polarity and 
expression of hepatocyte markers was kept 169. A variant of this cell line was 
generated via genomic integration of the Ras proto-oncogene (MIMp16/19ARF-/-
Ras), rendering these cells independent of growth factors stimuli and facilitating 
handling of cells 170. Transfection of pMSCV plasmids encoding murine Stat5b, the 
GR, the EpoR and subsequent cytokine stimulation with 25 U/ml Epo and 10 nM Dex 
for 30 min induced significant increases in LUC activity in both cell lines: The 
increase in LUC activity was more pronounced MIMp16/19ARF-/-Ras cells (~6.5fold; 
Figure 19 bar 7) compared with MIMp16/19ARF-/- cells (~4.5fold; Figure 19, bar 3). 
Stimulation with 25 U/ml Epo alone led to limited inductions of LUC activity in both 
cell lines (~2.5fold; Figure 19, bar 2 and 6). Treatment with 10 nM Dexamethasone 
led to increases in LUC activity of borderline significance.  
Thus, we demonstrated, that full Socs2 transactivation is regulated by linear 
Stat5-GR signaling also in hepatocytes. As the liver represents the primary site of 
action for GH-mediated Stat5 activation, potent GR signaling as observed under 
stress conditions might modulate the magnitude of Stat5-derived Socs2 transcription 
in vivo and thus affecting liver function, metabolism and body growth. 
 
 




Figure 19. Full Socs2 promoter transactivation in primary hepatocytes is dependent on the Stat5-GR 
interaction 
The Stat5-GR co-dependent transactivation of Socs2 LUC construct No. III (as schematically shown in Figure 14) 
was determined. Briefly, MIMp16/19ARF-/- and MIMp16/19ARF-/-Ras cells were transfected with pMSCV 
plasmids encoding for murine Stat5b, GR and EpoR. After 48 h, cells were stimulated with 25 U/ml Epo and/or 10 
nM Dex. Cellular extracts were prepared and LUC activity measured as described in Methods. Equal transfection 
efficiency was determined by co-transfection of a beta-Gal expression plasmid and normalization of LUC activity 
to beta-Gal activity. Assays were performed in triplicate.  
 
3.2. Compound loss of hepatic Stat5 and GR signaling leads to steatosis 
 
Fat accumulation in the liver (steatosis) is either the result of excessive fatty acid 
biosynthesis relative to oxidative clearance 171 or alternatively impaired hepatic 
release of lipids and thus net deposition of fat in hepatocytes 10. Fatty acid synthesis, 
clearance and release are regulated by multiple endocrine factors including 
hypothalamic and adrenal effectors like GH and glucocorticoids. Stat5 mediates the 
body’s response to numerous cytokines and growth factors including GH 125. Both, 
gain- and loss-of-function studies have shown a critical role of hepatic Stat5 in 
regulation of postnatal body growth, sexual dimorphism and detoxification control 122. 
These GH-derived effects are largely attributed to activated Stat5 efficiently 
transcribing IGF-1. We could demonstrated in vivo that the GR binds as essential 
cofactor to the aminoterminus of Stat5b in order to fully drive IGF-1 synthesis upon 
GH action 122. IGF-1 in turn inhibits GH secretion in the anterior pituitary 123, 127, 
constituting an auto-inhibitory feedback loop preserving appropriate pathway 
activation 130. In addition to the existence of a Stat5b knockout line, mice harbouring 
N-terminal truncations in both Stat5 isoforms were reported (Stat5ΔN mice). Both 
Stat5 knockout strains exhibit reduced peripheral lipid reservoirs 123, 127 resembling in 
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many ways the lipodystrophic phenotype of growth hormone receptor deficient (GHR-
/-) mice. This and once again supports the notion of GH-Stat5 negative feedback 
inhibition 133. 
In contrast to GH and Stat5, adrenally derived glucocorticoids such as corticosterone 
signal through the glucocorticoid receptor (GR) and trigger multiple downstream 
effects including inhibition of peripheral lipolysis. Glucocorticoids constitute a critical 
arm of the HPA axis, a neuroendocrine system which integrates stress signals to 
modulate multiple processes including digestion, immune activation, and energy 
supply. Like GH, glucocorticoids tightly regulate their own secretion through an 
autocrine negative feedback loop, the impairment of which leads to one of several 
hypercortisolic conditions characterized in part by pathological accumulation of lipids 
in peripheral adipose tissues 139. Deletion of the GR in hepatocytes leads to well-
studied defects in hepatic glucose metabolism such as impaired gluconeogenesis 
leading to fasting-induced hypoglycaemia 136. In this study, we addressed the 
question whether Stat5 and GR proteins act separately in regulating hepatic lipid 
homeostasis or rather require a functional Stat5-GR signaling axis. In vitro studies 
claimed an inhibitory role of Stat5 during adipogenesis 172. Thus, we generated mice 
lacking Stat5 and/or the GR in hepatocytes.  
By macroscopic examination we discovered a remarkable dependence on Stat5 and 
GR proteins in regulating hepatic lipid homeostasis: Preliminary macroscopic 
analyses at sacrifice revealed graded hepatic pathologies between genotypes. 
Whereas both control and GRAlfpCre mice displayed normal liver morphology, hepatic 
steatosis and hepatomegaly were observed in both Stat5AlfpCre and Stat5/GRAlfpCre 
mutants as early as 4 weeks postnatally. Strikingly, while the extend of steatosis in 
Stat5AlfpCre single mutants remained mild and stable at all time points analysed, 
Stat5/GRAlfpCre mutant mice displayed a marked and progressive pathology exhibiting 
3-4 fold increases in liver mass by 12 months of age (Figure 20A, B) and ~8fold 
increases in the triglyceride content as early as 2 months of age (Figure 20C). 
Further, whereas control and GRAlfpcre animals displayed only mild pathologies with 
time, detailed histopathological analysis revealed marked age-dependent micro- and 
macrovesicular steatosis in livers from both Stat5AlfpCre (moderate) and Stat5/GRAlfpCre 
(extreme) mice (Figure 21B) suggesting a critical role for Stat5 in the regulation of 
hepatic lipid homeostasis. As an additional testament to the severity of disease in 
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Stat5/GRAlfpCre double mutants, maximal fatty degeneration of hepatocytes was 
detected as early as 8 weeks of age (Figure 21B) in these mutants.  
 
 
Figure 20. Liver steatosis in Stat5AlfpCre and Stat5/GRAlfpCre mice 
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(A) Macroscopic appearance of steatosis in 12-months-old mutant mice. (B) Livers from 8-weeks-old 
and 12-months old male mice of the indicated genotypes (top). Liver/Body Weight (LW/BW) ratio in 
male mice at indicated time points (bottom). Data represent mean ± SEM (n=8/genotype/timepoint). 
(C) Hepatic triglyceride content as measured by colorimetric assays in 8-weeks-old male mice. Data 
represent mean ± SEM (n=5/genotype). 
 
Also observed with a consistent graded severity between genotypes were elevated 
serum ALT levels (Table 3) and extensive lobular and portal fibrosis histopathologies 
(Figure 21A). Thus, hepatic Stat5 deficiency caused mild, stable steatosis that, when 
coupled to a GR loss, initiated overt progressive hepatosteatosis reminiscent of 
human NAFLD.  
 
Figure 21. Histological steatosis in Stat5AlfpCre and Stat5/GRAlfpCre mice 
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(A) Histological analyses of liver sections from 8-weeks and 12-months-old mutant mice. Tissue 
sections were fixed and stained with HE (row 1 and 2). Lipid accumulation was visualized by Sudan III 
on cryosections (row 3). Electron microscopy analysis of subcellular fat distribution in liver samples 
(row 4). (B) Histological degree of steatosis in HE-stained livers was scored semi-quantitatively by two 
certified pathologists [in collaboration]. 
 
3.2.1. Loss of hepatic Stat5 signaling leads to increased lipogenesis  
 
Since hepatic steatosis can either result from an imbalance in fatty acid synthesis 
and oxidation or from an imbalance in build-up versus shuttling of lipids out of 
hepatocytes we examined these processes in more detail. As no apparent changes 
in lipoprotein particle-mediated shuttling of TG were observed (Figure 27, see below), 
we postulated that Stat5AlfpCre and Stat5/GRAlfpCre mutant phenotypes were caused 
either by an induction of hepatic de novo lipid synthesis or by inhibition of hepatic 
fatty acid catabolism. Affymetrix whole-genome expression and subsequent 
molecular signature analysis identified a marked induction of genes controlled by the 
lipogenic master regulators SREBP-1c and PPARgamma in Stat5AlfpCre and 
Stat5/GRAlfpCre mice (Table 2).  
 




Table 2. Analysis of transcription factor signatures upregulated in Affymetrix profiling 
Lipid metabolism-related genes significantly deregulated under either knockout condition (Stat5AlfpCre, 
GRAlfpCre or Stat5/GRAlfpCre). Genes are clustered according to upstream transcription factor activation 
(PPARalpha/gamma) or gene function (lipogenic, catabolic or others). Other major liporegulatory 
master genes are included for interpretation of the metabolic phenotype. 
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Indeed, quantitative RT-PCR (qPCR), Western blot, and immunohistochemical 
analyses confirmed induction of both critical liporegulatory transcription factors at 
both the transcript and protein levels (Figure 22A, B and Figure 23A, B). Importantly, 
upregulation of gene expression of lipogenic SREBP-1c (FASN, SCD1 and SCD2) 
and PPARgamma targets (DGAT1, DGAT2, CD36, FABP4 and MOD1) were shown 
to be increased over 2-fold in both Stat5-deficient lines indicating a strong underlying 
role for SREBP-1c/PPARgamma-regulated de novo lipogenesis in the observed 
phenotype. Though somewhat counterintuitive in the context of steatosis, 
transcription of catabolic genes regulated by PPARalpha also appeared upregulated 
in Stat5AlfpCre and Stat5/GRAlfpCre animals. Expression profiling (Table 2) and qPCR 
(Figure 22C) analyses revealed significant increases in PPARalpha expression as 
well as the downstream targets ACOX1, EHHADH, ACADM, ACADL, ACADVL and 
CPT1, important mediators of peroxisomal and mitochondrial beta-oxidation. Also 
noteworthy, the typically adipose tissue specific transcription factors C/EBPalpha and 
C/EBPbeta which control adipogenesis and lipogenesis in concert with PPARgamma 
173 showed similar elevations in both Stat5AlfpCre and Stat/GRAlfpCre further supporting 
the idea of an induced lipogenic/adipogenic program (Figure 22D). Interestingly, 
neither the PPARgamma coactivators PGC1alpha and RXRalpha, nor the hepatocyte 
transcriptional marker HNF1alpha showed evidence of altered expression (Figure 
22D and Figure 23A).  
Thus deletion of Stat5 in the liver causes a marked induction of lipogenic and 
adipogenic programs including de novo lipogenesis. 
 




Figure 22. Induction of de novo lipogenesis in Stat5AlfpCre and Stat5/GRAlfpCre mice 
Relative hepatic mRNA levels were quantified by qPCR in 8-weeks-old mice of indicated genotypes. 
Ct values were normalized to endogenous GAPDH levels (ΔCt method). n=6/genotype; *, p<0.05; **, 
p<0.01, ***, p<0.001. Error bars represent mean ± SEM. Genes with known functions in hepatic lipid 
metabolism were subdivided into the following four groups: (A) Lipogenic genes transcriptionally 
regulated by SREBP-1c. (B) Lipogenic (left) or other (right) genes transcriptionally regulated by 
PPARgamma. (C) Lipolytic genes transcriptionally regulated by PPARalpha. (D) Other lipid 
metabolism-related genes. 
 




Figure 23. Increased SREBP-1c/PPARgamma protein expression upon Stat5 deletion in liver 
(A) Representative immunoblots showing expression of nuclear SREBP-1 and PPARgamma protein in 
liver. HNF1alpha served as hepatocyte-specific marker. HSC70 was used as loading control. (B) 
Immunohistochemical staining for PPARgamma protein expression in liver.  
 
3.2.2. Loss of hepatic Stat5 signaling induces hepatic insulin resistance 
 
One hallmark of most steatotic disorders is an impaired insulin responsiveness of the 
liver (hepatic insulin resistance). Preliminary measures of fasting and fed glucose in 
concert with significant hyperinsulinaemia and elevated levels of serum resistin 
pinpointed towards insulin resistance in Stat5AlfpCre and Stat5/GRAlfpCre mice (Table 3). 
Administration of 0.75 U/kg body weight insulin intraperitoneally revealed blunted 
hypoglycaemic responses in both Stat5AlfpCre and Stat5/GRAlfpCre mutants (Figure 
24A), corroborating the notion of insulin resistance in Stat5-deficient animals. Next, 
glucose tolerance tests were performed to assess overall glucose homeostasis. They 
yielded similar findings: GRAlfpCre and Stat5AlfpCre mice displayed mild glucose 
intolerance in response to 1 g/kg body weight oral glucose, while double mutant mice 
exhibited overt diabetes. Of note, Stat5AlfpCre and Stat5/GRAlfpCre mice displayed 
marked fasting and glucose-challenged hyperinsulinaemia further suggestive of 
significant insulin resistance (Figure 24A). The significantly mitigated insulin 
sensitivity observed in Stat5/GRAlfpCre double knockouts in comparison to Stat5AlfpCre 
mutants may reflect the additive and independent effects of pronounced insulin 
resistance (due to deletion of Stat5) and established glucose intolerance (due to 
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deletion of GR). Finally, Western blot analysis of Stat5AlfpCre and Stat5/GRAlfpCre liver 
revealed severely impaired insulin receptor (IR) downstream signaling 15 min after 
intraperitoneal insulin administration. Tyrosine phosphorylation of the insulin receptor 
beta-subunit (IRbeta), insulin-response substrates -1 and -2 (IRS-1 and IRS-2) and 
the downstream effector kinase AKT were reduced in Stat5/GRAlfpCre livers (Figure 
24B). Once again, changes in the Stat5AlfpCre mice were more modest with reductions 
in phosphorylation only observed in IRS-1 and Akt.  
Thus, hepatocyte-specific deletion of Stat5 alone or in combination with GR 
leads to marked hepatic insulin resistance.  
 
Table 3: Biochemical and metabolic serum parameters in male mutant mice 
 
Eight weeks old male mice were fed with given chow and sacrificed by carbon dioxide asphyxiation. 
Results are expressed as mean ± SEM for indicated number of mice from each genotype. ALT, 
alanine transaminase; ALP, alkaline phosphatase; FFA, free fatty acids; TG, triglycerides; TNFa, 
tumour necrosis factor alpha; ND = not determined. All values represent mean ± SEM. a = p-Value 
<0.05 vs. Control, b = p-Value <0.01 vs. Control, c = p-Value <0.001 vs. Control 
 




Figure 24. Impaired Glucose and Insulin Metabolism in Control, GRAlfpCre, Stat5AlfpCre and 
Stat5/GRAlfpCre mice 
Male mice were analysed at 8-weeks-of age for Insulin Tolerance Tests (ITT) and Oral Glucose 
Tolerance Tests (OGTT). (A) ITT: Insulin was injected intraperitoneally following a 4h fast. Blood 
glucose levels were determined at given time points (row 1). OGTT: Mice were fasted overnight and 
glucose orally administered. Blood glucose levels were determined at given time points (row 2). 
Plasma insulin levels following OGTT challenge. The insulin levels were determined by ELISA (row 3). 
For ITT/OGTT analyses: n=6-8/genotype; *, p<0.05; **, p<0.01, ***, p<0.001. Error bars in ITT/OGTT 
assays represent mean ± SEM. (B) Phosphorylation of proteins downstream of the insulin receptor 
upon insulin challenge in 8-weeks-old mice. Levels of phosphorylated and total protein were 
determined 15 min after intraperitoneal insulin injection by immunoprecipitation and phospho-tyrosine-
specific immunoblot analysis.  
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3.2.3. Compound loss of hepatic Stat5 and GR signaling leads to peripheral 
lipodystrophy. 
 
Interestingly, despite the divergent steatotic phenotypes observed between 
Stat5Alfpcre single and Stat5/GRAlfpcre double knock-outs, SREBP-1c/PPARgamma-
dependent de novo lipogenesis appeared equally induced in both sets of animals. 
These findings suggested an additional independent stimulus for lipid deposition in 
Stat5/GRAlfpcre livers and prompted us to examine peripheral fat stores as a potential 
source of additional lipid fuels. Interestingly, while the independent single mutants 
exhibited either modest increases (+29 %; GRAlfpCre) or decreases (-28 %; Stat5AlfpCre) 
in white fat pad mass, double mutant animals displayed a clear depletion of both 
white and brown adipose tissue stores (-58 %, Stat5/GRAlfpCre; Figure 25A, B). 
Histological analysis of Stat5/GRAlfpCre white (WAT) and brown adipose tissues (BAT) 
confirmed peripheral lipodystrophy characterized by grossly reduced lipid droplet size 
(Figure 25C). Interestingly, measurement of multiple serum lipid regulators revealed 
elevated levels of GH and decreased levels of IGF-1 in Stat5AlfpCre and Stat5/GRAlfpCre 
mice (Figure 26A, B). Consistent with systemically elevated serum GH levels, Stat5 
phosphorylation in WAT was significantly increased (Figure 26C). In addition, in 
GRAlfpCre and Stat5/GRAlfpCre mutants, serum corticosterone and ACTH were elevated 
(Figure 26D, E) consistent with increased nuclear translocation of the GR in WAT 
(Figure 26F) and the lipodystrophic phenotype in the double mutants. Thus, 
Stat5/GRAlfpCre mice displayed peripheral lipodystrophy driven by the compound 
effects of hepatocyte non-responsiveness towards GH action. This eventually led to 
elevated lipolytic drive through additive effects of elevated GH and corticosterone 
levels mobilising lipids in the adipose tissue. 
 




Figure 25. Atrophy of peripheral adipose tissues (lipodystrophy) in Stat5/GRAlfpCre mice 
For all subsequent panels, male mice at 12 months of age were analyzed. (A) Macroscopic 
appearance of intrascapular BAT and epidydimal WAT. (B) WAT/Body Weight (WAT/BW) and 
BAT/Body Weight (BAT/BW) ratios. n=8/genotype; *, p<0.05; **, p<0.01, ***, p<0.001. Error bars 
represent mean ± SEM. (C) Histology of BAT and WAT. Tissues were fixed and stained with HE. Inlets 
show higher magnification (top row) or quantification of cell density in adipose tissue. Adipocyte 
circumference versus area (Cell density) in WAT as determined by HistoQuest software (bottom) was 
plotted on y-Axis. X-Axis data represent haematoxylin staining intensity and mean X values were 
arbitrarily set =1. 
 




Figure 26. GH resistance and impaired GC negative feedback regulation in Stat5/GRAlfpCre mice 
For all subsequent panels, male mice at 12 months of age were taken. (A, B) Levels of GH (A) and 
IGF-1 (B) were determined by ELISA. For all subsequent serum analyses: n=8/genotype; *, p<0.05; **, 
p<0.01, ***, p<0.001. Error bars represent mean ± SEM. (C) GH-mediated activation of Stat5 in 
epidydimal WAT. Levels of phosphorylated Stat5 (pY-Stat5), total-Stat5 and total-GR were analysed 
using immunoblot analysis. (D, E) Levels of corticosterone (D) and ACTH (E) were determined by RIA. 
(F) Nuclear translocation of the GR in white adipose tissue (WAT) was analysed by 
immunohistochemistry.  
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3.2.4. Compound loss of hepatic Stat5 and Glucocorticoid Receptor signaling 
does not affect lipoprotein particle-mediated lipid distribution  
 
Apart from imbalances in fatty acids synthesis and breakdown, liver steatosis can 
result from altered shuttling of lipids to and from the liver. Thus, we examined these 
processes in more detail. We isolated the hepatic organic phase, prepared density 
fractions using FPLC and determined the qualitative lipoprotein composition (see 
Methods). No apparent differences in lipoproteinparticle-mediated shuttling of 
triglycerides were observed, although the triglyceride and cholesterol content in 
serum of GRAlfpCre mice was generally lower (Figure 27). Thus, we concluded that the 
phenotypes observed in Stat5AlfpCre and Stat5/GRAlfpCre mutants were rather caused 
by induction of hepatic de novo lipid synthesis as shown above (Figure 22 and Figure 
23) then by dysfunctional lipoprotein-mediated shuttling of lipids. 
 
 
Figure 27. Unaltered lipoprotein particle profile in 8-weeks old male mice 
Lipoprotein distribution was analysed by FLCP fractionation and subsequent TG and total cholesterol 
quantification in each fraction (n=5/genotype). 
 
3.2.5. Loss of Stat5 is not compensatory counteracted by Stat1 and Stat3 
activation 
 
A recent publication reported the limited onset of liver steatosis in mice conditionally 
deleted for hepatic Stat5 signaling using Albumin Cre recombinase mediated excision 
of Stat5 alleles (Stat5AlbCre) 124. Compensatory activation of Stat1 and Stat3 
transcription factors accompanied the fatty accumulation. Researchers proposed 
mechanistically that Stat1 and Stat3 proteins were compensatory recruited to the 
GHR without mechanistic proof. Moreover, aberrantly activated interferon signaling 
pathways normally associated with antiviral, immunomodulatory and antitumor 
activities were present in Stat5AlbCre mutants. In contrast to the strategy followed by 
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Cui et al 2007, we warranted excision of floxed Stat5 alleles using AlfpCre 
recombinase which recombines more efficiently in liver hepatocytes and biliary cells 
114, 122. Supportive of the findings observed by Cui et al., loss of hepatic Stat5 proteins 
mediated by AlfpCre recombinase led to significant increases in total Stat1 and a 
slight increase in total Stat3 levels (Figure 28; row 1, 3 and 5). In stark contrast to Cui 
et al., we observed no increased phosphorylation of Stat1 or Stat3 proteins in 
Stat5AlfpCre and Stat5/GRAlfpCre mice (Figure 28, row 2 and 4). Thus, we explained the 
accumulation of lipids upon hepatic loss of Stat5 using AlfpCre as being a direct 
consequence of Stat5 deletion in the liver. The metabolic syndrome-like phenotype 
observed in Stat5AlfpCre and Stat5/GRAlfpCre was thus irrespective of compensatory 
Stat1 and Stat3 signaling. 
 
 
Figure 28. Loss of hepatic Stat5 is not compensatory counteracted by Stat1 and Stat3 
activation 
Representative immunoblots of liver homogenates from 8-weeks-old male mice. Amount of 
phosphorylation and total levels of Stat family members were determined using specific antibodies. 
HSC70 served as loading control. 
 
3.2.6. Development of steatosis is independent of Jak2 upstream kinase 
 
Upstream stimuli for Stat5 activation are conveyed by Janus kinases upon cytokine 
and growth factor stimulation; specifically Jak2 was shown to activate Stat5 upon GH 
action 109. As shown before, ablation of hepatic Stat5 signaling leads to inductions of 
hepatic de novo lipogenesis and concomitant onset of insulin resistance under 
steady-state conditions. We aimed to shed further light on the role of Jak2 in 
steatogenesis. To achieve hepatic losses of Jak2 proteins, we crossed mice 
harbouring floxed Jak2 alleles with mice expressing the AlfpCre recombinase 
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(Jak2AlfpCre). Interestingly, Jak2AlfpCre mutants had macroscopically normal livers 
(Figure 29A), exhibited neither increases in the LW/BW ratio (~5 % LW/BW) nor 
other obvious alterations upon macroscopic examination of livers. Histopathological 
analysis confirmed these observations: In contrast to Stat5AlfpCre and Stat5/GRAlfpCre 
animals, Jak2AlfpCre mutants exhibited no lipid accumulation in hepatic tissues. In 
addition, no fibrotic or necrotic processes could be observed (Figure 29B). Thus, we 
concluded that Jak2-dependent signal transduction is dispensable for the Stat5-
mediated steatogenesis. Rather, this pinpointed towards direct repressive functions 
of Stat5 proteins on hepatic lipid biosynthesis. Interestingly, Jak2AlfpCre animals 
displayed perturbations in normal postnatal growth (not shown herein), further 




Figure 29.  No liver steatosis upon loss of hepatic Jak2 signaling in Jak2Alfpcre mice 
(A) Liver/Body Weight (LW/BW) ratio in 6-months-old male mice. (B) Histological analyses of liver 
sections from 6-months old male mice. Tissue sections were fixed and stained with HE. 
 
3.3. Loss of hepatic Stat5 leads to severe liver fibrosis in MDR2- mice 
 
The transgenic MDR2- mouse line strain harbours genetics deletions of the multi-drug 
resistance protein 2 (MDR2), a liver-specific P-glycoprotein responsible for bile acid 
transport across the apical hepatocyte membrane 174. The MDR2- strain is widely 
used for studying the onset and progression of inflammatory liver cancer 175. To 
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investigate possible roles of hepatic Stat5 during liver carcinogenesis, we crossed 
MDR2- mutants with mice specifically deleted for Stat5 in hepatocytes (Stat5AlfpCre). 
By respective intercrossing we obtained four genotypes (Controls, MDR2-, Stat5AlfpCre 
and MDR2-/Stat5AlfpCre) which were born at Mendelian ratios. Postnatally, both Stat5-
deficient lines, Stat5AlfpCre and MDR2-/Stat5AlfpCre exhibited profound defects in 
postnatal growth (Figure 30A, D), an effect caused by impairments in Stat5-mediated 
transcription of growth promoting genes such as IGF-1 (see section 3.1). In addition, 
livers of Stat5AlfpCre and MDR2-/Stat5AlfpCre mutants were yellowish and enlarged 
starting with four weeks of age (Figure 30B). Again this reflects the crucial role of 
Stat5 in hepatic lipid metabolism demonstrated earlier (see section 3.2). Strikingly, 
livers from MDR2-/Stat5AlfpCre compound knockouts were texturized and sclerotic, 
pinpointing towards increased wound-healing and scar-formation processes leading 
to increased collagen deposition, a process widely observed during liver fibrogenesis 
(Figure 30B). Severe jaundice (Figure 30C) was observed in MDR2-/Stat5AlfpCre 
double mutants and hinted towards perturbed bile flux across hepatocyte membranes 
or towards defective bile secretion into the intestine due to obliterated bile ducts 
(cholestasis). Serum levels of bile acids and bilirubin were increased dramatically 
(~19fold and ~23fold vs. controls). These are two parameters frequently elevated in 
cholestatic disorders such as PBC (primary biliary cirrhosis) and PSC (primary 
sclerosing cholangitis). Additional serum parameters indicative of extrahepatic 
cholestasis like high ALP and ALT (increased ~4.2fold and ~7fold respectively) were 
observed (Table 4). To investigate these processes in more detail, we undertook 
histopathological analyses of tissue specimens obtained from all four genotypes: HE 
staining of eight weeks old mice revealed no histopathologies in control animals and, 
interestingly, MDR2- mutants. Stat5AlfpCre knockout animals displayed significant 
steatosis as described earlier (see section 3.2). Interestingly, MDR2-/Stat5AlfpCre 
mutant livers displayed marked perilobular fibrosis and a profound disruption of 
normal liver architecture (Figure 30E, top panel). Chromotrop Anilinblue (CAB) 
staining as collagen-specific marker revealed massive perivenular and perilobular 
collagen accumulation, indicative of severe liver fibrosis. Closer examination revealed 
marked pericellular collagen deposition (chicken wire fibrosis), an indicator for late-
stage liver fibrosis (Figure 30E, bottom panel). Periodic acid-Schiff (PAS) staining as 
hepatic glycogen marked revealed defects in hepatocyte functions leading to 
defective synthesis and storage of glycogen in livers from MDR2-/Stat5AlfpCre mutants. 
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Significant PAS negative areas were indicative of degenerative processes such as 
necrosis (Figure 30E, bottom panel). Thus, MDR2-/Stat5AlfpCre knockouts exhibited 
severe liver fibrosis observed on the macroscopic and microscopic level. Fibrosis 
was accompanied by extensive extrahepatic cholestasis, jaundice and 
hepatomegaly. The respective single mutants exhibited mild histopathologies, in part 
reported before (see section 3.2).  




Figure 30. Loss of hepatic Stat5 in MDR2- mice leads to cholestasis, jaundice and liver fibrosis 
(A) Macroscopic appearance and (B) Livers and (C) serum from 8-weeks-old male mice of the 
indicated genotypes. (D) Body Weight (left) and Liver/Body Weight (LW/BW) ratio (right) in 8-weeks-
old male mice. Data represent mean ± SEM (n=8/genotype/timepoint). (E) Histological analyses of 
liver sections from 8-weeks old mutant mice. Tissue sections were fixed and stained with HE (row 1). 
Collagen deposition was visualized by CAB staining. Inlets show higher magnification of vascular 
structures (row 2). Hepatic glycogen was visualized by PAS staining (row 3). 
 
Table 4: Biochemical and metabolic serum parameters in male mutant mice 




Eight weeks old male mice were fed with chow and sacrificed by carbon dioxide asphyxiation. 
Concentrations of given serum parameters are expressed as mean ± SEM for indicated number of 
mice from each genotype. ALT, alanine transaminase; ALP, alkaline phosphatase; TG, triglycerides. a 
= p-Value <0.05 vs. Control, b = p-Value <0.01 vs. Control, c = p-Value <0.001 vs. Controls. 
 
3.3.1. Deletion of MDR2 proteins causes hepatic Stat5b activation  
 
Tetracarbonchloride (CCl4) treatment leads to artificially induced liver fibrosis in mice. 
Recently, a report demonstrated important roles for hepatic Stat5 in CCl4-induced 
fibrogenesis. Insensitivity to GH action (GH resistance) and blunted Stat5-mediated 
signal transduction accompanied the disease. Thus, Stat5 was claimed to constitute 
an importer repressor of liver fibrosis in mice.  
To address the question whether Stat5 similarly counteracts MDR2-driven liver 
fibrogenesis, we isolated livers of all genotypes, prepared liver homogenates and 
determined the activation status of Stat5 and other important Stat family members 
using immunoblot analysis. Strikingly and in line with previous observations (section 
3.2.5), loss of hepatic Stat5 leads to significant increases in basal Stat1 (strong) and 
Stat3 (mild) protein levels (Figure 31). Notably, no compensatory Stat1 or Stat3 
hyperphosphorylation was observed. Interestingly, MDR2- animals expressed 
significantly elevated levels of phosphorylated Stat5 (pY-Stat5). Thus, we reasoned 
that Stat5 might exhibit fibrogenesis-repressing functions during development or 









Figure 31. Loss of MDR2- leads to compensatory hyperactivation of hepatic Stat5 
Representative immunoblots of liver homogenates from 8-weeks-old male mice. Amount of 
phosphorylation and total levels of Stat family members were determined using specific sera. HSC70 
served as loading control. 
 
3.3.2. MDR2-/Stat5AlfpCre mice display autocrine growth factor loops 
 
Hepatic stellate cells (HSC) under normal conditions perform important vitamin A 
storage functions, but upon a variety of liver insults transdifferentiate into pro-
fibrogenic and pro-inflammatory myofibroblasts (MFB) 176. MFB upon liver damage 
proliferate and accumulate at the site of tissue repair and synthesize ECM 
components like collagen. Kupffer cells, macrophage-like liver cells of mesenchymal 
origin secrete mitogenic PDGF and TGFb under fibrotic conditions, further favouring 
HSC transdifferentiation and ECM synthesis. To evaluate the impact of TGFb and/or 
PDGFb growth factor circuits in MDR2-/Stat5AlfpCre-associated fibrosis, we isolated 
hepatic RNA and quantified TGFb and PDGFb mRNA levels by qPCR analysis. 
Interestingly, we observed only modest increases (~1.5fold vs. controls) of TGFb 
mRNA levels in MDR2-/Stat5AlfpCre mutants. In contrast, TGFbR mRNA levels were 
drastically increased (~3.5fold vs. controls) in MDR2-/Stat5AlfpCre mutants, thereby 
triggering potent TGFbR-dependent signal transduction even under conditions of 
moderately elevated TGFb (Figure 32, left). Unambiguously, PDGFb (~150fold vs. 
controls) and PGFbR mRNA (~40fold vs. controls) were elevated in MDR2-
/Stat5AlfpCre animals (Figure 32, right). Thus, autocrine PDGFb and, less pronounced 
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TGFb signaling is activated in fibrotic MDR2-/Stat5AlfpCre double knockout animals. 
These observations reflect the current notion of an essential role of PDGFb and 
TGFb during hepatic fibrogenesis.  
 
 
Figure 32. MDR2-/Stat5AlfpCre mutants harbour hyperactive TGFb and PDGFb growth factor 
circuits 
Quantitative PCR (qPCR) analysis of hepatic mRNA expression in male mice of indicated genotypes. 
For qPCR analysis, mice were sacrificed at eight weeks of age. Hepatic mRNA was isolated using 
Trizol, transcribed into cDNA and analysed by qPCR using intron–spanning, gene specific primers. Ct 
values were normalized to GAPDH mRNA levels using the ΔCt method. Data represent mean ± SEM. 
N=6/genotype were used. 
 
3.3.3. Fibrogenesis in MDR2-/Stat5AlfpCre mice is accompanied by ECM 
remodelling 
 
Fibrosis is believed to secondarily occur due to repetitive liver insults and 
concomitant wound-healing processes. Following acute injury, the liver parenchyma 
undergoes intensive cellular proliferation in order to replace degenerative 
hepatocytes, accompanied by inflammatory processes and moderate deposition of 
collagen. Finally, the sum of liver insults leads to overt fibrosis, which can progress to 
late-stage liver pathologies such as cirrhosis, defined by the circumlobular deposition 
of collagen (Figure 30E). Molecularly, the massive build-up of ECM hails from 
imbalances between synthesis (predominantly collagen 1 and 3 (COL1 and COL3)) 
and proteolysis (predominantly Matrixmetalloproteases (MMP) members, especially 
MMP2, MMP3 and MMP13) of ECM components. Most MMPs are synthesized as 
latent pro-enzymes and require proteolytic activation by MMP14 and MMP15 to 
liberate their proteolytic properties. Tissue inhibitors of MMP1 and 2 (TIMP1 and 
TIMP2) effectively quench MMP proteolysis. Transcriptional activation of TIMPs and 
decrease of MMP mRNA synthesis is frequently observed during fibrotic processes. 
To assess the extend of ECM remodelling, we isolated hepatic mRNA of all four 
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genotypes and quantified transcript levels of important ECM modulators. The 
synthesis of collagen COL1 (~70fold vs. controls) and COL3 mRNA (~30fold vs. 
Controls) was massively induced in fibrotic MDR2-/Stat5AlfpCre animals. TIMP1 
(~30fold vs. controls) or TIMP2 (~5foldvs. Controls) mRNA transcription was 
concomitantly upregulated. Interestingly, MMP2 (~45fold), MMP3 (~10fold) and 
MMP13 (~25fold) mRNA transcript levels were severely upregulated compared to 
controls. The same was true for mRNA levels of membrane-tethered MMP activators 
MMP14 (~6fold vs. controls) and MMP15 (~3fold vs. Controls). 
 
 
Figure 33. Fibrogenesis in MDR2-/Stat5AlfpCre mice is accompanied by potent ECM remodelling 
Quantitative PCR (qPCR) analysis of hepatic mRNA expression in male mice of indicated genotypes. 
For qPCR analysis, mice were sacrificed at eight weeks of age. Hepatic mRNA was isolated using 
Trizol, transcribed into cDNA and analysed by qPCR using intron–spanning, gene specific primers. Ct 
values were normalized to GAPDH mRNA levels using the ΔCt method. Data represent mean ± SEM. 
N=6/genotype were used. 
 
Thus, fibrogenesis in MDR2-/Stat5AlfpCre animals is accompanied by 
imbalances in ECM turnover. Potent synthesis of COL1 and COL3 in concert with 
strong inhibition of ECM proteolysis exerted by TIMP1 and TIMP2 was observed, 
leading to a massive build-up of collagen deposition. Interestingly, MDR2-/Stat5AlfpCre 
mutant mice were also characterized by significant increases in MMP-dependent 
proteolysis. Notably, although MDR2- animals exhibit modest liver fibrosis at eight 
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weeks of age, no significant remodelling of the ECM was observed on the transcript 
level. 
 
3.3.4. Loss of hepatic Stat5 in MDR2- mice leads to impaired bile acid 
circulation  
 
An essential function for hepatocytes is the synthesis and recycling of bile. The 
underlying hepatobiliary transport processes are crucial for proper secretion and flux 
of bile 177, 178. These processes are regulated by an array of bile transporters located 
either on the basolateral (facing the hepatic sinusoids) or apical side (protruding into 
the bile canaliculi) of hepatocytes (reviewed in 179). Dysfunctional bile transporters 
expression is frequently observed in cholestatic diseases artificially induced by bile-
duct ligation (BDL) 180. Common to animal models characterized by cholestatic-
induced fibroses is the reduction of two major basolateral bile pumps; sodium 
independent organic anionic transporter (OATP1) and sodium dependent bile acid 
transporter (NTCP1). Dysregulation basolateral bile pump expression was also 
observed upon artificial induction of liver fibrosis 181. Interestingly, NTCP1 182 and 
OATP1 183 are experimentally confirmed Stat5 target genes; a finding pinpointing 
towards essential roles of Stat5 in bile circulation homeostasis. We thus addressed 
the question whether loss of hepatic Stat5 in MDR2- mutants leads to dysfunctional 
bile acid flux due to aberrant NTCP1/OATP1 transporter expression. As shown in 
Figure 34A, NTCP1 and OATP1 transcript levels were severely downregulated in 
both Stat5-deficient mouse strains. In contrast, apical bile transporters (i.e. MRP2, 
MRP3, MDR1b and BESP) did not differ significantly in their transcript levels, 
although modest reductions in OATP2 and BSEP mRNA could be observed (Figure 
34B). To confirm our findings, we prepared liver homogenates and probed with 
antibodies specific for afore mentioned bile transporters (Figure 34C). In line with 
reduced mRNA levels, OATP1 protein levels were reduced to below the detection 
limit in mice devoid of Stat5 (Figure 34C, row 3). NTCP1 was residually expressed in 
Stat5AlfpCre single mutants, yet significantly lower compared to control animals and 
undetectable in MDR2-/Stat5AlfpCre animals (Figure 34C, row 4). Protein levels of 
MRP2 and MRP3 were unaltered (Figure 34C, row 1, 2). Thus, we could show that 
hepatic Stat5 loss in the MDR2- background led to the downregulation of two major 
basolateral bile transporters, notably NTCP1 and OATP1 at the transcript and protein 
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level. This presumably results in impaired bile flux across the hepatocyte and 
retention of bile in the serum (Table 4). Residual NTCP1 expression in Stat5AlfpCre 
animals might suffice to ensure physiological bile flux, reflected in the observation 
that serum bile acids are only moderately elevated (Table 4). 
 
Figure 34. Loss of hepatic Stat5 defective NTCP1/OATP1-mediated bile flux 
(A, B) Quantitative PCR (qPCR) analysis of hepatic mRNA expression in male mice of indicated 
genotypes. For qPCR analysis, mice were sacrificed at eight weeks of age. Hepatic mRNA was 
isolated using Trizol, transcribed into cDNA and analysed by qPCR using intron–spanning, gene 
specific primers. Ct values were normalized to GAPDH mRNA levels using the ΔCt method. Data 
represent mean ± SEM. N=6/genotype were used. (C) Immunoblot analysis of liver homogenates from 
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male mutant mice using specific antibodies. Endogenous beta Actin (bACTIN) served as loading 








4.1. A linear Stat5-GR axis controls postnatal body growth 
 
We could demonstrate the critical role of GR–Stat5 protein interactions in regulating 
postnatal body growth and expression of maturation-related genes. Our hypothesis 
that this functional interaction is a direct consequence of physical Stat5-GR 
interaction is supported by the following results:  
(i) Affymetrix expression profiling revealed an extensive overlap of gene expression 
changes induced by the loss of either hepatic Stat5 or GR (Figure 9A).  
(ii) A tight correlation of the magnitude of expression changes for Stat5-GR 
coregulated genes was demonstrated for the single mutants (Stat5AlfpCre and 
GRAlfpCre, Figure 9B).  
(iii) Combined ablation of GR and Stat5 transcription factors did not affect postnatal 
body growth or the expression of the Stat5-GR coregulated genes more than loss of 
Stat5 only (Figure 8). 
(iv) Aminoterminal truncation of Stat5 disrupted the protein–protein interaction of 
Stat5 the with GR (Figure 11C,D) but led to similar growth retardations. Moreover, it 
resulted in abrogated transcription preferentially of those Stat5-responsive target 
genes that are also dependent on GR cofactor recruitment (Figure 12). 
This is further supported by previous data, showing that GR is present on Stat5-
dependent regulatory regions of growth hormone induced genes and that mice with a 
mutation in the dimerization domain of the GR (GRdim mice) leading to defective DNA 
binding of GR, display normal growth and intact transcription of GH-responsive genes 
114. Collectively, these data support a model in which GH-activated Stat5 binds to 
Stat5 responsive DNA elements and uses the GR as a cofactor to promote body 
growth by inducing appropriate gene transcription. Our results have a clear 
implication for the long-standing discussion on the role of the liver in postnatal 
growth. According to the original “somatomedin hypothesis” from 1956, GH triggers 
the hepatocyte to secrete a secondary mediator (later suggested to be IGF-1) 
promoting postnatal growth. This hypothesis was later contradicted since it was 
shown that peripheral administration of GH promotes growth 154 and that deletion of 
IGF-1 in hepatocytes does not cause any major growth perturbations 157. It was also 
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shown recently that mice harbouring a muscle-specific loss of Stat5 show an 
approximate 20 % reduction in growth 184. However, researchers 155 showed that 
mice lacking ALS in all cells and IGF-1 exclusively in hepatocytes display abrogated 
growth behaviour. This suggested a role of the hepatocyte in somatic growth, 
although the conclusions of the study are somewhat limited since ALS was also 
deleted in non-hepatic tissues, such as in the developing cartilage. In addition, the 
confounding effect of IGF-1 deletion on general body growth was small and transient. 
We provide unequivocal evidence for the importance of Stat5 and GR in hepatocytes 
for postnatal growth. Thus, GH triggers growth both through endocrine factors 
secreted by the liver and through paracrine mediators produced in the target organs. 
In the study by Yakar et al., the blunted growth of the ALS/IGF-1 double-mutant mice 
was suggested to result from the fact that they had even lower levels of circulating 
IGF-1 than the liver-specific IGF-1 mutants. However, the growth disturbance of the 
mice in our study might depend on additional GH-target genes, further with actions 
different from simply regulating levels of circulating IGF-1. Thus, IGF-1 serum levels 
are only moderately reduced in the growth-retarded GR mutants (28 % reduction) 114, 
while it is much lower in liver-specific IGF-1 mutants (75 % reduction), which show no 
overt growth defect. This implies that other genes found to be dependent on GR-
Stat5 interactions in our study are actively involved in growth promotion. Identification 
of those additional hepatic GH-induced mediators of growth remains to be done and 
will probably be challenging since simultaneous and hepatocyte-specific deletions of 
several genes might be necessary. The second major finding was the unexpectedly 
high fraction of transcriptional activation mediated by GR and Stat5 dependent on a 
physical Stat5-GR interaction (42 % and 26 %, respectively). We could also 
demonstrate that the GR is not a mere general positive modulator of Stat5 action 
since the whole Stat5 transcriptome was divided in relatively clear sets of GR-
dependent and GR independent genes. Interestingly, these sets fall into different 
functional groups. Thus, the genes dependent on Stat5–GR protein interactions were 
preferentially enriched in functional groups related to growth and maturation. 
However, a small group of Stat5-responsive genes are not totally, but still partially, 
dependent on GR. We show that the N-terminal domain of Stat5b constitutes the 
docking domain for the GR, while it is also involved in chromatin binding. Accordingly, 
it is required for the expression of genes dependent on physical Stat5-GR interaction 
in vivo and for maintaining physiological postnatal growth. We have recently 
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demonstrated that this domain is also important for the oligomerisation of Stat5 185. 
The AF-1 domain of GR may constitute its cognate binding partner, since it has been 
shown to be necessary for Stat5-GR interaction 140. In conclusion, we show an 
unexpectedly prominent role for the GR in acting as coactivator for Stat5 in 
hepatocytes. We provide in vivo evidence that this Stat5-GR interaction is not an 
unselective requirement for all Stat5 signaling processes but rather preferentially 
affects gene sets involved in growth and maturation. In line with this, we show that 
Stat5-GR protein interactions in hepatocytes are instrumental for maintaining 
physiological postnatal growth and that the coactivating action of GR involves the 
amino terminus of Stat5. This provided insight into the mechanism of growth control 
and we solved and supported the challenged somatomedin hypothesis at the 
transcriptional level, which postulated a critical role for hepatic GH signaling in 
postnatal growth. 
As an example for Stat5-GR synergism in gene transactivation we chose Suppressor 
of Cytokine Signaling 2 (Socs2). Using Luciferase (LUC) reporter assays we could 
demonstrate that Stat5-mediated transactivation of the Socs2 promoter also 
necessitates GR signaling. We confirmed the dependence of synergistic Stat5- and 
GR signaling in a standard cell line (COS7) as well as in immortalized primary 
hepatocytes.  
Generally, Stat5 signaling plays a key role in mediating cytokine and growth factor 
action. Constitutive signaling leads to malignant transformation and thus has to be 
tightly controlled. Stat5 feedback inhibition is in part mediated by transcription of 
Socs2 proteins leading to Jak2 or GHR degradation by ubiquitin-mediated proteolysis 
186. No reports have so far demonstrated a role for GR signaling in modulating Stat5-
mediated transactivation of Socs2. Interestingly, the estrogen receptor (ER), a closely 
related nuclear hormone receptor was shown to negatively regulate GH signaling by 
inducing Socs2 transcription 187. Although the findings presented in this study are 
reminiscent to results presented in the former report, no protein interaction between 
the ER and Stat5 were observed, putatively due to differences in the AF-1 domain, 
which is poorly conserved among nuclear hormone receptors, but it is crucial for 
Stat5-GR interaction 140. We thus conclude that Stat5-GR-dependent transactivation 
of the Socs2 promoter represents an unrelated finding. The significance of synergistic 
Stat5-GR co-dependent Socs2 transcription might open new avenues for keeping 
unbalanced Stat5 activity at bay. This is physiologically relevant, as hyperactivation 
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of Stat5 might lead to malignant transformation under certain conditions. 
Pharmacological activation of GR signaling in diseases, e.g. by established GR 
agonists (e.g. Prednisolone or Dex) would result in potent transactivation of the 
Socs2 promoter, leading to indirect suppression of Jak2-Stat5 signaling, presumably 
ameliorating disease. 
 
4.2. Compound loss of hepatic Stat5 and GR signaling causes steatosis 
 
Deletion of Stat5 in hepatocytes causes modest, non-progressive steatosis. 
Surprisingly, combined ablation of Stat5 and the GR induced severe, progressive 
steatosis, and steatohepatitis. Thus, we propose a two-step model of steatogenesis 
in Stat5AlfpCre and Stat5/GRAlfpCre mice.  
(i) Hepatocyte-deletion of Stat5 leads to insulin resistance and steatosis due to 
induction of hepatic de novo lipogenesis. This is reflected by the phenotype observed 
in young Stat5AlfpCre and Stat5/GRAlfpCre mutants (‘1st step’). Peripheral adipose 
tissues are unaltered at this time point.  
(ii) Additional deletion of the GR mobilizes lipids from peripheral fat stores which 
eventually accumulate in the liver of older animals. This is reflected by the dramatic 
phenotype seen in older Stat5/GRAlfpCre mice (‘2nd step’).  
Triglyceride synthesis in the liver is mainly controlled by two transcription factors: 
Firstly, SREBP-1c controls cholesterol and fatty acid synthesis 188, 189. Secondly, the 
nuclear hormone receptor PPARgamma promotes lipogenesis in concert with 
C/EBPalpha 43, 190. In addition, SREBP-1c potentiates activation of the adipogenic 
PPARgamma/C/EBPalpha axis 48. Overexpression of SREBP-1c or PPARgamma 
factor induced steatosis in transgenic mice 45, 46, 191. Molecular signature analysis 
revealed a potent upregulation of SREBP-1c/PPARgamma-dependent de novo 
lipogenesis in Stat5AlfpCre and Stat5/GRAlfpCre animals. This was in line with a rising 
number of mouse models for liver steatosis which are characterized by SREBP-1c 47, 
192 and/or PPARgamma upregulation 47, 193, 194. The importance of PPARgamma and 
SREBP-1c has been underscored by their deletion in steatotic ob/ob mice. In both 
cases a reversion of hepatic fat accumulation was observed 39, 44. PPARalpha 
constitutes another important PPAR family member regulating beta-oxidation of fatty 
acids. High PPARgamma levels can lead to aberrant transactivation of the 
PPARalpha promoter 195. The induction of PPARalpha-dependent peroxisomal and 
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mitochondrial catabolism could be caused by this cross reactivity. Another, more 
speculative explanation for combined induction of PPARgamma and PPARalpha 
signaling pathways could be putative repressive functions of Stat5 in 
PPARalpha/gamma transcription. Indeed, Stat5 responsive elements were found in 
the human PPARgamma promoter 196 and an inhibitory function of Stat5 on 
PPARalpha/gamma-dependent transcription was demonstrated in vitro 197. Recently, 
a report underlined the significance of Stat5/PPARgamma interplay in hematopoietic 
disorders 198. Yet, the molecular nature of Stat5/PPAR interplay in epithelia remains 
enigmatic without further investigation.  
In most cases, a tight correlation exists between steatosis and hepatic insulin 
resistance 64, 199. The hyperinsulinaemic conditions subsequently lead to increased 
de novo lipogenesis via SREBP-1c 200 and a blunted suppression of FFA release 
from adipose tissues via HSL. High circulating levels of FFA can induce steatosis by 
aberrant deposition of lipids in hepatocytes. Increased plasma levels of FFA, resistin 
and insulin in Stat5AlfpCre and Stat5/GRAlfpCre mice suggested insulin resistance. This 
was confirmed by functional glucose and insulin tolerance tests. A molecular defect in 
phosphorylating the IR-adaptor proteins IRS-1 and IRS-2 upon insulin challenge was 
concomitantly observed. Two possible mechanisms might explain the insulin 
resistance observed in Stat5AlfpCre and Stat5/GRAlfCre animals:  
(i) The insulin resistance is secondary to the lipid accumulation caused by increased 
SREBP-1c/PPARgamma-dependent de novo lipogenesis. A similar effect is seen 
upon short term high-fat diet feeding of mice. These animals develop primary 
steatosis without concomitant insulin resistance 201. Hepatic insulin resistance 
develops later due to impaired IRS-1 and IRS-2 phosphorylation, as high levels of 
SREBP-1c are correlated to impaired transcription of IRS-2. Indeed, reduced levels 
of IRS-2 protein in concert with high SREBP-1c levels are observed in Stat5AlfpCre and 
Stat5/GRAlfpCre mice (Figure 24B and Figure 23A). 
(ii) Hepatic insulin resistance in Stat5AlfpCre and Stat5/GRAlfpCre animals could be due 
to a putative IR-docking function of Stat5b. This was reported by multiple studies 
relying e.g. on Yeast 2-Hybrid screens 52, 54. Insulin-dependent activation of Stat5 
was demonstrated to be independent of Jak2 upstream kinases 202. Our data support 
the latter notion, especially as mice harbouring conditional deletions of Jak2 in 
hepatocytes (Jak2AlfpCre) did not develop steatosis (Figure 29A, B). Thus, conditional 
deletion of Stat5 in hepatocytes might lead to primary defects in IR-dependent signal 
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transduction. The aggravated insulin resistance phenotype of Stat/GRAlfpCre mice 
compared with Stat5AlfpCre animals was a reflection of the combination of both, 
pronounced insulin resistance (due to deletion of Stat5) and glucose intolerance (due 
to deletion of GR) (Figure 24A). This condition might be due to either increased 
internalisation or prolonged cytoplasmic retention of the IR, a compensatory 
mechanism described in vitro 203. This was reflected in the reduced phosphorylation 
of the IR itself upon insulin action in Stat5/GRAlfpCre animals. Surprisingly, we could 
not detect any significant in vivo tyrosine phosphorylation of Stat5b upon insulin 
injection over different time points and doses. Our data currently suggest a 
cytoplasmic role for Stat5b proteins in insulin signaling, but further proof would be 
required to clarify the role of Stat5b proteins in the IR signal transduction cascade. 
Steatosis is not only found in obese but also in lean patients suffering under 
depletion of peripheral adipose tissues (lipodystrophy). The extend of hepatic fat 
accumulation correlates well with degeneration of peripheral fat depots 204. The 
homeostasis of adipose tissues is usually tightly controlled. Among others, GH 
possesses potent lipolytic properties. High levels of GH reduce adipose tissue mass 
via increased basal lipolysis 205 and leads to increased levels of FFA 148. This effect is 
dependent of Stat5 activation in adipose tissues 206.  
Glucocorticoids in contrast have anti-lipolytic properties and favour fat accumulation 
in adipose tissue via stimulation of LPL 145. Interestingly, a combination of both (GH+ 
glucocorticoids) leads to dramatic lipolysis exceeding the lipolysis induced by GH 
alone 148, 149. The secretion of GH is controlled via negative inhibition by IGF-1. 
Hepatic deletion of Stat5 reduced the synthesis of IGF-1 which was followed by high 
systemic levels of GH (GH resistance) 126. This liver-neuroendocrine feedback 
mechanism was reflected in the modest depletion of fat storages in Stat5AlfpCre knock-
outs 123, 127 and was consistent with previous reports showing high levels of 
circulating GH levels upon hepatic Stat5 deletion 207. The GH-mediated lipolysis was 
reflected in high phosphorylation of Stat5 in WAT of Stat5AlfpCre and Stat5/GRAlfpCre 
animals.  
In contrast, GRAlfpCre mice harboured enlarged fat pads and showed signs of 
hypercorticolism (preliminary data, not shown). We could show that high levels of 
corticosterone in GRAlfpCre and Stat5/GRAlfpCre animals were caused by elevated 
concentrations of ACTH. High levels of corticosterone subsequently led to increased 
nuclear translocation of the GR in WAT. A liver-mediated inhibitor of glucocorticoid 
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secretion (as seen for IGF-1 regulating GH secretion) was so far not described. Yet, 
mouse models with defects in hepatic gluconeogenesis (as seen in GRAlfpCre mice 136) 
showed elevated levels of ACTH and corticosterone 208. We excluded ectopic 
expression of the AlfpCre recombinase in the pituitary gland due to the reported 
obesity phenotype observed upon Stat5 deletion using Nestin-Cre., which deletes 
also in the pituitary 209. We can currently not exclude that mechanisms upstream of 
the pituitary might contribute to ACTH release upon hepatic GR or Stat5/GR deletion. 
Taken together, Stat5/GRAlfpCre animals harboured a hyperactive HPA axis leading to 
elevated levels of GH and glucocorticoids. This led to potent lipolysis of adipose 
tissues resulting in peripheral lipodystrophy. Increased mobilisation of triglycerides by 
combined GH and glucocorticoid action subsequently resulted in the massive flux of 
FFA into the liver of Stat5/GRAlfpCre mice (‘2nd hit’). This aggravated the mild steatosis 
caused by increased de novo lipogenesis upon Stat5 deletion in hepatocytes (‘1st 
hit’).  
 
4.3. Loss of hepatic Stat5 signaling leads to severe liver fibrosis in the 
MDR2-/- mouse model of inflammatory liver cancer 
 
Liver fibrosis constitutes a severe liver pathology induced by constant liver damage 
and concomitant wound-healing processes. Repetitive liver insults such as chronic 
alcohol abuse or viral infections result in abundant collagen deposition around 
hepatic lobes, a process in which dynamics and magnitude of fibrotic damages are 
orchestrated by the nature of the damaging agent. It is widely established that bile 
flux perturbations and impairments in hepatic bile uptake result in cholestasis, in turn 
constituting a major risk factor for developing liver fibrosis. In various mouse models 
for cholestasis, the expression of NTCP1 and OATP1, two major basolateral bile 
pumps are severely compromised 179, 180. Whether these observations were 
causative for the development of cholestasis or mere compensatory consequences 
secondary to elevated serum bile levels could not be fully answered. NCTP1 and 
OATP1 183 are established Stat5 target genes, transcribed upon prolactin action. It 
was thus conceivable that loss of hepatic Stat5 would result in profound defects of 
bile flux across the hepatocyte. Interestingly, this did not induce cholestasis in 
Stat5AlfpCre mutants alone. We hypothesized that additional insults due to loss of the 
apical MDR2 bile transporter are necessary to induce overt cholestasis as observed 
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in MDR2-/Stat5AlfpCre double mutants. Generally, cholestasis and the concomitant 
retention of toxic bile in hepatocytes leads to constant hepatocyte damage, 
transdifferentiation of HSC, ECM remodelling and degeneration of hepatocytes. 
Thus, MDR2-/Stat5AlfpCre mutants constitute a valuable murine model for liver fibrosis 
and could assist in further investigating molecular mechanisms underlying hepatic 
fibrogenesis. One especially intriguing aspect could be the pharmacologically 
induction of Stat5-dependent bile transporters putatively leading to alleviation of the 
disease. 
 In summary, my work on the Stat5GR transcription factor gene regulatory 
network contributes to our molecular understanding of postnatal body growth, the 
regulation of hepatic lipid metabolism and fibrogenesis in the liver. Hopefully, these 
results will lead to therapeutic inventions leading to amelioration of disease. 
 
 
5. Materials and Methods 
 
5.1. Materials  
 
5.1.1. Chemicals and enzymes: 
 




 VWR international, Darmstadt, Germany 
Sigma-Aldrich, Vienna, Austria 
Lactan, Graz, Austria 
Eppendorf, Vienna, Austria 
Amersham, Vienna, Austria 
Fisher Scientific, Vienna, Austria 
Sarstedt, Wr. Neudorf, Austria 
Qiagen, Vienna, Austria 
Biorad, Vienna, Austria 
PAA, Pasching, Austria 
Applied Biosystems, Foster City, USA 
Neolab, Heidelberg, Germany 
BD Biosciences, Franklin Lakes, USA 
Novo Nordisk Pharma, Vienna, Austria 
MP Biomedicals, Illkirch, France 
IBL Hamburg, Hamburg, Germany 
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Enzymes: 
Invitrogen, Karlsruhe, Germany 
Roche, Mannheim, Germany 
New England Biolabs, Schwalbach, Germany 
Fermentas, St. Leon-Rot, Germany 
DAKO, Glostrup, Denmark 
 
Radionucleotides: 
Amersham, Vienna, Austria 
 
5.1.2. Standard solutions 
 
10 x Phosphate buffered saline (PBS): 
80 g     NaCl 
2 g     KCl 
14.4 g    Na2HPO4 
2.4 g     KH2PO4 
? adjust pH to 7.4, fill up with H2Odd to 1 L and autoclave 
 
10 x TBE (Tris borate EDTA) buffer : 
108 g     Tris 
55 g     boric acid 
40 ml     0.5 M EDTA 
? fill up with H2Odd to 1 L and autoclave 
 
50 x TAE (Tris acetate EDTA) buffer: 
242 g      Tris  
57.1 ml Acetic acid 
100 ml 0.5 M EDTA (pH 8.0) 
? fill up with H2Odd to 1 L and autoclave 
 
TE buffer: 
10 mM   Tris/HCl pH 8.0 
1 mM    EDTA pH 8.0 
 
5.1.3. Media for bacterial cultivation 
 
LB medium: 
10 g    Bacto-Trypto1   
5 g    Yeast Extract    
5 g    NaCl     
--> fill up with H2Odd to 1 L, set pH =7.2 using NaOH and autoclave 
  
LB agar: 
1 x LB medium 
1.5 % (w/v) bacto agar  
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5.1.4. Plasmid constructs 
 
pMSCV: 
The pMSCV (Murine Stem Cell Virus) plasmids, originally designed as expressed 
vectors optimised for efficient protein expression in stem cell lines, are widely used in 
other mammalian cell lines. pMSCV plasmids harbour mutated MSCV-derived long 
terminal repeats (LTR) ensuring high transcriptional activity, driving abundant protein 
expression of cloned target genes. In addition, pMSCV plasmids harbour ampicillin 
resistance cassettes for selection of transformed bacteria. Hygromycin (hygro) 
resistance cassettes allow stable transfection of mammalian cell lines. A green 
fluorescent protein (GFP) is situated at the 3’ end of the cloned target gene under the 
control of an internal ribosomal entry site (IRES) allowing for quantification of 
transfection efficiency using FACS (fluorescence activated cell sorting) analysis. The 
multiple cloning site (MCS) harbours restriction sites for standard restriction 
endonucleases used in molecular biology. 
 
pE2F-Luc reporter plasmids: 
pE2F-Luc was originally designed for monitoring E2F-promoter-dependent (a major 
target gene of the retinoblastoma (Rb) tumour suppressor, a critical cell-cycle 
regulator) transcriptional activation. To adapt the pE2F-Luc vector for quantifying 
Stat5-dependent transactivation of the Socs2 promoter, respective 5’ promoter 
regions were cloned 3’ of the TA minimal promoter (Figure 14). Thus, Luciferase 
transcription is driven by (i) the minimal TA promoter in concert with E2F enhancer 
elements and (ii) a variable Socs2 promoter region.  
 
5.2. Molecular biology  
 
5.2.1. Standard techniques 
 
5.2.1.1. DNA electrophoresis 
 
Routinely, DNA fragments were analysed by separation according to their molecular 
weight using agarose gel electrophoresis. Briefly, 1-2 % (w/v)  low-melting agarose 
(Roche Cat. No. 1388991) was dissolved in 1 x TAE buffer, boiled in a microwave 
oven and allowed to cool down to approximately 40-50 °C. Five μl of ethidium 
bromide (10 mg/ml) was added per 100 ml agarose solution, the gel cast in plastic 
trays and allowed to solidify at RT. Depending on the size and agarose concentration 
of the gel a voltage between 80-130 V was applied. The migratory behaviour of the 
DNA fragments was visualised using a short-wave UV lamp. 
 
5.2.1.2. Extraction of DNA fragments from agarose gels 
 
Following size-separation by agarose gel electrophoresis, gel slices containing 
desired DNA fragments were excised under a UV lamp using a sterile blade. The 
DNA was separated from the agarose and purified using the QIAquick Gel Extraction 
Kit (Qiagen Cat. No. 28704) according to vendor’s instructions. After column-based 
purification,  the DNA was eluted with H2Odd and stored at -20 °C until needed.  
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5.2.1.3. Transformation of bacteria 
 
Chemically competent E.coli DH5alpha Library efficiency (LE, Invitrogen Cat. No. 
18263012) were used for standard plasmid amplification and transformation. For 
transformation, 200 μl of chemically competent LE were thawed on ice and 100 
μl/reaction transferred to a prechilled 15 ml Falcon tube. Depending on the 
application either (i) 100 ng of plasmid DNA or (ii) 2 μl of ligation reaction mixture 
were added on ice and mixed gently. The reaction was incubated on ice for 20-30 
min followed by a heat shock at 42 °C for exactly 90 s. Subsequently, the tube was 
allowed to chill on ice for 2 min and 900 μl of prewarmed LB medium added. The 
reaction was incubated at 37 °C for 60 min under shaking at 225 rpm and various 
dilutions of the reaction mixture plated on appropriated agar selection plates 
overnight.  Positive single cell clones were picked using a sterile tip and transferred 
to a 15 ml Falcon tube containing 4 ml LB medium plus antibiotics. 
 
5.2.2. Vector cloning 
 
Cloning of truncated Socs2 promoter fragments (see Figure 14) into the pE2F-Luc 
Luciferase vector was performed using established protocols from Sambrook et al. 
(1989). Briefly, respective genomic sequences were amplified using primers 
containing appropriate restriction endonucleases sites. The PCR fragments were 
then cut by restriction enzymes, dephosphorylated using calf intestine phosphatase 
and ligated using T4 ligase into appropriately cut vectors. Purification of DNA 
fragments was carried out using the QIAquick Gel-Extraction Kit (Qiagen) according 
to supplier’s protocol. Chemically competent DH5alpha E.coli was heatshock 
transformed and plated on agar selection plates. Positive clones were confirmed by 
restriction analysis and DNA sequencing. 
 
5.2.2.1. Cloning strategy for Socs2 reporter constructs 
 
In the following, DNA sequences of primers are given which were used for PCR 
amplification of Socs2 promoter regions for subsequent cloning into the pE2F-Luc 
Luciferase reporter vectors: 
 
PrimerID Sequence (Localisation 5’ of Socs2 mRNA transcription start) 
 
S2Clon1 GCG CGG CCA CGC GTT CTG TGC AAA GGC CCA GGA GGG   
 (bp -4696 to -4675 5’ of Socs2 mRNA ATG) 
 
S2Clon2 GCG CGG CCA CGC GTG CAT CCT GCT AAG TTA CTC CC 
 (bp -3402 to -3364 5’ of Socs2 mRNA ATG) 
 
S2Clon3b GCG CGG CCA GAT CTA GTG TGC GCG CGA CTT CCC AG 
 (bp -1845 to -1865 5’ of Socs2 mRNA ATG) 
 
S2Clon4b GCG CGG CCA GAT CTG GGA GAT GAG TCA ACA CGT CC 
 (bp 1 to -20 5’ of Socs2 mRNA ATG)     
  
 Mlu I site 
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 Bgl II site 
 
5.2.3. DNA isolation and analysis 
 
5.2.3.1. Isolation of plasmid DNA from bacteria  
 
Plasmid DNA was isolated using commercially available plasmid isolation kits 
(Qiagen Cat. No. 27106) according to vendor’s manual. Briefly, bacteria were lysed, 
cellular debris removed and the supernatant given onto a DNA-binding matrix 
column. The column was rinsed extensively with ethanol and the DNA eluted using 
nuclease-free H2Odd. The DNA concentration was determined using UV/VIS 
spectrophotometry: The OD at 260 nm was used for calculation of DNA concentration 
and the OD ration of 260 nm/280 nm served as indicator of DNA purity. Generally, 
DNA exhibiting a 260 nm/280 ratio = 1.8-2.0 were used for subsequent experiments. 
The DNA was used instantly for cloning purposes or stored at -20 °C for long-term 
storage. 
 
5.2.3.2. Isolation of tail DNA for genotyping  
 
Pubs were weaned between day 17-21 post natum and identified using ear tags. In 
addition, a 1-2 mm tail piece was clipped using sterile scissors, transferred into a 1.5 
ml reaction tube and digested in 200 μl of NID buffer containing 2 μl of Proteinase K 
(stock solution 10 mg/ml) overnight at 56 °C. The next morning, the proteolytic 
activity was inactivated by heating to 95 °C for 10 min. Two μl of supernatant used as 
template for genotyping the mice using gene-specific genotyping PCR. 
 
NID buffer: 
50 mm   KCl  
10 mM    Tris-HCl (pH 8.3) 
2 mM     MgCl2 
0.1 mg/ml   Gelatine 
0.45 %    NP-40 
0.45 %   Tween-20 
 
 
5.2.3.3. Genotyping PCR  
 
To determine the allele status of specific genes, 2 μl of tail DNA were analysed by 
gene-specific PCR using Taq-polymerase (Roche) following manufacturer’s 
instructions. The cycling conditions used for all genotyping PCR were as follows: 
  
 95 °C    5 min   Initial denaturation 
 (1 cycle) 
  
 95 °C    20 s   Denaturation 
 55 °C    20 s   Annealing 
 72 °C    90 s   Elongation  




 72°C    10 min  Final elongation 
 (1 cycle) 
 
Following PCR amplification, the reaction mixture was diluted with DNA loading 
buffer and analysed using 2 % agarose gel electrophoresis containing 5 μl ethidium 
bromide (10 mg/ml) per 100 ml gel.  
 
In the following, DNA sequences of primers used for gene-specific genotyping PCR 
are given. All oligonucleotides were obtained commercially (MWG Biotech, Munich).  
 
Primer ID    Sequence      
GR flox1    5´ – GGC ATG CAC ATT ACG GCC TTC T – 3´ 
GR flox4    5´ – GTG TAG CAG CCA GCT TAC AGG A – 3´ 
GR flox8    5´ – CCT TCT CAT TCC ATG TCA GCA TGT – 3´ 
 
Amplicons: 
GRwt    225 bp,  
GRflox    275 bp 
GRnull    390 bp 
 
Primer ID    Sequence      
S5del1685    5’ – GAA AGC ATG AAA GGG TTG GAG – 3’ 
S5fl1686    5’ – AGC AGC AAC CAG AGG ACT AC – 3’  
S5fl1842    5’ – AAG TTA TCT CGA GTT AGT CAG G – 3’ 
  
Amplicons: 
  Stat5wt  450 bp 
  Stat5flox  200 bp 
 
Primer ID    Sequence      
Cre1      5’ – CGG TCG ATG CAA CGA GTG ATG AGG – 3’ 
Cre2     5’ – CCA GAG ACG GAA ATC CAT CGC TCG – 3’ 
 
Amplicons: 
  AlfpCre+  700 bp 
 
Primer ID    Sequence      
MDR2for    5’ – GCT GAG ATG GAT CTT GAG – 3’ 
MDR2rev    5’ – GTC GAG TAG CCA GAT GAT GG – 3’ 
 
Amplicons: 
  MDR2wt  362 bp 
   
Primer ID    Sequence      
NEOgeno1    5’ - ATC CAA AGC CAG AGC ACC GG – 3’ 
NEOgeno4    5’ – TTT GTC ACG TCC TGC ACG ACG C – 3’ 
 
Amplicons: 
  MDR2-  700 bp 
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5.2.4. RNA isolation and analysis  
 
5.2.4.1. Isolation of messenger RNA from murine livers 
 
High quality mRNA was isolated from frozen organs (e.g. liver, adipose tissues). 
Approximately 50 mg of frozen tissue were transferred into a prechilled 14 ml round 
bottom Falcon tube containing 5 ml of Trizol reagent (Fisher Scientific Cat. No. 
VX15596018). Tissue specimens were homogenized directly in Trizol using a rotating 
blade homogenator. The resulting homogenate was incubated for 2-3 min at RT to 
sequester RNA from bound nucleoprotein complexes and transferred into a new 
nuclease-free reaction tube. Chloroform was added (200 μl per initial 1 ml of Trizol 
reagent), vigorously shaken and centrifuged at 12,000 rpm for 15 min at 4 °C. The 
upper aqueous phase, containing hydrophilic RNA was transferred into a new tube, 
carefully ensuring no cross-contamination with the lower organic phase. For 
precipitation, 0.7 x (v/v) 2-propanol was added and incubated for 10 min at RT. Two 
μl of glycogen were added to facilitate pellet handling at later stages. Centrifugation 
at 12,000 for 10 min led to pelleting of precipitated RNA, which was washed two 
times with 75 % DEPC-Ethanol. Finally, the solvent was removed, remaining ethanol 
droplets carefully removed using a pipette and 100 μl of DEPC-H2O added for 
solubilization of the RNA. The solubilization was facilitated by incubating the tube at 
37 °C for 10 min. Isolated RNA was used for Affymetrix expression profiling or 
reversely transcribed into cDNA for quantitative RT-PCR (qPCR) analysis. Samples 
were stored at -80 °C and repeated freeze-thawing avoided by appropriate aliquoting.  
The RNA quality and quantity was determined using agarose 1 % RNAse-free 1x 
MOPS gel electrophoresis: For this, 500 ng of isolated RNA were diluted in 10 μl 
RNA denaturation buffer and incubated at 65 °C for 10 min. Following denaturation, 
samples were loaded onto the gel and separated at low voltage (< 80 V). High RNA 
quality could be ascertained by three clearly discriminable bands for 28 S, 18 S and 
5.8 S of ribosomal RNA (rRNA). The ratio between 28 S to 18 S RNA bands should 
be approximately 2:1. 
 
H2O/DEPC 
1 l    H2Odd 
1 ml    Diethylpyrocarbonate (DEPC) 
? The mixture was stirred, incubated overnight at RT and autoclaved 
 
RNA denaturation buffer: 
5 μl    Ethidium bromide 
0.5 μl    10x MOPS buffer 
5 μl     Forma mide 
1.75 μl    Formaldehyde 
0.55 μl    Nuclease-Free H2O 
 
MOPS buffer: 
41.8 g    [N-Morpholino] propanesulfonic acid (MOPS) 
6.8 g    Sodium Acetate 
20 ml    0.5 M EDTA 
? fill up with DEPC-H2O to 1 L, autoclave and store at 4 °C in the dark. 
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In addition, the concentration of isolated RNA was quantified using UV/VIS 
spectrophotometry at 260 nm. The 260 nm/ 280 nm ratio was an indicator of RNA 
purity and should by >1.8.  
 
5.2.4.2. Reverse transcription 
 
For synthesis of complementary DNA (cDNA) from respective mRNA samples, 1 μg 
of total RNA were used. The cDNA synthesis was carried out using commercially 
available kits (Applied Biosystems). Total RNA was diluted to 2 μl and incubated with 
MuLV reverse transcriptase (Applied Biosystems Cat. No. N8080018) buffer, oligo-dT 
primers (Applied Biosystems Cat. No. N8080128), RNAse inhibitor (Applied 
Biosystems Cat. No. N8080119) and DEPC-H2O for 5 min at 70 °C for annealing of 
oligo-dT primers onto poly-A sequences of the mRNA. Afterwards, the samples were 
incubated on ice for > 2 min and 1 μl MuLV reverse transcriptase (Applied 
Biosystems Cat. No. N8080018) were added, followed by an incubation for 60 min at 
42 °C. A final heat inactivation step at 70 °C for 10 min removed residual reverse 
transcriptase activity. The cDNA was diluted 1:5 and was used instantly or stored at -
20 °C. 
 
5.2.4.3. Quantitative RT-PCR (qPCR) 
 
Five μl of diluted cDNA samples (section 5.2.4.2) were used for quantification of 
gene-specific transcript levels via quantitative RT-PCR (qPCR). For this, the diluted 
cDNA was amplified using commercially available Taq polymerase kits (Eppendorf 
Cat. No. 0032007724) according to manufacturer’s instructions. Intron-spanning 
primers ensured amplification of specific mRNA transcripts. Cross-contamination of 
genomic DNA (gDNA) was excluded by regular testing of mRNA samples not 
reversely transcribed. The SYBR green method was applied for determining 
concentrations of double stranded PCR products obtained after PCR using intron-
spanning primers. The PCR cycle in which a given mRNA specific fluorescent signal 
crossed an arbitrary threshold was defined as CT.cycle. The difference of a gene-
specific CT value to that of an endogenous housekeeping gene (GAPDH) was called 
ΔCT value.. Individual ΔCT for all genotypes were calculated and compared relatively 
to controls. The primer sequences were designed manually and DNA 
oligonucleotides obtained from a commercial supplier (MWG Biotech, München). The 
DNA sequences of primers used for qPCR analysis are given in (Table 5). 
 
Gene symbol Accession No. Sequence 
   
Srebp-1 NM_011480 for: GCG TGG TTT CCA ACA TGA CC  rev: CTC CAG CTC AGC TGT AGT GC 
Fasn NM_007988 for: TGT CTG ACA CTG GCA ATC TGA T rev: CGG TCA CAC GGG TAG GTA GC 
Scd1 NM_009127.3 for: CGC TCT TTA CCC TTT GCT G rev: ATA GTC AGT TGC TCG CCT CAC 
Scd2 NM_009128.1 for: ATC TGC AGG ATT GCC TCT GGG rev: TCT CAT GCT CAC ACC TAC CCG 
Acaca NM_133360.2 for: GGA CTT CAT GAA TTT GCT GAT TCT CAG TT rev: GTC ATT ACC ATC TTC ATT ACC TCA ATC TC 
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Acacb NM_133904.1 for: AGT GTG TAA GAA GCT CGT GGG rev: CCT CCA GTA GAA GAA GGT GCG 
Pparg NM_011146.2 for: ACC CAA TGG TTG CTG ATT AC rev: CGG GAA GGA CTT TAT GTA TGA G 
Dgat1 NM_010046.2 for: TGT GGT GAT GCT GAT CCT GAG rev: GGA TAG GAT CCA CCA GGA TGC 
Dgat2 NM_026384.3 for: TGG CAT AAG GCC CTA TTT GG rev: ATG GTG TCT CGG TTG ACA GG 
Cd36 NM_007643.3 for: CCT TAC TTG GGA TTG GAG TGG rev: CGG CTT TAC CAA AGA TGT AGC C 
Fabp4 NM_024406.1 for: TTC GAT GAA ATC ACC GCA GA rev: AGG GCC CCG CCA TCT 
Mod1 NM_008615.1 for: AGT TGC TCT TGG GGT GGT GGC rev: TAG TGC TGT ACA TCT GGG AGG 
Ppara NM_011144.3 for: ATC GCG TAC GGC AAT GGC TTT A rev: GCC TCG GAG GTC CCT GAA CAG 
Acox1 NM_015729.2 for: CCG CCT ATG CCT TCC ACT TTC TC rev: CGC CAC TTC CTT GCT CTT CCT GT 
Ehhadh NM_023737.2 for: CCG GTC AAT GCC ATC AGT CC rev: GGT AGA AGC TGC GTT CCT CTT GC 
Acadm NM_007382.2 for: ATG ACG GAG CAG CCA ATG A rev: ATG GCC GCC ACA TCA GA  
Acadl NM_007381.3 for: AGC TGA TCG CAA GAC AGA TCG rev: AGA ATC CGC ATG AGC TGC ATG 
Acavdl NM_017366.2 for: CCC GGT TCT TTG AGG AAG TGA A rev: AGT GTC GTC CTC CAC CTT CTG 
Cpt1 NM_009948.1 for: CGA GGA TTC TCT GGA ACT GC rev: GGT CGC TTC TTC AAG GTC TG 
Pgc1a NM_008904.1 for: CCG ATC ACC ATA TTC CAG GT rev: GTG TGC GGT GTC TGT AGT GG 
Cebpa NM_007678   for: ATG GAG TAC AGC GGT GAG TAT TC rev: GTT GCC ACT GGA CAT CTC TTC 
Cebpb NM_009883.2 for: GGT GGA CAA GCT GAG CGA CGA GTA rev: AAC AAG TTC CGC AGG GTG CTG AG 
Hnf1a NM_009327.2 for: CCA CGT TCA CGA ACA CGG GCG CC rev: TGG AGG CCT CTG TGT CTG AGG TG 
Rxra NM_011305.3 for: CGA GCC ATT GTC CTG TTC AAC CC rev: TGG CTT GAT GTG GTG CCT CCA GC 
Tgfb1 NM_011577.1 for: GGC ACC GGA GAG CCC TGG ATA CC rev: CGG CAC GCA GCA CGG TGA CGC CG 
Tgfbr NM_009370.2 for: TTG CCA GGA CCA TTG TGT TA rev: GGA ACC ATG AAC GCT CTT CT 
Pdgf1 NM_011057.3 for: CCC ACA GTG GCT TTT CAT TT rev: GTG GAG GAG CAG ACT GAA GG 
Pdgfr NM_008809.1 for: TCA ACG ACT CAC CAG TGC TC rev: TTC AGA GGC AGG TAG GTG CT 
Col1 NM_007742.3 for: CAC CCT CAA GAG CCT GAG TC rev: TGG CGG GCT GAT GTA CCA GT 
Col3 NM_009930.1 for: GGG GAC CAG GGC GAC CAC T rev: CAG GTG AAC CCG GCA AGA ACG 
Timp1 NM_011593.2 for: TCC TCT TGT TGC TAT CAC TGA TAG CTT rev: CGC TGG TAT AAG GTG GTC TCG TT 
Timp2 NM_011594.3 for: GGG ACA CGC TTA GCA TCA CCC rev: GAA GAA CTT GGC CTG GTG CCC 
Mmp2 NM_008610.2 for: TCC CTG ATA ACC TGG ATG CCG rev: GCA GCG ATG AAG ATG ATA GGG C 
Mmp3 NM_010809.1 for: CAT TCA CAC CCT GGG TCT CCC rev: GCT TCA AAG ACA GCA TCC ACC C 
Mmp13 NM_008607.1 for: TCT TCT CTG AGA ACC ACG TGT GG rev: GAC TCT CAC AAT GCG ATT ACT CC 
                                                                                                   Materials and Methods 
95 
Mmp14 NM_008608.2 for: GGG TGT TTG ACG AAG CCT CCC rev: GCT GAC TTG GGA TAC CCT GGC 
Mmp15 NM_008609.3 for: ATC CCC ACC TCT CCC AAA GGG rev: TCC CGC AGG ATG GAT TTG GGG 
Ntcp1 NM_011387.1 for: ACC TTC CCC CCT GAA GTC ATT GG rev: GGA TTA TTC CCG TTG TGG GTA CC 
Oatp1 NM_013797.2 for: GTT TCA TCT TCT CAC TCG CAG CC rev: TTG ATC CTC TCA CTG CTG CAG GC 
Bsep NM_021022.3 for: CAA CAC CAA AGA GAT CTC CGT GG rev: CAA TGA CAA TAC AGG TCC GAC CC 
Mdr1b NM_011075.1 for: TTG TGA GGG CAG CCA AGG AGG CC rev: CAC AAT GCA GGT GCG GCC TTC CC 
Mrp2 NM_013806.2  for: TTG TGG CTG GCC TGC AAC TTG GG rev: CAA TCT TGC CGC TGT CTA GGA CC 
Oatp2 NM_178235.2 for: GAA TTG AAA TCA CTT GGA ATG GG rev: TTA AAG CTA TAC TCA AAC CCA CG 
Mrp3 NM_029600.3 for: GCA GGC CTG GAT TTC CAG TGC GC rev: ATT CAG CTA CTA CTC CTT TGT CC 
Table 5. Primer sequences used for qPCR experiments 
 
5.2.4.4. Whole genome expression profiling (Affymetrix) and bioinformatics 
 
For each microarray, three livers were pooled. Total RNA was isolated using RNeasy 
kits with DNAseI digest on column (Qiagen). RNA quality was assessed using the 
Bioanalyzer 2100 Lab-on-chip system (Agilent Technologies). Ten μg of isolated 
RNA were labelled and hybridised onto mouse U74Av2 arrays (Affymetrix), 
containing 12,500 sequences. We used three arrays for each mutant group 
(Stat5AlfpCre, GRAlfpCre, Stat5/GRAlfpCre and Stat5ΔN) and nine arrays for the control 
group (littermates to the mutant mice). Arrays were normalized using GCRMA. 
Genes with a mean expression of <25 in all of the groups were excluded. 
Significance levels were calculated in affylmGUI. As criterion for calling a gene 
significantly changed we used p < 0.001, or the combined criterion of p < 0.0025 and 
a log ratio >1 or less than −1 (fold change >2 or <0.5). Investigation of coordinated 
changes in functional gene sets was done using MAPPfinder. We limited the analysis 
to approximately 100 predefined groups, of which some where custom made. The 
two criteria for inclusion of genes were p < 0.01 and p < 0.05. Gene sets with p-value 
<0.05 after correction for multiple comparisons were considered significant. 
 
5.2.4.5. Molecular signature analysis of Affymetrix expression data 
 
We performed a specific molecular signature analysis for genes involved in lipid 
metabolism on raw data from microarray analysis previously described (section 
5.2.4.4). In order to find molecular signatures in the data we looked for coordinated 
changes in functional gene-sets using MAPPFinder 159. We limited the analysis to 
around one hundred hand-picked, pre-defined groups, of which some where custom-
made from papers describing profiles from the livers of mice lacking different 
transcription factors or administered with specific agonists or antagonists. Many lists 
were also taken from the GSEA software and consist of genes with certain motifs in 
their promoter regions as identified in a systematic study of regulatory motifs in 
mammals 210. The two criteria for inclusion of genes in the MAPPFinder-analysis 
were p<0.001 or p<0.05. This was done to pick up high magnitude changes of small 
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groups of genes and low-amplitude changes in large groups, respectively. Gene-sets 
with p-value <0.05 after correction for multiple comparisons were considered as 
significant. 
 
5.3. Protein chemistry 
 
5.3.1. Protein isolation 
 
5.3.1.1. Preparation of liver homogenates 
 
For preparation of murine liver homogenates, approximately 100 mg of tissue were 
transferred to a 15 ml round-bottom tube loaded with 1 ml of IP buffer containing 
Proteinase/phosphatase inhibitors (IP+ buffer). Using a tissue homogenator with 
rotating blades, liver specimens were solubilised directly in IP+ buffer until no tissues 
clumps were visible. Foam generation should be avoided to minimize protein 
denaturation. The homogenate was transferred to a fresh 1.5 ml reaction tube and 
cellular debris removed by centrifugation at maximum speed for 15 min at 4 °C in a 
table micro centrifuge. The supernatant was again transferred to a new tube and 
centrifugation repeated until the solutions turned translucent. The supernatant was 
either mixed instantly with 4xSB (reducing sample buffer) for SDS-PAGE, incubated 
with antibodies for immunoprecipitation purification or shock frozen in liquid N2 and 
stored at -80 °C. 
 
IP buffer: 
25 mM    HEPES pH 7.5 
150 mM    NaCl 
10 mM    EDTA 
0.1 %     Tween-20 
0.5 %     NP-40 
10 mM    beta-Glycerophosphate 
 
IP+ buffer = IP buffer containing: 
1 mM     Na3VO4 
1 mM     NaF 
10 μg/ml    Leupeptin  
10 μg/ml    Aprotinin 
1 mM     PMSF 
1 tablet  Complete protease inhibitor cocktail (Boehringer 
Cat. No. 1697498) 
 
4 x SDS sample buffer (reducing): 
240 mM    Tris/HCl pH 6.8  
40 mM    DTT    
8 %     SDS    
0.01 %    Bromphenol blue   
40 %     Glycerol    
? aliquoted and stored at -20 °C 
 
                                                                                                   Materials and Methods 
97 
5.3.1.2. Preparation of cell line extracts 
 
Cellular extracts from HEK293 cells used for EMSA analysis were prepared using 
whole cell extract (WCE) buffer. If not indicated otherwise, cells were harvested from 
Petri dishes using a sterile blade. Cells were washed two times with ice-cold PBS, 
followed by centrifugation at 12,000 rpm for 15 min at 4 °C and solubilisation in twice 
the cell pellet volume in WCE buffer. Disruption of cells was facilitated by incubation 
for 1 h at 4 °C under vigorous shaking using a horizontal shaker. Subsequently, 
cellular debris was removed by centrifugation at maximum speed for 15 min at 4 °C 
using a tabletop micro centrifuge. The supernatant was either directly used in EMSA 
analysis or shock frozen in liquid N2 and stored at -80 °C. 
 
WCE buffer: 
20 mM    Hepes pH 7.9 
20 %     Glycerol 
50 mM    KCl 
1 mM     EDTA 
1 mM     DTT 
400 mM    NaCl 
5 μg/ml    Leupeptin  
5 mM     Beta-Glycerophosphate  
1 mM     PMSF 
5 μg/ml    Aprotinin 
10 mM    NaF 
5 mM     Na3VO4 
? aliquot and store at -20°C 
 
5.3.1.3. Protein quantification with the Bradford method 
 
Protein  concentration in liver homogenates were quantified using Bradford reagent 
(Bio-Rad Cat. No. 500-0006). Briefly, a standard curve including protein 
concentrations ranging from 1 to 20 μg/μl was prepared in microcuvettes according to 
manufacturer’s instructions. The unknown protein sample was pipetted into a 
separate cuvette. When necessary, 1/10 dilutions of the unknown samples were 
prepared in the respective homogenisation buffer. Finally, the standards and samples 
were diluted in 1 ml of a 1:5 mixture of water and Bradford reagent, incubated for 5 
min and the absorption of measured at 550 nm. The protein concentration of 




For certain applications, enrichment of proteins was necessary prior to immunoblot 
analysis due to low expression of the respective protein. Immunoprecipitation utilised 
high-affinity binding of Sepharose bead-bound antibodies to the respective protein 
epitope. Briefly, 1000-2000 μg of tissue homogenate in IP+ buffer were diluted with 
IP+ buffer to a final volume of 600 μl. One μg of antibody/antiserum was added and 
antibody-antigen complexes allowed to form overnight under constant agitation using 
a wheel shaker. Subsequently, 40 μl of pre-swollen protein A Sepharose beads (GE 
Healthcare Cat. No. 17-0780-01) were added and incubated for 1 h at 4 °C on the 
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wheel shaker. The Fc region of the utilised antibody was bound with high affinity by 
the Protein A and stable Bead-Antibody-Epitope complexes were formed. After 
incubation, the Sepharose beads were rinsed three times with 700 μl of IP+ buffer 
and spun down in a micro centrifuge at 2,000 rpm for 1 min at 4 °C. After a final spin 
at 12,000 rpm for 5 min at 4 °C, the supernatant was discarded and pelleted 
Sepharose beads dissolved in 40μl of reducing SDS sample buffer. Finally, the 
mixture was heated to 95 °C for 5 min and the supernatant transferred into a new 1.5 
reaction tube. It was subsequently analysed instantly using Western Blot analysis or 
stored at -20 °C. Antibodies were used for immunoprecipitation as indicated in  
 
 
Table 6. Antibodies used for immunoprecipitation of respective proteins 
 
5.3.3. Western Blot  
 
5.3.3.1. Sodium Dodecylsulfate Polyacrylamide Gel Electrophoresis 
 
Cellular extracts or tissue homogenates diluted in 4x SDS sample buffer were boiled 
for 5 min prior to SDS-PAGE analysis including 5 % (v/v) of fresh beta-
Mercaptoethanole. According to original protocols introduced by Laemmli, proteins 
were separated in a discontinuous gel consisting of  
(i) A stacking gel with a low acrylamide percentage for focussing of migratory bands. 
 
Stacking gel (4 % acrylamide, 4 ml for two gels): 
0.5 ml    1.0 M Tris (pH 6.8)  
0.67 ml    30 % Acrylamide Mix 
20 μl    20 % SDS 
40 μl     10 % APS 
4 μl     TEMED 
2.7 ml    H2Odd      
 
(ii) A separation gel with variable acrylamide percentages for separation of proteins 
according to molecular weight. To facilitate polymerisation, the gel is overlaid with 2-
Propanol. Routinely, a 6 cm Minigel system was used (Bio-Rad Cat. No. 170-3940). 
The following separation gels were routinely casted: 
 
8 % gel (20 ml for 2 x 1.5 mm gels):  
5 ml    1.5 M Tris (pH 8.8) 
5.3 ml    30 % Acrylamide 
100 μl    20 % SDS 
200 μl    10 % APS 
12 μl     TEMED 
9.3 ml    H2Odd 
                                                                                                   Materials and Methods 
99 
 
10 % gel (20 ml for 2 x 1.5 mm gels): 
6.7 ml    1.5 M Tris (pH 8.8) 
5 ml     30 % Acrylamide 
100 μl    20 % SDS 
200 μl    10 % APS 
8 μl    TEMED 
7.9 ml    H2Odd 
 
10 x Laemmli buffer: 
25 mM    Tris-HCl (pH 8.3) 
192 mM    Glycine 
1 % (w/v)    SDS 
? fill up with H2Odd to 1 L and store at RT 
 
SDS-PAGE was carried out in 1 x Laemmli buffer running at 20-30 mA/gel until the 
dye in the loading buffer was running out of the gel. After electrophoretic separation 
gels were subjected to immunoblotting (section 5.3.3.2).  
 
5.3.3.2. Protein transfer onto Nylon membranes 
 
Protein transfer was carried out using Bio-Rad semi-dry blotting or wet blotting 
devices and proteins blotted onto 0.45 μm nitrocellulose membranes (GE Healthcare 
Cat. No. RPN303E) pre-equilibrated in transfer buffer. A current of 0.8 mA/cm2 was 
applied and proteins were allowed to transfer for 90 min (semi-dry transfer, RT) or 3 h 
(wet transfer, 4 °C). Following protein transfer, the membranes were rinsed with 
H2Odd and transfer efficiency controlled via staining with Ponceau S solution for 5 
min. Excess Ponceau staining was removed with multiple washes o H2Odd.  
 
 Ponceau S solution: 
0,1 %     Ponceau S dye 
5 %     Acetic Acid 
 
Transfer buffer: 
48 mM    Tris 
39 mM    Glycine 
0.037 % (v/v)   SDS 
20 %     Methanol 
 
5.3.3.3. Immunoblot analysis (antibody staining) 
 
Following Ponceau S staining, nitrocellulose membranes were washed twice with 
H2Odd and blocked for 1 h in blocking solution (5 % BSA in 1x TBST). The membrane 
was sealed in plastic foil and incubated overnight with respective primary antibodies 
diluted in TBST + 1 % BSA. Subsequently, the membrane was rinsed three times for 
10 min in 1x TBST and incubated for 30-45 min with an appropriate species-specific 
antibody conjugated to horseradish-peroxidase (HRP) in a dilution of 1:2000 to 
1:5000. Afterwards, membranes were washed three times with 1x TBST. For specific 
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detection of bands corresponding to the utilized antibody, an enhanced 
chemiluminiscence (ECL) system (Amersham Biosciences Cat. No. RPN 2132) was 
used to expose ECL films (THP Pierce Cat. No. PI-34091). The exposition times 
varied between the antibodies used. Primary antibodies were utilised as indicated in 
(Table 7). Membranes could be stripped of the primary antibody by immersion in 
stripping buffer for 30 min at 55 °C under constant agitation. Afterwards, the 
membrane could be blocked and re-incubated using different antibodies. 
 
Stripping buffer: 
6.25 ml   1 M Tris-HCl pH 6.8 
0.675 ml   beta-Mercaptoethanol 
10 ml    20 % SDS 
? fill up with H2Odd to 100 ml 
 
10 x TBST: 
500 mM    Tris-HCl    
1.5 M     NaCl    
 0.5 %     Tween-20   
 ? adjust to pH 8 and fill up with H2Odd to 2 L  
 
 




Electromobility shift assays (EMSA) constitute a widely utilised technique for studying 
in vitro the interaction between DNA binding proteins (e.g. transcription factors) and 
respective DNA elements. Briefly, radiolabeled DNA oligomers migrate along an 
electric current. The migration behaviour is influenced by interaction of DNA-binding 
protein interacting with respective DNA sequences and decelerating their migratory 
velocity (‘shift’). Additional binding of specific antibodies leads to further deceleration 
of the DNA-binding protein velocity (‘supershift’). For analysis of the DNA binding 
properties of full-length and N-terminally truncated Stat5 isoforms in vivo, we 
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prepared liver homogenates from PBS and GH-treated control as well as Stat5ΔN 
mice directly in IP+ buffer. The binding properties of GH-activated Stat5 were tested 
on classical Stat5 responsive DNA elements from the bovine beta Casein promoter. 
Similarly, the putative binding properties of GH-activated Stat5 on three putative 
Stat5 responsive elements found in the Socs2 promoter (Socs2 Stat5 RE #1-3) were 
assessed. To verify our findings in cell culture, we transfected HEK293 cells with 
pMSCV expression plasmids encoding for Stat5 and the erythropoietin receptor 
(EpoR). Subsequent Epo stimulation for 30 min led to potent activation and 
phosphorylation of cytoplasmic Stat5 molecules. The binding properties of Epo-
activated Stat5 on putative Stat5 responsive elements in the Socs2 were assessed 
using EMSA analysis. Single stranded DNA oligonucleotides applied for EMSA 
analysis (Table 8) were annealed at equimolar concentrations (~100 μM/oligomer) in 
200 µl annealing buffer (10 x = 0.625 x PCR buffer II (Roche); 9.4 mM MgCl2) by 
heating to 95 °C for 10 min, followed by slow cooling to RT and subsequent 
incubation on ice for > 15 min. Annealed double stranded DNA oligos were diluted to 
2.5 μM for radiolabeling. The labelling reaction (5 pmol of annealed dsDNA incubated 
with 10 U of polynucleotide kinase (PNK) and 5 µl of ATP 32P (Amersham 
Biosciences; 8,000 cpm/μl) were incubated at 37 °C for 1 h. Radiolabeled 
oligonucleotides were purified on size exclusion columns (Bio-Rad Cat. No. 7326221) 
and stored at –20 °C until needed. For analysis of Stat5-DNA binding interaction 
using EMSA, 20 µl reaction mixtures were prepared for each sample, containing 2 µl 
BSA solution, 2 µl poly-dI-dC (Roche Cat. No. 108812), 4 µl 5x binding buffer and 1 
µl of radiolabeled oligonucleotides. Usually 20-30 μg of liver homogenate or cellular 
extract were used per reaction. Protein extracts were incubated for > 5 min at RT 
before loading of the gel. For supershift analysis, the reaction mixture was incubated 
for >10 min with 1 µl of a rabbit polyclonal anti Stat5 specific antiserum. Complexes 
were separated on non-denaturating 4 % acrylamide gels containing 0.25 x TBE and 
run in 0.25 x TBE running buffer at 200 V for 2-3 h. The reaction was stopped after 
the Orange G dye, which migrates with a comparable velocity as unbound oligos, 
was running out of the gel. The gel was dried on a vacuum drier at 80 °C for 2 h and 
subjected to autoradiography. Coated Kodak MR films (Sigma Cat. No. Z350370) 
were exposed > 1 d at -80°C. 
 
BSA solution: 
10 mg/ml    BSA in 20 mM KPO4 
50 mM    NaCl 
0.1 mM    EDTA 
5 %     Glycerol 
 
5 x Binding buffer: 
50 mM    Tris 
5 mM     DTT 
1 mM     PMSF 
0.5 mM    EDTA 
25 %     Glycerol 
250 mM    NaCl 
0.5 %     KPO4 
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Table 8. DNA sequence of Stat5 responsive oligonucleotides used in EMSA analysis 
 
5.3.5. Tissue analysis and paraffin embedding 
 
Experimental mice were killed by asphyxiation or cervical dislocation and isolated 
organs cut in 2-3 mm thick slides, fixed for 48 h in phosphate-buffer 10 % 
formaldehyde solution and dehydrated using graded ethanol. The dehydrated organs 
were washed three times with xylene, replaced with liquid paraffin and finally cast into 
metal moulds and let solidify. Solid paraffin blocks were stored at RT until needed for 
histological or immunohistochemical analyses. Two μm thick sections of paraffin 
blocks were generated using a microtome (Leica) and subsequent smoothening in a 
50 °C water bath. Finally, the tissue sections were transferred onto poly-Lysine 
coated Superfrost glass slides (Lacton Cat. No. 193515000) and let dry at RT 
overnight. Tissue sections can be stored at RT for several weeks until needed for 




For standard histology using haematoxylin/eosin (HE) staining, paraffin sections of 2 
μm thickness were prepared, deparaffinised by incubation for 2x5 min in xylene and 
dehydrated using a decreasing ethanol (EtOH) gradient (2x2 min 100 % EtOH; 20 
dips in each 95 % EtOH, 95 % EtOH, 70 % EtOH, 50 % EtOH, H2Odd, H2Odd). 
Subsequently, sections were incubated in Mayer’s haematoxylin solution (VWR Cat. 
No. 1092490500) and rinsing with tap for 5-10 min to differentiate the staining 
intensity. Slides were counterstained with eosin solution (Roth Cat. No. 7089.2), 
dipped in H2Odd rehydrated using the aforementioned graded ethanol in reverse 
order. After a final incubation in xylene, tissue sections were mounted on Superfrost 
glass slides using Eukitt mounting medium (Lactan Cat. No. 361894G). 
 
Eosin solution: 
30 ml    1 % Eosin 
270 ml   70 % Ethanol 




For immunohistochemical analysis of PPARgamma and GR protein expression, 
overnight-dried paraffin sections were heated for 2 h at 60 °C or 30 min at 70 °C to 
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remove excess paraffin. Finally paraffin slides were rehydrated using graded ethanol 
(2x2 min 100 % EtOH; 20 dips in each 95 % EtOH, 95 % EtOH, 70 % EtOH, 50 % 
EtOH, H2Odd, H2Odd). Subsequently, the sections treated with 3 % Tris-buffered 
hydrogen peroxide for 15 min to block endogenous peroxide activity. Endogenous 
avidin- and biotin-activity was masked using a commercially available blocking kit 
(Eubio Cat. No. SP-2001). Slides were blocked with 5 % Tris-buffered BSA and 
incubated overnight with an antibody recognising mouse/human PPARgamma (sc-
7273, dilution 1:100, Santa Cruz Biotech.) or murine GR (sc-1004; dilution 1:1000, 
Santa Cruz Biotech.). The slides were rinsed three times using 1x TBST and 
incubated with a polyvalent biotinylated antibody and streptavidin-HRP each for 10 
min (both ID labs Cat. No. IDST1007). Specific signals were detected using a AEC-
substrate detection kit (IDLabs Cat. No. IDST1007). After appropriate staining 
intensity had developed the reaction was stopped by immersion in H2Odd and 
mounted on Superfrost glass slides using aqueous Aquatex mounting medium 
(Lactan Cat. No. 1085620050). 
 
5.3.6. Electron microscopy 
 
For electron microscopy, mouse livers were cut into 1-2 mm thin pieces and fixed 
overnight in 1.6 % glutaraldehyde. Images were recorded using various 
magnifications (1,500 x – 4,000 x) using a standard transmission electron microscope 
(TEM). 
 
5.4. Cell biology 
 
5.4.1. Cell lines  
 
Cultivation of cell lines was carried out in incubators maintaining a temperature of 37 
°C, humidity of 95 % and 5 % CO2. Cells were passaged and handled under sterile 
conditions.  
 
5.4.2. Handling of cell lines and transient transfection 
The following cell lines were routinely used for in vitro transfection experiments: 
 
HEK 293 cells 
 
Human embryonic kidney cells (HEK 293 cells) were cultivated and propagated in 
Dulbecco’s Modified Eagle Medium with high glucose (DMEM; Invitrogen Cat. No. 
41965-062); 10 % fetal calf serum (FCS; PAA Cat. No. 41965-062), 1 mM L-
Glutamine and 1 % penicillin / streptomycin. Transient transfection were carried using 
a modified version of the Sambrook  Ca3(PO4)2 method: Briefly, HEK 293 cells were 
seeded out at a final concentration of 1x105 cells/ml medium in 100 mm Petri dishes 
and were allowed to adhere to the dish for 2-6 h. 10 μg of total plasmid DNA were 
diluted in 450 µl sterile water. Subsequently, 50 µl of 2.5M CaCl2 solution were 
added, followed by drop wise addition of 500 µl 2x HBS buffer under constant 
vortexing. The solutions were incubated for 1 min until precipitation of calcium 
phosphate crystals was observed by a foggy appearance of the reaction mixture, 
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which was given onto the adherent cells in a swirling manner. Proper precipitation of 
crystals was confirmed by microscopy. After 18 h, the medium was replaced and 
transfected cells from one 100 mm Petri dish were distributed onto 2x 6well dishes to 
allow for multiple cytokine stimulation conditions. Cells were allowed to adhere 
overnight and were stimulated with various cytokines. Subsequently, culture dishes 
were rinsed two times with ice-cold PBS, scraped off using a sterile blade and 
pelleted by centrifugation for 1 min at 6,000 rpm. Finally, cells were taken up in WCE 
buffer for EMSA analysis. 
 
2 x HBS buffer: 
50 mM    Hepes pH 7.05 
10 mM    KCl 
 280 mM    NaCl 
 1.5 mM    Na2PO4 
? dissolve in 950ml H2Odd and adjust pH to 7.1 with 1 N HCl. Fill up with H2O 
to 1 L and sterilize using 0.22 μg filters. Aliquot in 50 ml reaction tubes and 
store at -20 °C. 
 
 
MIMp16/19ARF-/-Ras and MIMp16/19ARF-/- cells 
 
MIMp16/19ARF-/- and MIMp16/19ARF-/-Ras cells are primary hepatocytes isolated 
from mice deleted for p16/19ARF proteins and exhibited sustained proliferative 
capabilities in cell culture. Both cell lines were maintained and extended in RPMI 
medium (Sigma Cat. No. R0883-6x500ml), supplemented with 10 % FCS, 1 mM L-
Glutamine and 1 % penicillin / streptomycin in Petri dishes coated with rat collagen 
(BD Cat. No. 354236). Moreover, MIMp16/19ARF-/- were dependent on growth factor 
stimulation with 80 ng/ml TGFalpha (Sigma Cat. No. # T-7924), 60 ng/ml IGF-II 
(Sigma Cat. No # I-2526) and 2.8 μM insulin (Novo Nordisk). MIMp16/19ARF-/-Ras 
were stably transfected with the Ras proto-oncogene to allow for factor-independent 
growth. Both MIMp16/19-/- cell lines were transiently transfected with the 
Lipofectamine 2000® reagent (Invitrogen Cat. No. 11668-027) using a modified 
version of the vendor’s instructions: Briefly, cells were seeded out a final 
concentration of 1x105 cells/ml medium one day prior to transfection. Before 
transfection the medium was removed and replaced with RPMI containing only 1 mM 
L-Glutamine (RPMI+). The next morning, 8 μg of total plasmid DNA were mixed with 
750 µl of RPMI+ and 40 µl Plus® reagent (Mix I). Simultaneously, 60 µl of 
Lipofectamine 2000® reagent was diluted in 800 µl RPMI+ and incubated for 15 min 
(Mix II). Subsequently, Mix I and Mix II were pooled, mixed gently and incubated at 
room temperature (RT) for 15 min. The pooled reaction mixture was added to the 
cells under constant agitation. After 3 h, RPMI+ was removed and replaced with 
RPMI containing FCS, L-Glutamine and penicillin / streptomycin. After 18 h, the 
medium was replaced and transfected cells from one 100 mm Petri dish were 
distributed onto 2x6well dishes to allow for multiple cytokine stimulation conditions. 
Cells were allowed to adhere overnight and were stimulated with various cytokines 
after 48 h. Subsequently, culture dishes were rinsed two times with ice-cold PBS, 
scraped off using a sterile blade and pelleted by centrifugation for 1 min at 6,000 




                                                                                                   Materials and Methods 
105 
 
COS7 are epithelial african green monkey kidney cells immortalized using an origin-
defective mutant of SV40. COS7 are widely used in reporter assay analyses due to 
their rather basal transcription machinery. COS7 cells were maintained and 
propagated in DMEM (high glucose) supplemented with FCS, L-Glutamine and 
penicillin / streptomycin. For transient transfection experiment, one fully growth T75 
cell culture flask was trypsinised and detached cells allocated onto five 100 mm Petri 
dished one day prior to transfection. At the day of transfection, 544 µl of DMEM was 
pipetted into a 1.5 ml reaction tube and mixed with 48 µl of Fugene reagent (Roche 
Cat. No. 11814443001), flicked once and allowed to incubate for 5 min. 
Subsequently, 8 μg of total plasmid DNA was added to the reaction mixture, flicked 
and incubated for 5 min. The transfected reagent:DNA complex was given onto the 
cells in a swirling and drop wise manner. After 18 h, cells from one transfected 100 
mm Petri dish were distributed onto one 24 well dish to allow for multiple cytokine 
stimulations. COS7 sells were allowed to adhere overnight and were stimulated with 
various cytokines after 48 h. Subsequently, culture dishes were rinsed two times with 
ice-cold PBS, scraped off using a sterile blade and pelleted by centrifugation for 1min 
at 6,000 rpm. Finally, cells were taken up in KH2PO4 lysis buffer for reporter assay 
analysis. 
 
5.4.3. Luciferase reporter assay 
 
Luciferase reporter assays are used to quantify the ability of a given promoter 
sequence to drive the transcription of the firefly Luciferase gene. Luciferase itself is 
an enzyme catalysing the reaction a reaction in which Lucifer in is transformed into its 
decarboxylated isoform leading to emission of photons. As under standard conditions 
the amount of luciferin is supplied in excess, the amount of emitted light is 
proportional to the amount of Luciferase and constitutes an indirect measurement for 
the transactivation capability of a cloned promoter sequence. To determine the 
Luciferase activity in transfected cell lines, the pelleted cells were taken up in 50-100 
µl of potassium chloride lysis buffer. The pellets were pipetted up and down 
repeatedly and put on a horizontal shaker for 30 min to facilitate lysis of cells. 
Insoluble debris was removed by centrifugation for 15 min at 12,000 rpm in a cooled 
micro centrifuge. The supernatant was shock-frozen and stored at -80°C or used 
instantly. For measuring Luciferase activity, 20 µl of supernatant was transferred to a 
opaque 96 well microtiter plate and diluted with 50 µl of assay buffer (4 mM ATP, 200 
mM MgSO4 in Gly-Gly buffer). The plate was transferred into a luminometer equipped 
with a dispenser, automatically adding 50 µl of injection buffer (0.25 mM luciferin in 
Gly-Gly buffer) into each well. The subsequent light emission was detected at 560nm 
and counted for 2 s.  
The efficiency of each transfection was quantified via co-transfection of 0.5 μg 
plasmid vector DNA constitutively expressing beta Galactosidase. To assess the 
enzymatic Galactosidase activity as an indicator for efficiency of DNA transfection 
into cells, the complete Luciferase reaction mixture (120 µl) was transferred onto a 
fresh, translucent microtiter plate and 50 µl of CPRG (chlorophenolred-beta-D-
galactopyranoside, Sigma Cat. No. 59767100MGF) solution, a chromogenic beta 
Galactosidase substrate, pipetted into each well. Upon beta Galactosidase activity, 
the colourless CPRG solution turned yellow. The absorption was then measured in a 
spectrophotometer at 405 nm as an indicator of beta Galactosidase enzyme activity. 
For relative quantification of the transactivitation activity of a given promoter elements 
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each sample the Luciferase values were measured and normalised against the beta 
Galactosidase values as an indicator of transfection efficiency.  
 
KH2PO4 lysis buffer: 
13.6 g     KH2PO4   
0.1 %    Triton X-100  
? fill up with H2Odd to 1 L, adjust pH to 7.8 using NaOH 
 
CPRG solution: 
27,1 mg    CPRG  
0.5 %    BSA 
? fill up with 20 ml PBS, aliquot and store at -20 °C 
 
5.5. Colony breeding and management 
 
Mice were kept at the Decentralized Biomedical Facilities, Medical University of 
Vienna (MUW) under standardized conditions. All animal experiments were carried 
out according to an ethical animal license protocol and contract approved by the 
MUW and the Austrian Ministry BMBWK authorities. Mice are maintained on a 12 h 
light-dark cycle. 
 
5.5.1. Transgenic mouse lines 
 
(i) Mice harbouring a hepatocyte-specific deletion of the glucocorticoid receptor 
(GRAlfpCre) were generated by intercrossing with animals with a floxed third exon of 
the GR 211 with mutants carrying the Cre recombinase under the control of the 
albumin promoter and alpha-fetoprotein enhancer sequences 158. Animals deleted for 
hepatic Stat5 were generated by crossing mice harbouring the AlfpCre recombinase 
with mutants carrying a floxed Stat5a/b allele (Stat5AlfpCre) 119. Stat5/GRAlfpCre 
compound knockout animals were generated by respective intercrossing. Stat5ΔN 
mice were generated as described 127. All animals were maintained on a mixed 
C57/BL6 and 129SvEv background and genotyped as indicated. 
 
(ii) Mice deleted for MDR2 (MDR2-) were purchased from Jackson Laboratories. 
MDR2- mice were initially maintained on a FVB/N background. Due to appropriate 
intercrossing MDR2+/-, MDR2-, Stat5AlfpCre and MDR2-/Stat5AlfpCre animals were 
generated and experimental mice were regarded to be on a mixed background.  
 
5.5.2. Metabolic function tests 
 
5.5.2.1. Glucose tolerance test 
 
To assay the capability of transgenic mice to metabolize orally administered glucose, 
we performed oral glucose tolerance tests (OGTT). For this, mice were fasted 
overnight in a fresh cage prior to glucose gavage to obtain comparable basal glucose 
levels. The next morning, the body weight was determined and basal glucose levels 
analysed. For this, the tail vein was nicked and one droplet venous blood measured 
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using a glucometer (OneTouch Ultra, LifeScan). Glucose was orally administered at a 
concentration of 10 µl/g body weight using a gavage syringe. The measurement of 
glucose levels was done by sampling venous tail blood at indicated time points. 
Immediately after the experiment, mice were transferred into a fresh cage and 
provided with food ad libitum. 
 
5.5.2.2. Insulin tolerance test 
 
Insulin tolerance tests were performed with animals initially fasted for 4 h in a fresh 
cage. Subsequently, the body weight was determined and insulin (Novo Nordisk) 
injected peritoneally at a final concentration of 0.75 U/kg body weight. Blood samples 
were taken from the tail vein at indicated time points and glucose levels determined 
using a glucometer (OneTouch Ultra, LifeScan). Plasma insulin concentrations were 
analysed using a rat insulin ELISA (Crystal Chem Cat. No. INSKR020) following 
vendor’s instruction manual. 
 
5.5.3. Blood sampling and serum parameter quantification 
 
To determine serum concentration of cytokines and growth factors or biochemical 
parameters, blood was harvested from mice using heart puncture and collected in 
tubes precoated with EDTA. Blood samples were subsequently centrifuged at 5,000 
rpm for 5 in at RT to remove insoluble, coagulated blood components. The plasma 
(supernatant) was transferred into a new tube and analysed instantly using various 
techniques or shock frozen in liquid N2 and stored at -80 °C. 
Concentrations of important biochemical and metabolic serum parameters 
were determined using a Reflotron Plus analszer (Roche). Briefly, 30 µl of serum or 
plasma were pipetted onto an analyte-specific strip and inserted into the machine. 
Final concentration of were calculated taken possible pre-dilutions into account. 
 
5.5.3.1. Lipoprotein profile 
 
Plasma samples of five fed mice of each genotype were pooled and compared with 
five control littermates. Lipoproteins were isolated by FPLC. 200 μl pooled plasma 
samples were subjected to FPLC analysis and lipoproteins were eluted with 10 mM 
Tris-HCl, 1 mM EDTA, 0.9 % NaCl, and 0.02 % NaN3 (pH 7.4). Fractions of 0.5 ml 
each were collected and lipids (triglycerides and total cholesterol) assayed 
enzymatically using commercially available kits. To enhance sensitivity, reaction 
buffers were supplemented by the addition of sodium 3, 5-dichloro-2-hydroxy-
benzenesulfonate. 
 
5.5.4. Immuno assays 
 
Immuno assays (particularly enzyme linked immuno sorbent assays (ELISA) and 
radio immunoassay (RIA)) detect the concentration of an antigen in serum samples 
with high reproducibility and accuracy. Briefly, an antigen-specific antibody was 
immobilised and scavenges the desired antigen. Finally, the amount of trapped 
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antigen was converted to a signal using radiolabel led secondary antibodies (RIA) or 
a chromogenic enzyme activity coupled to the secondary antibody (ELISA). 
 
5.5.4.1. Radio Immunoassay (RIA) 
 
Serum corticosterone (MP Biochemicals Cat. No. 07-120102) and ACTH (MP 
Biochemicals Cat. No. 07-106102) levels were determined using commercially 
available RIA following instructions from the vendor. Briefly, a standard curve was 
prepared and subsequently the displacement of Corticosterone/ACTH-specific 
antibodies bound to radiolabel led Corticosterone/ACTH (Cort*/ACTH*) by serum 
Corticosterone/ACTH quantified using a gamma counter (Beckmann). Thus, 
extensive displacement of Corticosterone/ACTH antibodies from Cort*/ACTH* due to 
high levels of serum Corticosterone/ACTH led to a low radioactivity. The exact 
concentrations of serum Corticosterone/ACTH was deduced using the previously 
prepared standard curve. 
 
5.5.4.2. Enzyme Linked Immuno Sorbent Assay (ELISA) 
 
Plasma GH (Millipore Cat. No. EZRMGH-45K), IGF-1 (IBL Hamburg Cat. No. 
UK45021), Leptin, TNFalpha and Resistin concentrations (all Millipore Cat. No. 
MADPK-71K-04) were determined using ELISA kits. Briefly, plastic dishes precoated 
with the respective growth factor/cytokine specific antibody were incubated with 
serum samples according to manufacturer’s instructions. A secondary antibody 
coupled to an enzymatic function was added. Finally, the development of the 
chromogenic reaction was stopped and the concentration of the respective analyte in 
the serum determined measuring the OD at 450 nm using a spectrophotometer. The 
exact concentrations were calculated using an analyte standard curve. 
 
5.5.5. Colorimetric assays 
 
5.5.5.1. Quantification of free fatty acids (FFA) 
 
The concentration of serum FFA was determined using a colorimetric assay system 
(Wako Cat. No. 999-65406). Briefly, the assay relied on the catalytic oxidation of free 
carbonic acids such as FFA (R-COOH) by (i) Acyl-CoA synthase, (ii) Acyl-CoA 
oxidase and (iii) peroxidase: 
 
(i) R-COOH + ATP + CoA-SH ? ? Acyl-CoA + AMP + PPi 
(ii) Acyl-CoA + O2 ? ? 2,3-Enoyl-CoA  H2O2 
(iii) H2O2 + 4 H2N-phenanzon + 3-CH3-N-Ethyl-N (beta-hydroxyethyl)-aniline ? 
? quinoneimine (color) + 4 H2O 
 
A standard curve of oleic acid was prepared and 4 µl serum sample used for 
quantification. The experiment was carried out as given in the vendor’s instructions. 
The OD was measured at 550 nm and the final concentration of FFA calculated taken 
possible pre-dilutions into account. 
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5.5.5.2. Isolation and quantification of hepatic triglycerides 
 
Hepatic lipids were isolated from frozen liver tissues using the original method of 
Stanley and Folch. For this, approximately 100 mg were weighted and transferred 
into a 15 ml reaction tube pre-equipped with 2 ml of a chloroform/methanol (2:1 v/v) 
mixture. The tissue was homogenized until no tissues clumps were visible, followed 
by incubation for 20-25 min on a rotating wheel at RT. Cell debris and insoluble 
fragments were removed by centrifugation at 4,000 rpm for 10 min. The resulting 
supernatant was transferred into a fresh reaction tube and the organic phase 
extracted two times 0.9 % NaCl solution, followed by careful aspiration of the 
aqueous phase.  Then, 50 µl of the lipophillic phase were incubated with 10 µl of a 
TX-100/chloroform (1:1 v/v) mixture in a fresh reaction tube. Vigorous shaking was 
followed by evaporation of the solvent in a Speed vac. The remaining pellet, 
containing the organic phase of the liver was taken up in 50 µl of H2Odd and stored at 
-20 °C. 
To determine the concentration of triglycerides in hepatic tissues, this 
colorimetric assay (Sigma Cat. No. TR0100) relied on the enzymatic quantification of 
glycerol liberated from cleaved triglycerides (tricarboxylic acid esters of glycerol) 
since the stochiometric ratio between triglycerides and glycerol equals one. Four µl of 
isolated triglycerides from liver tissues were pipetted onto a 96 well microtiter plate. 
Glycerol at a concentration of 2.5 mg/ml (Sigma Cat. No. G7793) was included as 
positive control whereas blank values include water. 100 µl Free Glycerol Reagent is 
pipetted into each well and incubated for 5 min at 37 °C. The amount of glycerol not 
incorporated into triglycerides was determined by spectrophotometry measured at 
540 nm. A second 96 well plate containing the same samples was pipetted and 100 
µl of Triglyceride Reagent added. The plate was incubated for 5 min at 37 °C and the 
OD at 540 nm measured again. This time, the OD 540 nm was proportional to the 
total amount of glycerol (free glycerol and glycerol incorporated in triglycerides) in the 
respective sample. Subtraction of the two values and normalization blank values 
yielded the concentration of triglycerides in the respective sample. 
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